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Abstract 
A qualitative systematic review was conducted to assess the performance of tools which 
have been validated for the prediction of morbidity and/or mortality, in heterogeneous 
cohorts of surgical (non-cardiac, non-neurological) patients.  The Portsmouth- 
Physiological and Operative Severity Score for the enUmeration of Mortality and 
morbidity (P-POSSUM) and the Surgical Risk Scale (SRS) were found to be the most 
widely validated and accurate risk stratification tools.  
The POSSUM, P-POSSUM and SRS were then validated in a population of patients who 
had major non-cardiac surgery in a metropolitan UK hospital. Their accuracy 
(discrimination) was compared against two novel predictors - the additive POSSUM 
score and the POSSUM physiology score. P-POSSUM and the additive POSSUM score 
predicted short-term mortality with high-moderate accuracy. The POSSUM Physiology 
score was moderately accurate and therefore worthy of further evaluation. Both 
POSSUM and P-POSSUM were poorly calibrated for this population.  
The relationships between perioperative risk, postoperative morbidity (measured using 
the Post Operative Morbidity Survey, POMS), postoperative length of hospital stay, and 
short-term mortality, were explored in a series of univariate analyses. There were 
differences in short-term mortality, and the patterns and prevalence of POMS-defined 
morbidity between surgical specialities.  
Cox Proportional Hazards Modelling, using time-dependent covariates, was undertaken 
to explore the independent relationship between perioperative risk, postoperative 
morbidity and long-term survival. POMS-defined neurological morbidity (prevalence 
2.9%) was independently associated with reduced long-term survival. Prolonged 
postoperative morbidity, defined as the presence of POMS-defined morbidity on Day 15 
post-surgery (prevalence 15.6%), conferred a relative hazard for death in the first 12 
months post surgery of 3.52 (p<0.001; 95% C.I. 2.23-5.43) and for the next two years of 
2.33 (p<0.001; 95% C.I. 1.56-3.50). Postoperative morbidity is a significant public 
health issue and poses a risk to longer-term survival; it would be an important measure 
of the quality of perioperative healthcare.  
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“Systems awareness and systems design are important for 
health professionals, but are not enough. They are 
enabling mechanisms only. It is the ethical dimension of 
individuals that is essential to a system’s success. 
Ultimately, the secret of quality is love.” 
Avedis Donabedian  
Chapter One: Introduction 
1.1 Overview 
This thesis focuses on two distinct but closely related areas. The first is the prediction of 
perioperative risk. The second is the epidemiology of short and long-term outcome after 
surgery. In this introduction, these areas will be discussed in detail.  
Initially, an overview of the significance of perioperative morbidity to patients and the 
healthcare system is provided. Then, the factors that influence outcome in the 
perioperative period will be discussed. These include both patient (pathophysiological) 
and organisational (structure and process) risk factors, and methods for predicting and 
measuring them. Finally, the various definitions of outcome will be reviewed and 
appraised, before setting out the aims and objectives of this thesis.   
1.2 The scale of the problem 
An estimated 234 million major surgical cases occur worldwide each year.1 The impact 
of this burden on individual persons, healthcare providers, and society as a whole is 
difficult to estimate; however, there is convincing evidence that surgical morbidity and 
mortality is a major public health issue in both developed and developing world 
environments. Recent data suggest that in Europe, hospital mortality after inpatient 
surgery may be is as high as 4%, with wide variation in crude mortality rates between 
countries; the UK estimate of in-hospital mortality was 3.6%, which was considerably 
higher than had been previously thought.2 Complications may occur in between 3 and 
17% of patients, depending on the type of patients and surgery, and how complications 
are defined.3;4  In a study of over 6000 UK civil servants, absence from work of greater 
than 7 consecutive days due to surgery, was associated with the second highest hazard 
ratio for long-term mortality (after circulatory diseases) of any cause of sickness leave 
(Hazard Ratio [HR] 2.16; 95% C.I. 1.42-3.26, adjusted for age, gender and employment 
grade).5 A Finnish study has found that the standardised mortality ratio for patients 
undergoing most types of surgery is higher than age and sex matched controls drawn 
from a non-surgical population; this increase in mortality is greater in patients who are 
high resource consumers while in hospital (and therefore likely to have had a 
complicated post-operative course).6    
Data from a large epidemiological study looking at over 4 million surgical procedures in 
the United Kingdom, identified a ‘high risk surgical population’: the relatively small 
proportion of patients that fell into this group (12.3%) accounted for the majority of 
post-operative mortality (83.4%) and these patients had a significantly increased 
duration of hospital stay.7 Perioperative risk was related to increasing patient age and 
the complexity and immediacy of the procedure: 88.5% of patients in the high risk 
category underwent emergency surgery, as opposed to just 21.3% in the ‘standard risk’ 
population. Of particular interest, less than 15% of the patients who fell into the high 
risk category were admitted to critical care directly from the operating theatre. The 
authors noted that cardiothoracic patients (excluded from this study), who by definition 
have significant co-morbidity and are undergoing complex surgery, have a relatively 
low population mortality8 when compared to patients undergoing certain orthopaedic, 
general and vascular surgical procedures.9-12 This may be partly due to process-related 
issues, as the cardiac surgical population is relatively homogenous, allowing for more 
protocolised and streamlined care. However, the authors also postulated that the more 
intensive management afforded to cardiac surgical patients, as a result of routine 
admission to critical care post-operatively, may lead to better outcomes.  
These data may also reflect inaccurate pre-operative risk stratification and insufficient 
available resources for this high-risk population. They highlight the need for the 
accurate identification of patients at the highest risk of surgical complications, and who 
may therefore benefit from higher levels of support, such as elective postoperative 
critical care admission. Equally, identifying patients for whom this level of support is 
not required is just as important, so that limited resources are directed at those who are 
most likely to benefit. In order to explore these possibilities, we need to identify risk 
factors for adverse outcomes, related to both variations in individual patient physiology 
and healthcare service provision.  
1.3 Pathogenesis of surgical morbidity 
The biological mechanism responsible for the development of postoperative morbidity  
involves an inflammatory response which may clinically manifest as a Systemic 
Inflammatory Response Syndrome (SIRS); this may lead onto the Multiple Organ 
Dysfunction Syndrome (MODS) or may be limited milder clinical variants.13  As long ago 
as the 1970s, it was recognised that immune modulation occurred as a result of the 
surgical insult.14 Although Slade and team originally reported that the immune changes 
they observed were not linked to clinically significant adverse outcomes,14 since then 
perioperative inflammation has been linked to both generic morbidity and specific 
complications; furthermore, markers which reflect the severity of this response may be 
measured and have been found to correlate with post-operative outcome.15-21 For 
example, Endotoxin, which is a component of gram-negative bacteria and is normally 
found in high concentrations in the gastrointestinal tract, is thought to be a trigger for 
SIRS in the surgical setting.13  Endotoxaemia may occur as a result of gut mucosal 
impairment during and after major non-gastrointestinal surgery or from direct 
manipulation of the gut during abdominal surgery.22  Work looking at the level of anti-
endotoxin core antibody (EndoCAb) in preoperative patients has found that patients 
who have lower preoperative serum EndoCAb concentrations are more likely to have 
postoperative complications23-25 and reduced long term survival. 26 There are also links 
between surgical inflammatory responses and specific complications. Postoperative 
cognitive dysfunction is common and may lead to long-term harm; 27;28 in non-cardiac, 
non-neurological surgery it has been associated with increased levels of pro-
inflammatory cytokines (interleukin-6 and prostaglandin E2) in the cerebrospinal fluid. 
29 In animal models (elderly mice), the post-surgical inflammatory response has been 
shown to lead to cognitive decline associated with pathological changes similar to those 
of Alzheimer’s disease (for example beta-amyloidosis and gliosis).30  
Whether or not a patient enters into a clinically significant physiological 
decompensation after a surgical procedure is dependent on a number of factors. The 
physiological characteristics of the patient themselves will determine the likelihood of 
an adverse response to surgery. The ability of the patient to increase their oxygen 
delivery to meet the increased demands of the perioperative period is thought to be a 
fundamental determinant of outcome31;32 and it is this principle that underpins the 
strategy of perioperative haemodynamic optimisation. The causes of the uncoupling of 
oxygen supply and demand in the perioperative period relate both to the patient’s co-
morbidities and the severity of the surgical insult. The combination of a failing heart and 
microcirculatory dsyfunction33 which pre-date the surgical insult, but may then be 
exacerbated by it, may lead to poor oxygen delivery and utilisation and the development 
of postoperative complications.33 Goal directed fluid optimisation aimed at maximising 
oxygen delivery, using non-invasive monitors such as the oesophageal Doppler, has 
repeatedly been shown to be associated with a reduction in perioperative complications 
and hospital length of stay in certain types of surgical procedure.34 35  
1.4 Predicting patient risk for adverse perioperative outcomes 
1.4.1 Overview: Why predict perioperative patient risk? 
Accurate stratification of patients into ‘risk categories’ according to their own 
physiological characteristics may lead perioperative physicians to modify or abandon a 
planned surgical intervention if the risk is seen to outweigh the benefit, particularly in 
diseases where a more conservative alternative to major surgery is available. 
Alternatively, accurate preoperative risk stratification may allow clinicians to select 
those patients who may benefit from specific treatment strategies, such perioperative 
haemodynamic optimisation or an enhanced level of perioperative care such as in a 
critical care unit 36 or Post Anaesthetic Care Unit (PACU).37  Risk (or case-mix) 
adjustment is a related technique which is used in healthcare to account for patient risk 
factors when measuring quality and / or outcomes. The Physiological and Operative 
Severity Score for the enUmeration of Mortality and morbidity (POSSUM)  was first 
developed for the purposes of risk adjustment, to enable comparative audit in the 
National Health Service (NHS).38  
 
Hundreds of studies have shown both univariate and adjusted relationships between 
various risk factors and surgical outcome in different settings: these include advancing 
age,39 diabetes mellitus,40 renal impairment,41 and cardiac failure41 42 to name but a few. 
In recent years, a number of different methods of predicting perioperative risk have 
been developed which attempt to take into consideration the contributions of all the 
different risk factors which patients might have; these include risk stratification tools, 
measures or estimates of functional capacity, and biomarkers. Each of these will now be 
discussed in turn. 
1.4.2 Risk stratification tools 
Three of the most commonly used risk stratification tools, the American Society of 
Anaesthesiologists’ Physical Status Score (ASA-PSS), Charlson Age-comorbidity index 
(CACI), and the Physiological and Operative Severity Score for the enUmeration of 
Mortality and morbidity (POSSUM) are summarised in Table 1. There are also a number 
of tools in use which have been developed purely for the prediction of cardiovascular 
morbidity and mortality; the most widely used and recommended tool43 of these is the 
Lee Revised Cardiac Risk Index (RCRI).44;45  These tools, and the many others in 
existence, differ in their discriminant ability (accuracy) and reliability, and the types of 
patient, procedure and outcomes for which they are validated. A number of derivatives 
of these three systems have been validated in different surgical cohorts: the Surgical 
Risk Scale,46 and Donati’s Surgical Risk Score,47 are both based on the ASA-PSS, but also 
include details of the proposed surgical procedure; both systems demonstrate improved 
predictive accuracy when compared with the ASA-PSS used alone. However, caution 
should be exerted when considering the use of any of these risk stratification tools for 
clinical decision making on whether to proceed with a proposed intervention, as they 
demonstrate variable predictive precision, particularly at the extremes of age48;49 and 
calculated risk.50-52  
Despite these caveats, there are a number of potential benefits to using risk 
stratification tools. They are usually openly available, may be used on patients 
undergoing both elective and emergency surgery and in many cases, they are relatively 
simple to apply. Risk adjustment models developed for the purposes of comparative 
audit may also be used for patient risk stratification, as has been demonstrated with 
several models used in the critical care setting.53;54 While there are a large number of 
published studies reporting the validity of different surgical risk prediction rules, 
clinical experience tells us that they are not widely used, at least in the United Kingdom; 
there are several reasons why this may be so. First, many prediction rules have been 
developed for the prediction of specific morbid events after surgery, such as cardiac 
morbidity or renal dysfunction. While these complications are important, they are also 
relatively uncommon;55;56 furthermore, generic complications such as infectious and 
gastrointestinal morbidity and wound complications may carry significant morbidity in 
the short and long-term.55-57 It is therefore more useful for perioperative physicians to 
be able to predict generic morbidity and all-cause mortality, so that a patient’s care may 
be modified if they are identified as high risk. Second, many models predicting generic 
adverse outcomes have been validated in single surgical speciality cohorts: for example, 
after vascular or colorectal surgery.58;59 Most anaesthetists and perioperative physicians 
manage patients undergoing a wide variety of surgical procedures, and there would be 
clear advantages to a model which can be applied across surgical specialities. Finally, 
the reported accuracy of different risk stratification tools has varied in published 
studies, leading to uncertainty over their value. As a consequence, a number of 
modifications have been made to previously validated scores, such as the POSSUM 
system.  
 Other methods, such as exercise testing or biomarker assays which are discussed below, 
may be able to provide a more accurate assessment of a patient’s perioperative risk 
than currently available risk stratification tools. However, in certain patients, especially 
those undergoing emergency surgery, and who are therefore at particularly high risk of 
adverse outcomes, complex preoperative investigation is unlikely to be feasible. It may 
be unlikely that a ‘one size fits all’ risk prediction model would be able to accurately 
stratify patients worldwide, and over time, as a result of variation in structure and 
process between healthcare systems, differences in the type of surgery that may be 
offered to patients for a particular disease in different regions, and changes in how 
patients are looked after, as medical knowledge and management improves. This issue 
would be addressed by the development of large databases of patient demographics and 
risk factors, such as that of the United States’ Veterans’ Administration National Surgical 
Quality Improvement Program.60;61 Such systems would enable the development of 
‘bespoke’ risk stratification models which may be modified annually to reflect regional 
fluctuations in patient health and perioperative practice.  
In the meantime, if we are to use risk models to guide patient management, or for the 
purposes of risk adjustment for comparative audit, a clear understanding of their 
strengths and limitations is necessary.  In order to progress this understanding, and to 
summarize the evidence supporting the predictive precision of these tools, a systematic 
review of clinical prediction models used in major surgery is presented in Chapter 2.  
Table 1 Comparison of commonly used risk-stratification scoring systems 
Scoring system Description Background Validation Advantages Disadvantages 
American Society of 
Anaesthesiologists’ 
Physical Status 
Score (ASA-PS) 
Categorical 
numbered scale (I-
V) based on the 
severity of patient 
comorbidities  
First reported in 
1948 as a 
description of 
‘anaesthetic risk’ 
for the purposes 
of 
epidemiological 
study62 
Multi-centre validation for 
categorisation of population risk;63 not 
validated for prediction of individual 
patient risk64 
Simple, easily applied 
bedside tool not requiring 
complex calculation.  
Subjective; does not differentiate 
between different types of patient 
comorbidity; subject to wide inter-
observer variability;65 does not use 
information regarding the surgical 
procedure itself. Poor sensitivity and 
specificity for prediction of morbidity 
and mortality on an individual patient 
basis64 
Charlson Age-
Comorbidity Index 
(CACI) 
Additive score 
based on the 
presence and 
severity of different 
patient 
comorbidities  
First reported 
and validated in 
1994 for the 
purpose of risk 
classification in 
longitudinal 
studies 
Multi-centre; international. Originally 
validated for long-term population 
mortality prediction (3-5 years post-
operatively) in diabetic and 
hypertensive surgical patients; has since 
been validated for prediction of in-
patient mortality and morbidity in 
several cohorts 
Relatively simple; bedside 
calculation possible; more 
accurate predictor of 
outcome than ASA-PS;66 
accurate predictor of 
population risk according 
to assigned score67;68 
Uses no information regarding the 
surgical procedure itself; assessment of 
patient co-morbidity may be subjective 
Physiological and 
Operative Severity 
Score for the 
enUmeration of 
Mortality and 
morbidity 
(POSSUM) 
12 physiological 
and 6 operative 
variables; each 
variable is assigned 
a score and the total 
scores entered into 
logistic regression 
equations which 
calculate a 
percentage 
mortality & 
morbidity risk 
First reported in 
1991 to facilitate 
comparative 
audit between 
surgical services 
(by adjusting 
surgical outcome 
data for 
calculated 
predictive peri-
operative risk)  
Multi-centre, international. Portsmouth 
POSSUM (P-POSSUM) system69 uses the 
same dataset as the original POSSUM 
score, but using linear (rather than 
logistic) regression to calculate 
predicted mortality.  
Found to be an equivalent or superior 
predictor of mortality than the original 
POSSUM in different surgical 
settings;70;71 Surgery-specific variants 
such as Cr-POSSUM (colorectal), have 
been validated as better predictors of 
outcome than both ‘general’ POSSUM 
systems.72   
Validated for prediction of 
individual patient risk; 
POSSUM and its variants 
have been widely validated 
in different patient cohorts 
internationally; uses 
objective variables (such as 
blood test results) in 
dataset therefore reducing 
inter-observer variability 
Uses some subjective variables (such 
as chest radiograph interpretation and 
jugular venous pressure 
measurement) which may be subject to 
inter-observer variability. The 
operative variables are not available 
until during or after surgery.  
Logistic regression calculation means 
that the lowest possible mortality risk 
is 1.08%; predictive ability limited at 
extremes of age and calculated risk. 
Linear regression used in the P-
POSSUM modification may be more 
precise  
 
 35 
1.4.3 Assessment of functional capacity 
The estimation of cardiorespiratory fitness by simple direct questioning has long been a 
part of preoperative assessment by the anaesthetist, and the patient’s self-estimation of 
exercise tolerance has been shown to correlate with post-operative outcome.73 
However, more sophisticated methods of assessing functional capacity are now being 
evaluated and more widely implemented: these include subjective but structured 
estimation (e.g. the Duke Activity Status Index [DASI]), or objective measurement 
(incremental shuttle walk test [ISWT] and cardiopulmonary exercise testing [CPET]).  
The Duke Activity Status Index (DASI) is a simple questionnaire which categorises levels 
of exertion (for example, ability to climb stairs or complete household chores) according 
to the metabolic equivalent (MET) of oxygen consumption required to achieve the task. 
The DASI is correlated with peak oxygen uptake on exercise testing 74 and, as suggested 
in the American College of Cardiology / American Heart Association (ACC/AHA) 
guidelines on cardiovascular preoperative assessment, may be a useful element of a 
wider pre-operative evaluation, especially in the emergency situation where there is no 
opportunity for formal exercise testing.43 However, it is a patient reported and therefore 
subjective measure, which may therefore not always correlate with an individual 
patient’s true functional capacity.  
The incremental shuttle walk test (ISWT) involves a patient walking back and forth 
between two fixed points to the limit of their exertion. It is a validated and highly 
reproducible measure of functional capacity, and is likely to be most valuable for the 
screening out of patients with sufficient level of fitness that they do not require further 
investigation.75;76  Cardiopulmonary Exercise Testing (CPET) requires the patient to 
cycle on a bicycle ergometer at gradually increasing intensity during a ‘ramp’ exercise 
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protocol. The test results are summarized by a ‘nine panel plot’ which shows a number 
of variables including the peak oxygen consumption (VO2peak),  the Oxygen Pulse (the 
amount of O2 consumed from the volume of blood delivered to tissues by each 
heartbeat; O2 pulse=VO2/heart rate) and the anaerobic threshold (AT) (the point at 
which anaerobic metabolism starts to increase significantly, as oxygen delivery to 
muscles is surpassed by the metabolic demands placed by exercise).77 Studies 
conducted in the 1990s identified a correlation between an objective measure of poor 
functional capacity (anaerobic threshold <11ml/kg/minute) and peri-operative 
mortality in different surgical populations.78;79 Of note, exercise capacity was found to 
be a more significant correlate of outcome than the occurrence of exercise induced 
ischaemia; the prognosis was worst in patients who had both ischaemic exercise tests 
and a low anaerobic threshold. More recent work has also found VO2peak to predict 
outcome in a variety of other patient cohorts.80-82  
Recent work suggests that the DASI and the ISWT are highly sensitive and specific in the 
identification of patients at low risk of perioperative complications; however they may 
incorrectly categorise as high risk a significant number of patients who, on 
cardiopulmonary exercise testing, would be considered low risk (that is, with an 
anaerobic threshold of greater than 11mlO2/kg/min or peak VO2 >15mlO2/kg/min).83 
Such data suggest that following an algorithmic approach to the assessment of 
functional capacity  might be useful: the DASI ± ISWT may be used as inexpensive and 
quick screening tools to identify low risk patients who warrant no further investigation; 
patients identified as ‘high risk’ by these methods, may benefit from further evaluation 
using CPET.  For those patients identified as ‘high-risk’, management on critical care 
post-operatively, and the use of haemodynamic optimisation perioperatively, may be of 
 37 
benefit, although at present there are no published multi-centre studies examining the 
impact of specific management strategies on patients who have been risk- stratified 
using CPET. A study evaluating this issue is near completion (Cardiopulmonary exercise 
testing and pre-operative risk stratification: UKCRN ID 4187): patients are randomised 
to either having their place of postoperative care (Critical Care versus general ward 
care) determined by the results of the CPET (intervention limb) or by the perioperative 
team based on their best judgement (standard of care).  
1.4.4. Biomarkers 
A ‘biomarker’ has been defined as ‘a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention’.84 Thus, there is a huge 
spectrum of investigations which fall within this definition, and which may be used in 
the perioperative setting. Abnormal results from some routine preoperative tests (for 
example, blood pressure, ECG and measures of renal function such as serum creatinine) 
have been linked to poor outcome in general populations, and have been incorporated 
into surgical risk stratification tools such as the Lee Revised Cardiac Risk Index and the 
POSSUM predictors.38;44  
However, work continues to identify markers which may more specifically or accurately 
predict or quantify adverse surgical outcomes. For example, high sensitivity C-Reactive 
Protein (hsCRP) is well established as a marker of inflammation that may predict 
vascular and cardiac adverse events in the general population, independently of 
accepted risk factors such as smoking, hypertension and diabetes mellitus.85 It has been 
found to inversely correlate with functional capacity as measured by VO2peak even in 
symptom free individuals, 86 and the addition of hsCRP level to existing risk models for 
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the prediction of cardiovascular risk in the general population improves accuracy.87  
Recent work has examined the relationship between preoperative hsCRP level and 
surgical outcome, and found an independent association between elevated hsCRP levels 
and adverse events in orthopaedic88 and vascular surgical patients.89-91 Other studies 
show preoperative hsCRP to be independently associated with long term outcome in a 
variety of cohorts with surgically treated malignancies,92-94 and patients undergoing 
cardiac surgery.95;96 However, heterogeneity in the hsCRP level that was defined as 
‘high’ in these studies, means that, based on existing data, the generalizability of this 
assay for patient risk stratification remains limited.  
Biomarker assays being evaluated for the prediction of adverse cardiac events include 
Brain Natriuretic Peptide. The pre-operative level of N-terminal pro-Brain Natriuretic 
Peptide (NT-pro BNP) has been found to independently predict mortality and cardiac 
events after both major cardiac97-99 and major non-cardiac surgery.100-103 There are, 
however, several limitations of NT-pro BNP as a biomarker which should be considered. 
In the general population, there are age, gender and assay-specific variations in cut-off 
values for risk stratification.104  Renal impairment has been shown to impair the 
usefulness of the assay for the prediction of perioperative cardiac complications.105 
Nevertheless, in the future, NT-pro BNP (and similar biomarkers) may prove to be a 
useful part of a multi-factorial risk assessment: as with generic perioperative risk, the 
evaluation of cardiac risk is likely to involve a combination of the above strategies to 
achieve optimal predictive accuracy.  
Looking ahead, rapid advances in genomic sequencing mean that personalised 
diagnostics may be become a reality sooner rather than later,106;107 although cost is 
likely to remain an issue for some time. It is possible that in the future, the addition of 
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biomarker assays and measures of functional capacity to risk stratification scoring 
systems will lead to improvements in accuracy of perioperative risk prediction. 
Patient risk is a key determinant of perioperative outcome. However, it is known that 
clinical management may either mitigate or exacerbate pre-existing risk, and it is also 
known that there is wide variation in surgical outcomes (risk adjusted) between 
institutions. This variation may be explained by difference in the care that patients 
receive once they enter the surgical pathway; this is most succinctly explained using the 
‘structure process outcome’ model, which will be discussed now.  
1.5  How quality of healthcare affects outcome: the structure / 
process / outcome model 
1.5.1 Overview 
Over 40 years ago, Avedis Donabedian, the Lebanese-born Professor of  Public Health at 
the University of Michigan,  described the structure / process / outcome (SPO) model of 
evaluating quality in healthcare.108 ‘Structure’ refers to how healthcare is organised, 
‘process’ is the method by which healthcare is provided, and ‘outcome’ is the state 
resulting from healthcare processes. There is a growing body of literature using this 
model to describe quality, and demonstrating the impact that structure and process 
have on population outcomes for patients.  
1.5.2 Structure  
The description of structure incorporates a wide variety of variables specifically related 
to the environment within which healthcare is provided. Physical characteristics of 
hospitals, such as the number of beds,109 bed occupancy rate110 and the presence of 
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particular services associated with ‘high technology’ (such as cardiac or organ 
transplantation surgery) 111 have all been shown to be associated with improved 
surgical outcomes. Staff characteristics, such as nurse-patient ratios,112 compliance with 
training requirements, the proportion of nurses and doctors with higher qualifications 
or specialist experience,110 and payroll expenses110 have also been associated with 
hospital level outcomes. Then there are structural elements which might be considered 
more esoteric, such as those pertaining to the attitudes and behaviours of staff 
members; these include adherence to surgical checklists,113 engagement with audits 
monitoring quality of care,114 and critical incident reporting rates.115   
There is a plethora of evidence demonstrating the association between healthcare 
structures and population outcomes. A retrospective analysis conducted by the 
American College of Surgeons (ACS) National Surgical Quality Improvement Program 
(NSQIP) examined the outcomes of over 180,000 surgical cases and found a significant 
increase in 30 day mortality for the population of patients who had their elective 
inpatient surgery performed on a Friday as opposed to those who were operated on 
between Monday and Wednesday. This difference was only evident in patients who 
were admitted post-operatively to general wards, rather than day-case patients or those 
admitted to critical care.116 These data imply that reduced staffing levels on general 
wards at the weekends are having an adverse effect on patient outcomes, a 
phenomenon which has previously been reported in patients admitted via emergency 
departments with a wide variety of medical conditions.117;118 By contrast, the 
maintenance of normal staffing levels at night and weekends on critical care wards may 
explain why patients admitted to ICU post-operatively have similar outcomes 
irrespective of the day of their surgery. This theory is supported by previous data 
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showing no association between the time of admission and the case mix-adjusted 
outcomes of unselected patients admitted to critical care,119 but a significantly higher 
mortality in patients discharged from critical care to normal wards at night.120 In the 
UK, the disruption to NHS organisational structure at the beginning of August, as a 
result of the changeover of junior hospital doctors (and possibly also the absence of 
senior medical staff due to the holiday season) has been shown to be associated with 
excess patient mortality, particularly for medical admissions (OR 1.08 for patients 
admitted on the first Wednesday in August, 95% CI 1.01 to 1.16, p = 0.03).121  
Further work conducted by the NSQIP revealed a significant difference in surgical 
mortality between institutions, despite a similar case-mix adjusted morbidity rate.122  
This ‘failure to rescue’, in hospitals with higher mortalities, is likely to be associated 
with structure related issues: for example, medical and nursing staffing levels may 
influence the timely recognition and management of patients with post-operative 
complications.  Indeed, in a follow-up study focussing only on patients who had 
undergone pancreatectomy, significant differences between high and low performing 
institutions were identified in nurse-patient ratios, bed occupancy rates, technology 
provision and hospital size.109   
In many respects, structural metrics are an attractive method of assessing quality of 
healthcare, as the reporting and recording of these measures may be easier than 
process and outcome measures. In the UK, the Department of Health (DH) has adopted a 
strategy of incentivising healthcare institutions by rewarding then financially for 
adherence to the ‘Commissioning for Quality and Innovation’ or ‘CQUIN’ framework 
which was introduced in 2008.123 There are a number of CQUIN indicators which are 
measures of structure, rather than process or outcome: for example, the indicator 
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related to preventing harm from venous thromboembolism (VTE). The National 
Institute for Clinical Excellence has issued guidelines on best practice related to 
preventing VTE. Consequent to this, a CQUIN payment was introduced nationally, the 
award of which is determined not by a measure of outcome (e.g. reduction in VTE rate) 
or even process (e.g. proportion of patients receiving appropriate VTE prophylaxis) but 
of structure (>90% of patients having a documented VTE risk assessment on admission 
to hospital). Other examples of CQUIN payments attached to structural changes include 
the implementation of enhanced recovery programmes,124 and the Institute for Health 
Improvement Global Trigger Tool.125 
The CQUIN targets are structure-related metrics of quality which are relatively easily 
within the influence of clinical and managerial leaders within individual institutions. 
There are however, a number of other structural elements which healthcare providers 
may not necessarily be able to address. A number of cross-sectional studies reveal a 
volume - outcome relationship in healthcare: that is, that the greater the number of 
patients that a particular surgeon, physician or institution manages, the better the 
outcome for the cohort.126;127 This has been demonstrated consistently and in a wide 
variety of surgical specialities and healthcare systems worldwide.128-131 While this may 
not seem surprising, longitudinal studies do not confirm a ‘practice makes perfect’ 
explanation for these observations, implying that there are intrinsic differences 
between high and low volume hospitals in terms of standards of care132;133  - hence their 
appeal as measures of quality. However, one must be cautious about writing off ‘low 
volume’ institutions as poor quality, or considering that ‘bigger is always better’:134 
there are examples of outlying providers in most studies, the magnitude of the volume-
outcome relationship varies widely depending on the procedure being considered, and 
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indeed the  association may not be clinically (or statistically) significant in some 
conditions.126 Despite these caveats, the volume – outcome relationship is a major 
driver for service reconfiguration in the NHS, even though most studies in this field have 
been conducted in the US;135 it is true, however, that there is an emerging literature in 
the UK.131;136-139 
The main advantage of using metrics related to structure in the evaluation of healthcare 
quality is simplicity. Many variables, such as procedural volume, staffing levels and bed 
occupancy are easily measured using administrative data. However, this must be 
balanced against a number of disadvantages. First, changing structure to improve 
quality is not always possible: for example, an NHS provider is unlikely to be able to 
transform itself into being a high-volume institution without the influence of regional 
service reconfiguration. Second, structural metrics may be subject to ‘gaming’; an 
example of this was demonstrate in the NHS when data revealed a disproportionately 
high number of patients were being admitted into hospital towards the end of a four 
hour wait in the Emergency department when this was set as a government target.140 
Third, as already stated, structural variables reflect average figures for large numbers of 
institutions, not individualised results for specific providers – hence the likelihood that 
there will be outliers in the provision of healthcare quality which may be unjustly 
criticised or rewarded if measured against structure-associated standards alone.  
1.5.3 Process 
 ‘Process’ is the care which patients actually receive, and is not limited to describing 
pharmacological or procedural interventions. In primary care, the Quality Outcomes 
Framework (QOF) has been used to reward strategies aimed at early disease detection 
(blood pressure monitoring), disease prevention (provision of smoking cessation advice 
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or influenza vaccination) or disease control (referral to secondary care for management 
of ischaemic heart disease). In perioperative care, process measures may include the 
proportions of surgical patients who attended preoperative assessment clinics, or are 
reviewed postoperatively by specialist pain teams, or who are normothermic at the end 
of their surgical procedure.141  
Process measurement has clear appeal as a driver of quality assessment and 
improvement.  An evidence-based approach is possible, by measuring compliance with 
interventions which have been shown to be effective in clinical studies. Examples of 
evidence based process measures which are used across the world include correct 
prescription of perioperative antibiotic and VTE prophylaxis, or the proportion of 
patients who undergo Caesarean section under general anaesthesia (GA) – a higher 
proportion is viewed as unsatisfactory.141 Importantly, changes in process are often 
more easily implemented than structural amendments:  ensuring that >90% of elective 
surgical patients are seen in an established preoperative assessment clinic (process 
measure) may be somewhat easier than finding the physical space, financial and 
personnel resources required to set such a service up in the first place (structure 
measure). Process measures may also be viewed as being a more useful or somehow 
‘fairer’ reflection of quality (the preoperative assessment clinic is only worthwhile if the 
majority of surgical patients who would benefit from it, are actually seen in it, rather 
than it being inefficient or dormant). 
However, there are also disadvantages with the process measurement approach. First, 
the denominator for measurement needs to be clear and accurate in order for fair 
assessment to be made. For example, if the GA Caesarean section rate is higher than 
expected in a particular maternity unit, might this not be because in the specific 
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circumstances of those individual patients, a GA section was the safest approach? 
Second, compliance with process measures does not ensure better patient outcome, 
even if the intervention has been shown to be of benefit in clinical studies. An example 
of this is the use of the oesophageal Doppler monitoring device for perioperative fluid 
management. Simply inserting a Doppler probe into a patient in all relevant cases 
(easily measured process variable), does not ensure that the device is used correctly (or 
indeed used at all) in order to optimise patients’ fluid status appropriately, and 
therefore reduce postoperative morbidity as the studies suggest it should.142-144  
1.6 Outcome measures after major surgery 
In this section, I shall discuss the various options for measuring surgical outcome. 
Outcome can be defined as ‘what happens to the patient as a result of their treatment’. 
In surgery, the most commonly measured outcome is mortality.  
1.6.1 Mortality 
Mortality has several advantages as a quality metric, including that it is a dichotomous 
variable which is objective, clinically important, and not subject to inter-observer 
variability. Nevertheless, there are a number of issues that may limit its use as an 
outcome measure, or at least argue for the concurrent recording of other outcomes. 
Interpretation of mortality as an outcome is highly dependent on the timeframe of 
measurement: in-patient, 28 or 30 day or 1 year mortality (or survival) are commonly 
reported definitions but are not reliably related to each other; therefore, it is 
scientifically unsatisfactory to compare the results of studies or audits in which 
different mortality definitions are used.  Inpatient mortality has the advantage that the 
data should be easier to collect, with loss to follow-up being an infrequent problem; 
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however, confounding may occur as a result of different criteria for patient discharge. In 
studies which take longer term mortality as their outcome (28 day or longer), loss to 
follow up post-hospital discharge may be a concern, as may the influence that the 
natural course of co-morbid diseases has on patient survival.   
Another important issue, both for the assessment of quality in surgical care, and for 
clinical trials interventions, is the incidence of mortality in perioperative patients. As 
surgical and anaesthetic techniques have improved over time, this is reflected in 
published audit data and in longitudinal studies using short term patient mortality as an 
outcome. 145-147  Studies looking at the influence of haemodynamic optimisation on 
perioperative outcomes frequently fail to show an improvement on perioperative 
mortality as a result of intervention, although they consistently show an improvement 
in morbidity and also resource utilisation measures such as hospital or intensive care 
unit length of stay.35;148-150 The failure of such studies to demonstrate improvement in 
hospital survival may, in part, be responsible for the previously poor uptake of 
optimisation strategies by perioperative physicians. However, accumulating evidence of 
an association between perioperative morbidity and long-term survival, suggests that 
mortality data relating only to the acute surgical admission may not fully reflect the 
healthcare impact of the surgical episode.151  
Analysis of over 105000 patients in the NSQIP database revealed that the occurrence of 
any one of 22 peri-operative complications reduced median life expectancy by 69%.151 
This impact of morbidity on long-term mortality was found to be independent of 
preoperative comorbidities (multivariable analysis with Cox Proportional Hazards 
modelling) and was still significant after deaths within 30 days were excluded from 
analysis. The extent to which morbidity affected long term survival was related both to 
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the seriousness of the adverse event and the type of operative procedure.  Nevertheless, 
even complications which may be considered to be relatively minor (such as urinary 
tract or wound infection) occurring after procedures that may be considered to be 
relatively benign (for example, laparoscopic cholecystectomy) were shown to be 
associated with reduction in long term survival. This study is the largest to link long- 
term outcome with perioperative events, and is supported by a growing body of 
evidence in heterogeneous surgical populations.152-156 While there is currently no 
mechanistic explanation for these findings, there seem two likely possibilities. The first, 
is that the methodology for risk adjustment is flawed, and that the patients who 
developed postoperative complications were ‘predestined’ to do so on the basis of prior 
ill-health, which may not be overt at the time of surgery. The second possible 
explanation is that residual effects on functional capacity or the persistence of an 
ongoing inflammatory process associated with a postoperative complication is 
responsible for long term adverse outcomes. Whether such an inflammatory response 
occurs as a result of the postoperative complication, or whether the complication occurs 
as a result of an already existing (and unidentified) pro- inflammatory state, is unclear. 
There are data from other studies which support this theory. For example, the 
development of an asymptomatic rise in cardiac troponin levels within seven days of 
vascular surgery is associated with reduced long term survival (p<0.0001; median 
follow up 4.3 years, 25th-75th percentile 2.8-5.3 years).157 The question of whether this 
troponin rise results from myocardial ischaemia, or myocardial inflammation, is being 
investigated currently in the international Vascular Events in Non Cardiac Surgery 
Patients Cohort Evaluation (VISION) study.158 
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A further observation relates back to the issue of when after surgery mortality should 
be recorded. Data from the NSQIP study described above suggest that most informative 
time to measure mortality may differ between surgical procedures.151 Survival curves 
for patients undergoing each of the 9 different surgical procedures analysed, and who 
incurred at least one postoperative complication, all show an ‘inflection point’ where 
the mortality rate appears to change and flatten out. One interpretation of the inflection 
point is that this is the time point when the true impact of the surgical episode ends. Of 
interest, this point varies hugely between surgical procedures (from 27 days for total 
hip replacement to 180 days for carotid endarterectomy) and for all procedures except 
for hip replacement, the inflection point occurs beyond 30 days postoperatively. This is 
notable because 30 day mortality is one of the most commonly used endpoints for 
measuring surgical outcome, both in clinical practice and research. Furthermore, these 
data again highlight the inadequacy of inpatient mortality as an endpoint for quality 
measurement or research purposes. It should be noted that these inflection points were 
derived by plotting survival curves only for patients who developed postoperative 
complications; although this was not explicitly discussed in Khuri’s paper.  
  
 49 
 
Figure 1: Survival curve of patients who developed complications within 30 days of 
colectomy, showing the ‘inflection point’ 
Inflection points (days) for 8 other procedures is tabulated at the top right of the graph. 
(Taken from Khuri et al: Determinants of long-term survival after major surgery and the 
adverse effect of postoperative complications. Ann.Surg. 2005; 242: 326-41) 
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1.6.2 Morbidity 
In general, clinical outcome measures may be classified as disease specific or 
generic.159;160 Perioperative morbidity may be considered to be a type of disease specific 
measure, where the ‘disease’ is undergoing major surgery, and ‘morbidity’ is defined as 
the occurrence of any clinically significant non-fatal complication. However, the 
literature is inconsistent in its definition and reporting of complications. Traditionally, 
postoperative morbidity has been classified as either local (relating to the operative 
site) and general (relating to other organ systems) or specific (relating to the particular 
operation) and general (relating to any type of operation).161;162 Morbidity may also be 
classified as early, intermediate or late, defined by arbitrary time-points.  However, the 
classification of adverse events by any of these methods has a number of difficulties. For 
example, there may be significant interaction between the occurrence of a local 
complication (for example, wound infection) and a general outcome (for example, 
pyrexia). There may also be difficulties in attribution: while post-operative 
gastrointestinal dysfunction or ileus may be considered as a specific consequence of 
gastro-intestinal (GI) surgery, it is also a common complication of non-GI surgery with a 
multi-factorial aetiology,163 and therefore it may also be considered as a general 
complication.  
1.6.3. Which complications matter? Organ specific morbidity 
1.6.3.1 Cardiac morbidity 
Considerable attention has been focussed on the incidence of adverse cardiac outcomes 
following surgery. Cardiac complication rates may be as high as 13.5% in vascular 
surgery, 164 and 12.9% after major abdominal surgery, 165 although studies vary in their 
definitions of cardiac outcome. Comprehensive guidelines have been issued both in the 
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US43 and in Europe,166 aimed at guiding clinicians in the detection and management of 
cardiac risk and morbidity in the perioperative period. The ACC/AHA guidelines 
recommend a stepwise approach to pre-operative investigation of cardiac disease, 
based on the presence of clinical risk factors, the patient’s functional capacity and the 
severity of the proposed surgical intervention.  It is suggested that clinical risk factors 
may be assessed using the Lee Revised Cardiac Risk Index (Lee RCRI), which is a widely 
validated and simple composite scoring system, looking at 5 risk factors for cardiac 
disease, and the risk of the proposed surgery.44  Functional capacity may be assessed 
using the Duke Activity Status Index, as previously discussed. However, once a patient is 
identified as being at high cardiac risk using these simple screening tools, there remains 
controversy over the choice of non-invasive test which will most reliably identify 
significant coronary artery disease. The ACC / AHA guidelines recommend that the 
choice of investigation be determined by local availability and expertise, as there is no 
clearly superior test.43  
Whichever investigation is undertaken, the key decision in this process is determining 
whether the test results will influence subsequent management: that is, whether the 
results will help to identify high risk patients who may benefit from specific pre- or 
perioperative management interventions, such as coronary revascularisation or beta-
blockade.167 Furthermore, even in the case of patients in whom significant coronary 
artery disease is identified, the evidence in favour of particular treatment strategies is 
subject to debate. In patients with stable one, two or three vessel disease, for example, 
recent randomized controlled trials suggest that outcome is not improved by 
prophylactic revascularisation.168;169 The optimal management strategy in patients in 
whom more significant cardiac impairment is identified (for example, left ventricular 
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dysfunction, unstable angina or aortic stenosis) is not yet clear.168;169  Similarly, recent 
data suggest that in many patients, the perioperative introduction of beta-blockade may 
be more harmful than beneficial.167 It is a core role of the perioperative team to weigh 
up the potential risks and benefits to an individual patient of embarking on a cardiac 
optimisation programme, which may involve either surgery, percutaneous intervention 
or pharmacological manipulation, and all of which may necessitate at least a 6 month 
delay to surgery with the inherent risk of disease progression, particularly in cancer 
patients. Central to this decision making, is the understanding that ischaemic heart 
disease per se, is less likely to impact on overall postoperative outcome than cardiac 
failure, which may lead to multi-organ dysfunction.170;171  
1.6.3.2 Neurological 
Postoperative neurological complications have a wide disease spectrum, and include 
delirium, Post-Operative Cognitive Dysfunction (POCD) and cerebrovascular events 
(transient ischaemic attack or cerebrovascular accident). Delirium is defined as an 
acutely altered and fluctuating mental status, including features of inattention and 
fluctuation in conscious level and may be diagnosed using the ‘Confusion Assessment 
Method’ tool (CAM, or CAM-ICU for use in Critical Care settings). Delirium should be 
distinguished from the more subtle POCD, in which an alteration in thought processes 
leads to disturbances of cognition which may include visual and verbal memory, 
attention and language comprehension. Delirium may affect between 0% and 78% of 
patients depending on the population characteristics,172 and may be predicted by pre-
existing cognitive impairment and advanced age amongst other factors.172-176 
Perioperative management, such as the use of tertiary ammonium compound anti-
cholinergic drugs (for example, atropine) may also put patients at risk of delirium.172   
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Delirium is associated with increased length of hospital stay and increased 
mortality.176;177 A large international prospective study of POCD after non-cardiac 
surgery, found the incidence to be over 25% at one week postoperatively (25.8%; 95% 
C.I. 23.1-28.5) and 9.9% (8.1-12.0) at 3 months.27 A follow-up study of a sub-group of 
Danish patients found reduced long-term survival (median follow-up time 8.5 years) in 
patients who had POCD at 3 months postoperatively (HR 1.63 [95% C.I., 1.11–2.38], 
adjusted for sex, age, and cancer).178  
1.6.3.3 Renal 
Acute kidney injury occurring after surgery is a leading cause of renal impairment for 
hospitalised patients.179 While the aetiology may be multifactorial, the mechanism is 
usually acute tubular necrosis (ATN) as a result of hypoxic injury to medullary 
nephrons, secondary to hypotension, hypoxemia or hypovolaemia.180 The risk factors 
for acute perioperative kidney injury include pre-existing renal dysfunction, cardiac 
failure and iatrogenic causes, particularly non-steroidal anti-inflammatory drugs and 
contrast used for radiological investigation.181 After cardiac interventions, the 
occurrence of acute kidney injury is associated with reduced long-term survival.182  
1.6.3.4 Gastrointestinal 
Postoperative gastrointestinal (GI) dysfunction is common and is associated with 
prolonged length of hospital stay.56;183 While GI complications are also multifactorial in 
aetiology, a significant contribution may come from gut ischaemia, which may be sub-
clinical and not necessarily associated with surgery where the bowel is handled. Gut 
perfusion may be critically affected by changes in volaemic status, and if ischaemia 
occurs, cell death and necrosis may ensue, leading to clinical manifestations such as 
nausea, vomiting and intolerance of enteral nutrition.184 Furthermore, gut ischaemia 
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may herald more widespread morbidity, leading to increased costs, length of stay and 
increased perioperative mortality. 22;185;186 In addition, neurally mediated dysfunction 
(activated either via central mechanisms or local release of neurotransmitters), opiate 
and surgically driven gut stasis, bacterial translocation and endotoxaemia all combine to 
bring about gut dysfunction which may lead to a postoperative inflammatory syndrome 
and multiple organ dysfunction or failure.163;185-187  
1.6.4 The case for using a generic measure of morbidity 
1.6.4.1 Overview  
While it is important to understand the risk factors and underlying mechanisms of 
postoperative dysfunction in individual organ systems, a different approach would be to 
consider post-operative morbidity as a ‘syndrome’, in a similar manner to how Multiple 
Organ Dysfunction Syndrome (MODS) or sepsis are described and now defined by 
specific scoring systems.188-190 A syndrome is defined as a pathological condition 
associated with a cluster of co-occurring symptoms, usually three or more.191 Also 
central to the definition of a syndrome is the existence of an underlying common 
pathological process. While each of the individual organ system dysfunctions described 
above may have particular risk factors (for example, renal impairment from contrast-
induced nephropathy), it is also true that the postoperative SIRS response is a common 
feature in their aetiologies. It may therefore also be argued that a composite measure of 
postoperative morbidity may be a useful tool in the description of perioperative 
outcome for the purposes of audit and studies of clinical effectiveness and prognosis.  
Furthermore, there is a need to report postoperative complications in a uniform 
manner, so enabling academic comparison between studies, and clinical comparison 
between teams and institutions. Systematic 192 and structured 193 reviews have found 
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lack of consistency of definition of morbidity, and therefore wide variation in reported 
incidence of complications after surgery. Furthermore, even when complications are 
defined using a recognised system, the level of training, and indeed engagement, of 
those collecting the data, have a major influence on the quality of reporting and 
recording of outcomes.194  
1.6.4.2 Clavien, Dindo & Strasberg: Severity grading of surgical complications 
Clavien and Dindo described their system for reporting surgical complications in 
2004,195 which was a revised version of an earlier grading system (sometimes known as 
T92) which Clavien had developed using a cohort of patients undergoing 
cholecystectomy, with another surgeon, Strasberg.196  
The 2004 Clavien-Dindo system very clearly attempts to quantify the severity of 
postoperative adverse events but does not attempt between types of complication (for 
example by organ system) or aetiology (for example infectious); nor does it appear to 
consider morbidity as an over-arching construct. It is a summary measure which is 
recorded at the end of the surgical episode for the purposes of later audit, and has also 
been used as an outcome measure in many published surgical studies. In 2009, the 
authors published a five year review of their system; this incorporated a literature 
search for citing papers, and some elements of a validation process, such as inter-rater 
reliability (they posed several clinical scenarios to multiple assessors in different 
continents and reported the answers) and face validity (by asking patients, nurses and 
doctors to record their perception of the severity of complications in these clinical 
scenarios on a visual analogue scale [VAS]).197 By that time, 214 papers had cited or 
used their classification system to grade postoperative complications. Inter-rater 
reliability was not formally (statistically) tested but was reported in narrative form to 
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be reasonable. Interestingly, while all three groups were able to distinguish the 
difference between grades of complications appropriately, patients’ quantification 
(using the VAS) of complication severity was consistently and significantly higher than 
that of doctors or nurses; in addition, nurses generally perceived complications as more 
serious than doctors.197 This observation raises some interesting questions about the 
communication of risk to patients, and importantly, their perception of outcome, both of 
which will be discussed later in this introduction.  
Table 2: Clavien-Dindo Classification of Postoperative Complications 
Grade Definition 
Grade I Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic or radiological interventions 
Allowed interventions include drugs as anti-emetics, antipyretics, analgesics, 
diuretics, electrolytes and physiotherapy. This grade also includes wound 
infections opened at the bedside.  
Grade II Requiring pharmacological treatment with drugs other than those allowed for 
Grade I complications 
Blood transfusions and Total Parenteral Nutrition (TPN)  also included 
Grade III Requiring surgical, endoscopic or radiological intervention 
Grade IIIA Intervention not under general anaesthesia 
Grade IIIB Intervention under general anaesthesia 
Grade IV Life threatening complications (including CNS complications) requiring critical 
care management 
Grade IVA Single organ dysfunction (including dialysis) 
Grade IVB Multi-organ dysfunction 
Grade V Death of a patient 
Suffix ‘d’ If the patient suffers from a complication at the time of discharge, the suffix ‘d’ 
(for disability) is added to the respective grade of complication. This label 
indicates the need for a follow-up to fully evaluate the complication 
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The Clavien-Dindo classification was reviewed by its developers as a reliable tool for 
grading the severity of surgical complications.197  However, a contrary view was taken 
in a paper published in the same edition of Annals of Surgery. 192 Clavien’s partner in the 
development of the original T92 severity scale, Strasberg, led a review of the literature 
looking for evidence of the accurate utilisation of the Clavien-Dindo classification. One 
of their key findings was that the number of complications reported in studies using the 
Clavien-Dindo system varied between three and 720.198 Their recommendation was to 
adapt the T92 and Clavien-Dindo classifications into a modified system known as the 
‘Accordion Grading System’ (see Tables 3, 4 and 5). The Accordion system is so named 
as it can contract and expand to suit the requirements of the study or clinical setting in 
which it is being used.   
Grade Description 
1. Mild Requires only minor invasive procedures that can be done at the bedside such 
as insertion of intravenous lines, urinary catheters, and nasogastric tubes, and 
drainage of wound infections. Physiotherapy and the following drugs are 
allowed: anti-emetics, antipyretics, analgesics, diuretics, electrolytes, and 
physiotherapy. 
2. Moderate Requires pharmacologic treatment with drugs other than such allowed for 
minor complications, for instance antibiotics. Blood transfusions and total 
parenteral nutrition are also included. 
3. Severe All complications requiring endoscopic or interventional radiologic procedures 
or re-operation as well as complications resulting in failure of one or more 
organ systems. 
4. Death Post-operative death 
 
Table 3:  Accordion Severity Classification of Postoperative complications – 
Contracted Classification 
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Grade Description 
1. Mild Requires only minor invasive procedures that can be done at the bedside such 
as insertion of intravenous lines, urinary catheters, and nasogastric tubes, and 
drainage of wound infections. Physiotherapy and the following drugs are 
allowed: anti-emetics, antipyretics, analgesics, diuretics, electrolytes, and 
physiotherapy. 
2. Moderate Requires pharmacologic treatment with drugs other than such allowed for 
minor complications, for instance antibiotics. Blood transfusions and total 
parenteral nutrition are also included. 
3. Severe Invasive procedure without General Anaesthesia: Requires management by an 
endoscopic, interventional procedure or re-operation* without general 
anaesthesia. 
4. Severe Operation under General Anaesthesia 
5. Severe Organ System Failure 
6. Death Post-operative death 
 
Table 4:  Accordion Severity Classification of Postoperative complications – 
Expanded Classification 
 
 
 
It can be seen that the contracted and expanded systems are based on the T92 and 
Clavien-Dindo classifications; the definitions of organ failure are based on the gradings 
used in the Sequential Organ Failure Assessment (SOFA) score used in Critical Care.  
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Organ system Description 
Cardiac Need for any of the following medications in the following doses 
Norepinephrine: >0.1 mcg. kg. min-1;  
Epinephrine: >0.1 mcg. kg. min-1 
Dopamine: >15 mcg. kg. min-1 
Central Nervous System Glasgow coma scale equal to or less than 6. 
Haematology Platelet count less than 20 _ 109/L 
Liver Need for FFP to correct INR in patient with serum bilirubin >12 
mg/dL; OR: 
INR >2.5 in patient with serum bilirubin >12 mg/dL  
Renal Need for dialysis in patient not on dialysis preoperatively 
Respiratory Need for mechanical ventilation for greater than 24 h in a 
patient who requires re-intubation after surgery; OR: 
Need for mechanical ventilation of greater than 72 h in a patient 
who is not extubated on the day of surgery.  
Does not include patients already on a mechanical ventilator for 
respiratory failure 
Table 5:  Definitions of Organ Failure for Accordion Severity Classification 
 
The 2009 papers were accompanied by an Editorial written jointly by Pierre Clavien 
and Steven Strasberg,199 where despite the conflict between their proposed systems, 
they agreed that surgeons should be involved in determining how to take these systems 
forward. An invitation was made for surgeons to comment on the two systems, with the 
aim of the authors reaching a consensus for publication within six to twelve months. To 
date (April 2013) no consensus has been published. One may deduce that surgeons and 
perioperative physicians in general have’ voted with their feet’: while Strasberg’s 2009 
Accordion Classification paper has been cited 20 times to date, Clavien’s five-year 
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review of the Clavien-Dindo system paper has been cited 88 times in the same 
timeframe; furthermore, the Clavien-Dindo system has been adopted as an outcome 
measure by the Safe Surgery Saves Lives study group which developed the World 
Health Organisation Safer Surgery Checklist,113 and a number of other highly publicised 
initiatives which have led to widely accessed papers. However, it remains the case that 
none of these systems have undergone a formal development and validation process, 
using clinimetric and / or psychometric strategies.200  
1.6.4.3 The National Surgical Quality Improvement System Classification  
While the T92, Clavien-Dindo and Accordion classifications all deal with grading the 
severity of complications, there is also a clinical and academic need to be able to define 
the type of complications that patients endure. The National Surgical Quality 
Improvement Program (NSQIP) have developed their own system for classifying 
complications201 which has also been adopted by the Safe Surgery Saves Lives 
campaign.113  An example of the NSQIP complications classification is shown in Table 6, 
taken from a paper published in 2005. 
The data presented in Chapter 2 of this thesis show that there are subtle differences in 
the definitions of morbidity between NSQIP papers; however, broadly speaking, they 
have kept to this classification since 1995. No formal development or validation process 
has been published for this system. 
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System Description 
Cardiovascular Cardiac arrest requiring cardiopulmonary resuscitation, myocardial 
infarction, pulmonary oedema 
Respiratory Pneumonia, unplanned intubations, pulmonary embolism, failure to wean 
from the ventilator >48h post-op 
Gastrointestinal  Prolonged ileus 
Renal Progressive renal insufficiency, renal failure requiring dialysis, urinary 
tract infection 
Neurological Cerebrovascular accident (stroke), coma persisting more than 24 hours 
postoperatively, other neurologic deficits 
Infectious Sepsis 
Wound Superficial and deep wound infections, wound dehiscence 
Thrombosis  Deep vein thrombophlebitis 
Other Bleeding requiring  >4 U RBC transfusion, graft or prosthesis failure 
Table 6:  NSQIP definitions of postoperative complications taken from  
Alvord et al, 2005. 202 
 
 
1.6.4.4 The Post-Operative Morbidity Survey  
The Post-Operative Morbidity Survey (POMS) was developed in the United States as a 
composite measure of clinically significant short-term postoperative harm,183 and has 
been validated for this purpose in orthopaedic, general and urological surgical patients 
in the UK.56 It classifies post-operative morbidity into nine domains; these were derived 
on the basis of being complications of a type and severity that would delay hospital 
discharge,183 and could be defined by data that would be easy to collect and subject to 
minimal inter-observer variability.56 The POMS is being used increasingly in clinical 
effectiveness studies,165 and has been adapted for use in cardiac surgery.203  The 
original POMS was not validated for use as a cumulative score, as it lacked the necessary 
internal consistency between domains for such use.56  However, the C-POMS has been 
found to be valid as a score, with internal consistency of 0.7 (Cronbach’s alpha) on days 
5, 8 and 15 postoperatively; in addition, construct validity was demonstrated by a step-
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wise rise in subsequent length of stay for each additional POMS domain on each of the 
postoperative days of measurement.203  As this thesis is focussed on major non-cardiac 
surgery, the C-POMS will not be discussed further.  
There are potential disadvantages of the POMS. The use of administered treatments (for 
example, antibiotics and parenteral opioids) as morbidity-defining criteria poses 
difficulties when using POMS to compare outcomes between different care providers. 
Enhanced recovery programmes, for example, encourage clinicians to limit parenteral 
opioid use; it may therefore be argued that direct comparison between two surgical 
teams, one who has implemented enhanced recovery protocols, and one who has not, 
may be inappropriate using the POMS. In addition, provision of ‘as required’ medication 
may be seen as an indication of good quality care; so a patient on one ward who is left in 
pain and who might have benefitted from parenteral opioids will be recorded as 
morbidity-free on the pain domain whereas a patient on a ‘better’ ward who is 
administered appropriate analgesia will be recorded as POMS positive. Finally, while 
the validation study demonstrated high inter-rater reliability, it is possible that this was 
because the data were collected by two dedicated research nurses: these nurses were 
highly trained, and it is therefore possible that without this training – and the resources 
required to implement this – that the reliability of the survey may be jeopardised. 
However, this potential problem is not limited to the POMS. In a study conducted in 
their own institution, Clavien and Dindo found that the quality of recording of 
complications according to their 2004 system was extremely poor when conducted by 
surgical residents (compared with the ‘gold standard’ of research nurses), even after the 
residents received training in how to collect the data. 194 Lack of motivation and lack of 
time are cited as likely reasons for this observation. The use of trained dedicated 
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nursing staff is therefore advocated; the NSQIP has made the required investment to 
adopt this approach. 
Morbidity Type Criteria 
Pulmonary New requirement for oxygen or respiratory support 
Infectious Currently on antibiotics and / or has developed a temperature of 
>/= 38oC in past 24 hours 
Renal Presence of oliguria (<500ml urine /24 hours) 
Increased serum creatinine (>30% from pre-operative level) 
Urinary Catheter in situ 
Gastrointestinal Unable to tolerate enteral diet for any reason including nausea, 
vomiting and abdominal distension 
Use of anti-emetic 
Cardiovascular Diagnostic tests and /or treatment for any of the following in the 
past 24 hours: 
New myocardial infarction or ischaemia 
Hypotension (requiring fluid therapy >200ml/h or pharmacological 
therapy) 
Atrial or ventricular arrhythmias 
Cardiogenic pulmonary oedema 
Thrombotic event requiring anticoagulation 
Neurological New focal neurological deficit, confusion, delirium or coma 
Haematological Requirement for any of the following within the past 24 hours 
Packed erythrocytes; Fresh frozen plasma; Cryoprecipitate 
Wound Wound dehiscence requiring surgical exploration or drainage of 
pus from the operation wound with or without isolation of 
organisms 
Pain New post-operative pain significant enough to require parenteral 
opioids or regional analgesia 
Table 7: The Post-Operative Morbidity Survey (POMS) 
 
Despite these caveats, the POMS has a number of advantages as an outcome measure. 
Unlike other previously mentioned systems for reporting surgical outcome, the POMS 
has been robustly scientifically validated, which in itself is important and supports its 
use both as an audit and quality improvement tool, and as an outcome measure in 
clinical studies. The validation study showed that the POMS was acceptable to patients, 
had acceptably low inter-observer variability and demonstrated construct validity, as 
the POMS was shown to discriminate between patients at different risk levels, and also 
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to predict postoperative length of stay.56 Face validity was also achieved, in part by 
using simple objective criteria to define morbidity within each domain. The use of 
therapeutic interventions as criteria to define morbidity also has a number of 
advantages, despite the concerns raised above: namely high inter-rater reliability and 
face validity. While accepting that training may be required to ensure accurate data 
acquisition, the high inter-rater reliability reported is particularly important given the 
potential uses of a postoperative morbidity measure – namely, as an outcome measure 
in clinical effectiveness studies, for the purposes of comparative audit between teams 
and institutions, and to guide clinical decision making.  
Experience at the Surgical Outcomes Research Centre (SOuRCe) has shown that while 
the POMS is a useful and valid measure of postoperative harm, some Trusts may not be 
able to provide the financial resources (personnel) required to implement it on four 
postoperative days.  In addition, even in clinical trials, for the purpose of power 
calculations and clarity of results to the reader, there may be benefit to naming a single 
postoperative day on which to focus for POMS defined outcome. The original 1999 
POMS development paper183 has been cited 83 times and the 2007 validation paper56 27 
times. On reviewing these citations, 11 studies using original data were found which 
had used the POMS as an outcome measure in the form it was originally developed; 
these are listed in Table 8. (There are more studies which have used the POMS but 
which are either analyses of the same data as presented in previous papers,55 or have 
significantly modified it).204 It is clear from this brief evidence synthesis, that there is 
disparity between studies in the endpoints at which POMS is measured, and it would be 
beneficial to have clear guidance to offer future investigators.  
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Lead Author Publication year Study Design POMS days recorded 
Bennett-Guerrero24 2001 Interventional 11 
LeBuffe205 2004 Observational 2, 8 
Ackland206 2007 Observational 3, 5, 8, 15 
Scollay207 2009 Observational  5, 8, 15 
Snowden165 2010 Interventional 7 
Ackland41 2010 Observational  3, 5 8, 15 
Davies208 2011 Interventional  5 
Phypers209 2011 Interventional 5 
Hennis210 2012 Observational 5 
Ausania211 2012 Observational Throughout hospital stay 
Junejo212 2012 Observational Throughout hospital stay 
Table 8: Published papers using the Post Operative Morbidity Survey 
 
The POMS is an outcome measure in several major perioperative medicine studies 
currently underway in the UK. (UKCRN IDs 4187, 8132, 6307, 9750, 10526 and 10666; 
see http://public.ukcrn.org.uk/search/)  
 
1.6.5 Patient Reported Outcome Measures (PROMS) 
Patient reported outcome measures (PROMs) are questionnaires which are completed 
by patients and measure health status or health related quality of life (HRQOL). PROMs 
are measured before and after a clinical intervention so as to measure the change in the 
patient’s health status or HRQOL as a result of the intervention. PROMs may be disease- 
specific or generic and a large number of these tools have been developed and validated 
in different surgical cohorts. Generic questionnaires such as the Short Form -36 (SF-36) 
and EuroQOL (EQ-5D) are designed to reflect quality of life and may be particularly 
useful when assessing outcome in types of surgery which are principally aimed at 
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improving symptoms, such as joint replacements.213 Disease-specific PROMs such as the 
Oxford Hip and Knee Scores, aim to assess patient health status, and demonstrate 
improved responsiveness in the detection of treatment effects when compared to 
generic measures.214  Rasch analysis is a ‘goodness of fit’ estimation which may be used 
to evaluate instruments such as PROMs.215   
In general terms, there are a number of biases which limit the usefulness of PROMs for 
comparative audit or in clinical effectiveness studies. For example, experiences that 
patients may report as complications may be viewed as ‘normal’ or ‘expected’ by 
physicians (for example wound pain); and process issues such as the mode of 
administration of the questionnaire (e.g. telephone versus mailing) may affect the 
responses that patients give.216 It is issues such as these which may explain why 
feedback from PROMs to clinicians and managers has been shown to significantly 
influence process in healthcare, but has limited impact on patient health status. 217 
Equally however, it may be that PROMs are being used inappropriately as a result of a 
lack of knowledge and experience of the healthcare providers who are implementing 
them. 217    
Despite these reservations, the implementation of PROMs was a key recommendation of 
Lord Darzi’s 2008 report ‘High Quality Care for All’ in the United Kingdom.218 The 
mandatory use of PROMs as a measure of outcome throughout the National Health 
Service has now been implemented for four operations, all of which are aimed at 
improving symptoms as opposed to saving or prolonging life: these are total hip 
replacement, total knee replacement, varicose vein repair and inguinal hernia repair.   
Healthcare providers are incentivised to participate, as higher rates of data completion 
are rewarded with a reduction in NHS Litigation Authority (NHSLA) tariff payments.  
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Figure 2: Change in Health Related Quality of Life (EQ5D score); 2009-10  
(from Appleby ; BMJ 2011;343:d8191) 
 
Figure 3: Changes in case-mix adjusted health related quality of life (EQ5D): independent 
and NHS providers (2009-10)  
(from Appleby ; BMJ 2011;343:d8191) 
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The UK PROMS programme is now in its fourth year and interesting trends are apparent 
when examining the results. Taken at face value, outcomes after hernia and varicose 
vein repairs appear to be less beneficial to the overall patient population than joint 
replacements (see Figure 2). Independent sector hospitals also appear to be achieving 
better patient outcomes than some NHS providers (see figure 3). However, behind these 
figures are a number of confounding factors. First, there may be legitimate concerns 
raised over the case-mix adjustment methodology. Case-mix (or risk) adjustment is by 
linkage with Hospital Episode Statistics (HES) data; linkage rates vary between 75% for 
hernia repairs to 85% for hip replacements.219 Adjustment is made for age, gender, 
socioeconomic status, general health status (preoperatively), whether the operation is a 
primary or revision procedure, and HES defined comorbidities. Concerns have been 
raised over the quality of administrative data in the UK, and the use of such data for 
risk-adjustment;220;221 however, other researchers have devised complex models which 
have similar predictive precision to models using clinical data.222 Second, there is 
evidence of response bias.  Non-responders tend to be male, younger (under the age of 
55 years), of non-white ethnicity, from the lowest quintile of social deprivation, live 
alone, require assistance with questionnaire completion and have more 
comorbidities.219 There is also evidence of bias in terms of equity of use and patient 
reported outcome: patients who have more severe disease at the time of surgery and / 
or have had symptoms for longer, again tend to be from more deprived or ethnic 
minority (predominantly black) backgrounds.219 All of these biases require 
consideration when interpreting data which appear to show higher improvements in 
patient reported outcomes in independent sector hospitals than NHS Trusts.    
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Some parts of the medical profession have expressed concern at the interpretation of 
PROMs data by the government and Department of Health, and alarm bells have been 
raised, particularly given the financial difficulty in which the NHS finds itself at the 
moment. Selective reporting of generic PROMs data, rather than disease specific for 
patients undergoing joint replacements has infuriated the British Orthopaedic 
Association, as unsurprisingly, generic PROMs show less improvement than the Oxford 
Hip and Knee scores, and the surgeons are concerned that these data will be used to 
rationalise healthcare spending.223 Further alarm was raised by comments made by the 
Secretary of State for Health, Andrew Lansley, suggesting that in half of patients 
undergoing knee surgery, neither pain nor mobility was substantially improved.224 
Later clarification by the Department of Health seemed to suggest that his comments 
were based on generic PROMs outcome data: “The latest data from the NHS shows that 
only half of patients report any improvement in their health after a knee operation....”224 
The counter argument to the orthopaedic surgeons’ perspective, is that if the patient’s 
general quality of life does not improve (or even deteriorates) after an operation aimed 
at improving quality of life, can the surgery really be viewed as a success, either by the 
patient, the surgeon or the wider healthcare system? While the surgical profession may 
be focussed on specific outcomes, perhaps the patient and the NHS are rightly more 
concerned with generic? A similar analogy may be drawn when considering clinical 
effectiveness studies which use disease-specific mortality rates and all-cause mortality 
rates as separate outcome measures. While the difference between these two might be 
of academic interest and importance to clinicians, it is likely that patients are less 
concerned with the detail of which treatment might lead to which cause of death or 
morbidity: avoiding all-cause death and morbidity is likely to be the main focus. The 
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sour old joke ‘The operation was a success but the patient died” satirises this 
eloquently.  Understanding, what the patient thinks is important, and keeping this 
foremost in one’s thinking, is key to this area. Using data responsibly, and 
understanding its limits, particularly with relatively new outcome measures such as 
PROMs, is also paramount. The PROMs programme in the UK continues to expand, with 
pilot studies currently on-going in coronary artery bypass surgery and in various long-
term medical conditions.  
1.6.6 Patient satisfaction  
The NHS increasingly focuses on patient satisfaction and patient experience as 
measures of the quality of healthcare provision.218 The NHS Inpatient Survey is a 
measure of patient experience, which is conducted in every NHS Trust on an annual 
basis, and the results of which form part of the Care Quality Commission’s assessment 
process. Patient experience measures focus on the patient’s experience of the care 
environment: for example, staff attitudes, ward cleanliness, efficiency of transit through 
the hospital and so on. Patient satisfaction is a complex concept, and may encompass 
elements of both patient experience and patient reported outcome. The role of 
expectations, and the balance between these expectations and outcomes are key 
determinants of satisfaction for individual patients.225 Determinants of patient 
satisfaction include ‘patient related factors’ (for example age, gender, ethnicity), 
‘provider care’ (interactions with staff) and ‘processes of care’ (efficiency of transit 
through the hospital). Although it seems instinctive to believe that the competence of 
the provider is fundamental in the quality of care the patient receives, and therefore the 
patient’s subsequent satisfaction, this is not always the case, as patients can find this a 
difficult concept to grasp.226  
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Given the complexity of the concept, it is clear that validated, psychometrically 
developed measures of patient satisfaction should be used to measure this outcome 
both in clinical practice and in research studies. However, a systematic review of the 
anaesthesia literature which I led, found that despite patient satisfaction being 
measured as an outcome in over 3000 published studies, fewer than 10% of these used 
a validated psychometrically developed instrument: most simply posed the question: 
‘are you satisfied?’.227 Despite this, we also identified over thirty psychometrically 
developed and validated instruments which could be used to measure patient 
satisfaction with anaesthesia in a variety of clinical settings, including after the 
preoperative assessment process, during the perioperative period, in the maternity 
suite and in paediatric patients. We hope that this evidence synthesis will to help to 
guide future researchers and clinicians in their choice of instrument to use, so that the 
results of patient satisfaction surveys can be reliably and confidently used to measure 
and compare outcomes, and to improve quality of care.   
1.6.7. Surrogate outcome measures 
Structure and process measures have already been mentioned as potential indicators 
for the quality of patient care. In addition to these, surrogate outcome measures are 
used widely particularly in primary and secondary medical care.  Surrogate outcome 
measures have be defined by the US Institute of Medicine as “biomarker[s] intended to 
substitute for a clinical endpoint [and] expected to predict clinical benefit (or harm . . .) 
based on epidemiologic, therapeutic, pathophysiological, or other scientific evidence.”228  
The dominance of surrogate outcome measures in diabetes mellitus care was 
highlighted in a recent review, and the pitfalls of this approach discussed.229 For 
example, glycosylated haemoglobin (HbA1C) is used as a surrogate for glycaemic 
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control in the management of diabetes. However, two major concerns arise from this. 
First, HbA1C level may not truly reflect glycaemic control in patients with big swings of 
blood glucose level.230  Secondly, as an outcome measure HbA1C is of little relevance to 
patients, compared with for example, renal failure, blindness and amputation which 
may all occur as a result of poor diabetic control.  
Surrogates for morbidity and patient satisfaction are regularly used in the perioperative 
literature. Opioid consumption231 and blood transfusion rates232 are both examples of 
surrogate outcomes which have been used in clinical studies, but usually as secondary 
end-points, with primary outcomes of greater clinical importance (that is, morbidity or 
mortality). Surrogates in the perioperative field, as with general medicine, have some 
appeal as they are often more easily measured, and the results are usually available 
more quickly than true outcome measures. However, the relationship between 
surrogates and measures of true clinical outcome which are important to patients and 
doctors alike, is not always clear, and therefore surrogate outcomes should be carefully 
considered before acting on them. 233  
1.6.8 Resource utilisation measures 
Length of inpatient or critical care stay, are measures which are sometimes used as 
surrogates of postoperative recovery and therefore clinical outcome; however, the 
validity of using such measures for this purpose is limited for a number of reasons. First, 
there are inherent assumptions made when using length of stay as a surrogate of clinical 
outcome: namely, that every patient is discharged from hospital or critical care at the 
same level of ‘fitness’, and that their discharge is not affected by factors unrelated to 
physiological status (such as provision of social services or availability of ward beds). 
Such assumptions may lead to both intra- and inter- institutional bias, as non-clinical 
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issues affecting length of stay will vary between and within institutions depending on 
factors such as the provision of convalescent facilities and the patient’s own social 
support network. Rates of readmission to hospital or critical care are also used as 
surrogates of clinical outcome and are similarly subject to confounding, as the clinical 
threshold for admission and discharge will also vary between services.  
Even as a measure of resource utilisation alone, length of stay is of limited validity, as 
there are different costs associated with different levels of intensity of treatment (such 
as critical care versus ward care). Furthermore, using hospital length of stay as a 
resource utilisation measure, assumes that the cost of treatment is consistent 
throughout the patient episode. This approach is unlikely to accurately reflect the true 
cost: for example, the cost of patient care on the first day post-operatively is likely to be 
much higher than the cost on the day before discharge. Finally, the actual cost of a 
hospital episode will differ between healthcare systems based on the method by which 
hospitals charge for their services. Despite these limitations, length of stay (both 
hospital and critical care) continues to be a widely used outcome measure in clinical 
effectiveness studies, predominantly because of the ease of measurement and the lack 
of inter-observer variability in recording. 
1.6.9. Patient – centred outcomes 
Patient centred care is a buzz phrase of the 21st century NHS. The US Institute of 
Medicine defined patient centred care as: “Healthcare that establishes a partnership 
among practitioners, patients, and their families (when appropriate) to ensure that 
decisions respect patients' wants, needs, and preferences and that patients have the 
education and support they need to make decisions and participate in their own care.” 234 
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A central tenet of delivering patient centred care must be to ensure that we measure 
patient-centred outcomes, so that the quality of the care provided can be reported in a 
way that is both meaningful and important to patients. However, while the principle 
seems obvious, the implementation may be problematic. Which outcomes matter will 
vary between patients, procedures, clinical and sociodemographic settings.  For 
example, the relative importance of particular outcomes is likely to differ widely 
between patients having potentially life-saving cancer surgery (but which might leave 
the patient with a stoma) and a patient having cosmetic surgery or a varicose vein 
repair. These variances are merely the tip of the iceberg: the situation is further 
complicated by the potential conflict between which outcomes are considered 
important by the various members of the perioperative team, and what elements of 
‘quality care’ each of these outcomes represent. For example, the surgeon may want a 
safe (safety) fast (efficiency) anaesthetist who never cancels operations (??efficiency); 
the patient wants a safe (safety), kind (patient experience) anaesthetist who will 
alleviate their pain and suffering (patient satisfaction /patient experience). Novel 
methods of reporting outcome data are emerging which aim to consider and resolve 
some of these conflicts,235 but there remains a fundamental problem with precise risk 
adjustment, robust and accurate outcome data collection,  and providing feedback to 
clinicians in a timely manner. One might assume that all members of the extended 
surgical team (including the patients) want to know morbidity and mortality data, 
although we know that these are not necessarily routinely reported or even recorded.  
 
It is common sense that patients would wish to have efficient, safe, clinically effective 
care delivered to them by courteous and kind staff who communicate well, all of which 
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will leave them feeling satisfied with their experience – the central principles of quality 
in healthcare.218 Moving beyond these basic principles, it is also likely that patients are 
interested in knowing the chances of ‘success’, how long they are likely to stay in 
hospital or be off work, the risk of complications, and the risk of death within a 
meaningful timeframe from their surgery. How we communicate these data to the 
patients is another area worthy of lengthy discussion, but beyond the scope of this 
thesis.  
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1.7 Summary: The importance of predicting risk and measuring 
outcome 
Perioperative morbidity and mortality are significant public health issues.  
Accurate risk prediction is a fundamental component of individualised patient-centred 
care, as it enables the perioperative pathway to be appropriately planned, and perhaps 
most importantly, it provides information required for high quality informed patient 
consent. Despite the recommendations of numerous reports, published evidence and 
clinical experience both suggest that perioperative risk stratification is poorly 
understood and implemented. 
Routine, systematic outcome measurement is required to be able to measure the quality 
of healthcare, understand the relationship between risk and outcome, and to improve 
the quality of healthcare delivery. Risk adjustment of clinical data is required to 
meaningfully compare outcomes between teams and institutions, and to measure 
changes in performance over time. In the UK, the reporting of surgical outcomes is non-
uniform and sporadic, and this is in part due to the lack of a national reporting system in 
the UK, and a lack of understanding of the types of complications which occur after 
surgery, and their short and long-term implications.  
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1.8 Aim of this Thesis 
The aim of this thesis is to advance the understanding of the available risk stratification 
tools for perioperative morbidity and mortality, and the relationship between patient 
risk factors, short-term and longer-term surgical outcomes. 
The first study is an evidence synthesis: a systematic review of validation studies of risk 
stratification tools in heterogeneous cohorts of surgical patients. This summarises the 
reported accuracy of the available measures, and makes recommendations for which 
tools are most appropriate for use in the UK.  
The predictive accuracy and calibration of several of the risk stratification tools 
evaluated in the systematic review are then tested in a cohort of patients who 
underwent elective major non-cardiac non-neurosurgical procedures at the Middlesex 
Hospital between 2001 and 2005.  
The epidemiology of short and long-term outcomes in this cohort of patients is then 
described, using the Post Operative Morbidity Survey as an objective validated measure 
of postoperative outcome, and mortality at several time-points.  
Finally, a multivariable analysis of the relationship between perioperative risk, 
inpatient morbidity and long-term survival in this cohort of patients is presented, with 
discussion on the implications of these findings.  
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Chapter Two: Risk stratification tools 
for predicting morbidity and mortality 
in adult patients undergoing major 
surgery: qualitative systematic review 
2.1 Introduction 
Accurate prediction of perioperative risk is an important goal – to enable informed 
consent for patients undergoing surgery and to guide clinical decision-making in the 
perioperative period. In addition, by adjusting for risk, an accurate risk stratification 
tool enables meaningful comparison of surgical outcomes between providers for the 
purposes of service evaluation or clinical audit. Some risk stratification tools have been 
incorporated into clinical practice, and indeed, have been recommended for these 
purposes. 236 237   
Risk stratification tools may be sub-divided into risk scores and risk prediction models.  
Both are usually developed using multivariable analysis of risk factors for a specific 
outcome.238 Risk scores assign a weighting to factors identified as independent 
predictors of an outcome, with the weighting for each factor often determined by the 
value of the regression coefficient in the multivariable analysis.  The sum of the 
weightings in the risk score then reflects increasing risk.  Risk scores have the 
advantage that they are simple to use in the clinical setting. However, while they may 
score a patient on a scale on which other patients may be compared, they do not 
provide an individualised risk prediction of an adverse outcome.239 Examples of risk 
scores are the American Society of Anesthesiologists’ Physical Status score (ASA-PSS)62 
and the Lee Revised Cardiac Risk Index (RCRI).44  
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By contrast, risk prediction models estimate an individual probability of risk for a 
patient by entering the patient’s data into the multivariable risk prediction model.  
While risk prediction models may be more accurate predictors of an individual patient’s 
risk than risk scores, they are more complex to use in the day-to-day clinical setting.  
Despite increasing interest in more sophisticated risk prediction methods, such as the 
measurement of functional capacity by exercise testing,240 risk stratification tools 
remain the most readily accessible option for this purpose. However, clinical experience 
tells us that they are not commonly used in everyday practice.237;241 Lack of use may be 
due to poor awareness amongst clinicians of the available options, and concerns 
regarding their complexity and accuracy.242 In other clinical settings, low uptake of risk 
stratification tools has been ascribed to a lack of clarity on the precision of available 
tools, resulting from perhaps unnecessary efforts to make minor refinements to existing 
methods, or to developing novel methods, with the aim of achieving greater predictive 
accuracy. 243 
Thus the focus of this chapter is an evidence synthesis of the available risk stratification 
tools in perioperative care, in order to make recommendations about which methods 
are appropriate for use both in clinical practice and in research. 
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2.1.2 Aim and objectives 
2.1.2.1 Aim 
To conduct a qualitative systematic review of the available evidence to answer the 
following specific question: ‘What is the performance of risk stratification tools, 
validated for morbidity and/or mortality, in heterogeneous cohort of surgical (non-
cardiac, non-neurological) patients?’   
2.1.2.2 Objectives: 
1.  To summarize the available risk prediction methods 
2. To report on their performance (discrimination and calibration) 
3. To comment on their strengths and weaknesses, with particular focus on 
accuracy and ease of application. 
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2.2 Methods 
Previously published standards for reporting systematic reviews of observational 
studies were adhered to when undertaking this study.244  
2.2.1 Definitions for the purposes of this study 
A ‘risk stratification tool’ was defined as a scoring system or model used to predict or 
adjust for either mortality or morbidity after surgery, and which contained at least two 
different risk factors.  ‘Major surgery’ was defined as a procedure taking place in an 
operating theatre and conducted by a surgeon; thus, studies of cohorts of patients 
undergoing endoscopic, angiographic, dental, and interventional radiological 
procedures were excluded. A ‘heterogeneous patient cohort’ was defined as a cohort of 
patients including at least two different surgical specialities. Studies of gastrointestinal 
surgery, which included hepatobiliary surgery, were included. We excluded studies that 
consisted entirely of cohorts undergoing ambulatory (day case) surgery, and cohorts 
that included cardiac or neurological surgery.  
2.2.2 Search strategy and study eligibility 
A search for papers published between 1 January 1980 and 6 August 2011 was 
undertaken using Medline, Embase and ISI Web of Science. No language restriction was 
applied. The search strategy, and inclusion / exclusion criteria are detailed in Appendix 
1. Of note, papers reporting development studies were excluded, unless the paper 
included validation in a separate cohort.  
2.2.3 Data extraction and quality assessment of studies 
Data extraction was undertaken using standardised tables relating to the study 
characteristics, quality and outcomes. Study characteristics extracted from each paper 
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included the number of patients, the country where the study was conducted, the 
outcome measures and end-points of each study, and the risk stratification tools being 
assessed. Data were also extracted regarding the most detailed description of the types 
of surgery included in each study cohort reported in the manuscripts. Clinical outcome 
data (morbidity and mortality) for the cohorts in each study were also extracted from 
the manuscripts.  
Assessment of study quality was based on the framework for assessing the internal 
validity of articles dealing with prognosis developed by Altman.245;246  The following 
criteria were used: the number of patients included in analyses; whether the study was 
conducted on a single or multiple sites; the timing of data collection (prospective vs. 
retrospective); whether a description of baseline characteristics for the cohort was 
included (including comorbidities, type of surgery and demographic data); and selection 
criteria for patients included in the study (to assess for selection bias). Selection bias 
was judged to be present if a study restricted the type of patient who could be enrolled 
based on age, ethnicity, gender, premorbid condition, urgency of surgery or post-
operative destination (e.g. critical care). In addition, the setting of each validation study 
was recorded–that is, whether the validation was internal (that is, conducted in a split 
sample of the original development cohort), temporal (conducted in the same 
institution(s) as the development study but in a later cohort of patients) or external 
(that is, that the validation cohort was entirely different to that in which the tool was 
developed).247 Finally, as a measure of the clinical usability and reproducibility of each 
risk stratification tool, an assessment was made of whether each tool used variables 
which were objective (for example blood results), subjective (for example chest 
radiograph interpretation) or both.248  
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2.2.4 Data analysis and statistical considerations 
The performance of each risk stratification tool was evaluated using measures of 
discrimination and, where appropriate, calibration. Discrimination (how well a model 
or score correctly identifies a particular outcome) was reported using either the area 
under the receiver operator curve (AUROC) or the concordance (c-) statistic. An AUROC 
or c-statistic of < 0.7 was to taken to indicate poor performance, 0.7-0.9 to be moderate, 
and >0.9 to reflect high performance.249 Calibration is defined as how well the 
prognostic estimation of a model matches the probability of the event of interest across 
the full range of outcomes in the population being studied. Where reported, either 
Hosmer-Lemeshow or Pearson chi-squared statistics were extracted as an evaluation of 
calibration; p>0.05 was taken to indicate that there was no evidence of lack-of-fit.  
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2.3 Results 
2.3.1 Search results  
139,775 articles on Medline and 71,841 on Embase were listed in the initial search and 
the titles and abstracts of these were screened to identify articles which described risk 
stratification tools used in any adult non-cardiac, non-neurological surgery. 751 articles 
then underwent manuscript review. Hand searching of reference lists and citations 
identified a further 432 studies which were also reviewed in detail.  
Three studies were identified which graphically displayed ROC curves in their results 
but did not report AUROCs.38;250;251 The authors of these studies were contacted for 
additional information; none responded so these studies were excluded from the 
analysis. Six foreign language studies which may have been eligible for inclusion based 
on review of the abstracts, but for which we were unable to obtain translations, were 
also omitted from the analysis.252-257 The flow chart for the review is detailed in Figure 
4.  
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Figure 4: Flow diagram for the systematic review 
 
  
210865 excluded on review of titles and 
abstracts as not relevant to perioperative 
risk prediction   
Medline search = 139,775 
Embase search = 71,841 
Total papers screened = 211,616  
432 extra papers identified on hand-
searching of citation and reference 
lists 
27 papers included in final review 
6 foreign language papers excluded as 
unable to obtain full manuscripts for 
translation  
3 papers with diagrammatic 
representation of ROC curves, but no 
numerical AUROC published; all authors 
contacted 
1147 excluded on basis of listed 
inclusion / exclusion criteria 
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A total of 27 studies, evaluating 34 risk stratification tools were included in the analysis. 
All were cohort studies. Eight tools were validated in multiple studies; the most 
commonly reported were the American Society of Anesthesiologists’ Physical Status 
Score62 (ASA-PS) (4 studies, total number of patients, n =4014), the Acute Physiology 
and Chronic Health Evaluation II  scoring system,258 (APACHE II) (4 studies, n=5897) 
the Physiological and Operative Score for the enUmeration of Mortality and Morbidity 38 
(POSSUM) (3 studies, n=2915); the Portsmouth variation of POSSUM259 (P-POSSUM) (5 
studies, n=10648; mortality model only); the Surgical Risk Scale46  (SRS), (3 studies, 
n=5244; mortality model only), the Surgical APGAR Score260 (3 studies, n= 10795), the 
Charlson Co-morbidity Index 261 (2 studies, n=2,463,997) and Donati’s Surgical Risk 
Score 47 (2 studies, n=7121). The accuracy of a further 26 tools was evaluated in single 
validation studies. A comparison of tools that were validated in multiple studies is 
detailed in Tables 9 and 10. The general characteristics of all included studies are 
summarised in Table 11. 
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Table 9: Mortality models validated in multiple studies 
Model 
No of 
varia-
bles 
Pre- 
intra- or 
post op 
data used 
Original 
derivation cohort 
and outcome 
Studies 
(n) 
Author and 
year 
Patients 
(n) 
Type of surgery 
Surgical 
urgency 
End-point AUROC (CI) 
APACHE 
II 
16 Post Critical care 
patients; all 
diagnoses (not 
just surgical); 
Hospital 
mortality 258 
3 Jones  
1992 262  
117 GI, vascular, renal and urology All 30 day HDU admission 
score: 0.539 (+/- 
0.083) 
Osler  
1998 263 
5322 Non-cardiac All Hospital 
discharge 
ICU admission 
score: 0.806 
Stachon 
2008 
271 Ortho, spinal, trauma, visceral 
surgery, limb surgery 
All Hospital 
discharge 
First 24h worst 
score: 0.777 
ASA-PS 1 Pre General 
surgical 
patients62 
2 Sutton  
2002 46 
1946 GI, vascular, trauma All Hospital 
discharge 
0.93 (0.90-0.97) 
Donati  
2004 47 
1849 Abdominal, vascular, ortho, 
urology, endocrine, ENT, neuro, 
Gynae, eye, thoracic, other 
All Hospital 
discharge 
0.810 (0.792-
0.828) 
Charlson 17 Pre Medical 
patients; 10 
year 
mortality264 
2 Atherly 
2004 265 
2167 General, vascular  30 day 0.52 
Sundaraja
n 2004 266 
2,461,8
30 
All in-patient surgery All Hospital 
discharge 
0.85-0.87 (varied 
with  year & if ICD-
9 or ICD-10 used) 
POSSUM 18 Pre and 
intra 
General 
surgery; 30-day 
mortality38 
3 Jones  
1992 262 
117 GI, vascular, renal and urology 
Elective & emergent 
All 30 day 0.753 (+/-0.081) 
Donati, 
2004 47 
1849 See above All Hospital 
discharge 
0.915 (0.884-
0.947) 
Brooks 
2005 267 
949 General, colorectal, upper GI, 
urology, head and neck 
All 30 day 0.92 (0.90-0.95) 
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P-
POSSUM 
18 Pre and 
intra 
General 
surgery; 30 day 
mortality69;259 
5 Organ 
2002 268 
229 General, vascular, ENT, plastics, 
thoracic, urology, other 
All 30 day 0.68 (0.57-0.78) 
Donati, 
2004 47  
1849 Abdominal, vascular, ortho, 
urology, endocrine, ENT, neuro, 
Gynae, eye, thoracic, other 
All Hospital 
discharge 
0.912 (0.898-
0.924) 
Brooks 
2005 267 
949 General, colorectal, upper GI, 
urology, head and neck 
All 30 day 0.92 (0.90-0.95) 
Neary 
2007 269 
2349 General, vascular, ENT, urology, 
ortho, other 
Emerge
nt & 
urgent 
30 day 0.90 (0.87-0.93) 
1 year 0.90 (0.8-1.0) 
Haga  
2011 270 
5272 GI and HPB Elective 30 day 0.74 (0.63–0.86) 
Hospital 
discharge 
0.81 (0.75–0.88) 
Surgical 
APGAR 
3 Intra Colorectal; 30 
day mortality260 
2 Regenboge
n 2009 271 
4119 General and vascular All 30 day 0.81 
Haynes 
2011 272 
5909 Any non-cardiac All Inpatient 0.77 
Surgical 
Risk 
Scale 
3 Pre General 
surgery; 
inpatient 
mortality46 
3 Sutton 
2002 46 
1946 GI, vascular, trauma All Hospital 
discharge 
0.95 (0.93-0.97) 
Brooks 
2005 267 
949 General, colorectal, upper GI, 
urology, head and neck 
All 30 day 0.89 (0.86-0.93) 
Neary 
2007 269 
2349 General, vascular, ENT, urology, 
ortho, other 
Emerge
nt & 
urgent 
30 day 30 day: 0.85 (0.82-
0.89) 
1 year 1 year: 0.84 (0.75-
0.94) 
Surgical 
Risk 
Score 
(Donati) 
3 Pre General 
surgery; 
inpatient 
mortality47 
2 Donati 
2004 47 
1849 Abdominal, vascular, ortho, 
urology, endocrine, ENT, neuro, 
Gynae, eye, thoracic, other 
All Hospital 
discharge 
0.888 (0.838-
0.937) 
Haga 
2011 270 
5272 GI and HPB Elective Hospital 
discharge 
0.73 (0.63-0.83) 
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Table 10: Morbidity models validated in multiple studies 
Model 
Number 
of 
validation 
studies 
Pre- 
intra or 
post- op 
varia-
bles  
Original derivation 
cohort and outcome 
Author N 
Type of surgery and 
urgency 
Surgical 
urgency 
Endpoint AUROC for outcome 
ASA-PS 3 Pre General surgery62 Goffi 
1999 273 
187 General All 30 day (mortality and 
morbidity combined) 
0.777  
 
Hightower 
2010 274 
32 Major abdominal 
(GI, urology) 
Electiv
e 
7 day 0.688 (0.523 - 0.851) 
Makary 
2010 275 
594 Unselected 
inpatient 
All Hospital discharge 0.626 
APACHE II 1 Post Critical care patients; 
any diagnosis (not 
just surgical); 
Hospital mortality 258 
Goffi 
1999 273 
187 General All 30 day 
(mortality and 
morbidity combined) 
Hospital admission 
score: 0.866 
Pre-op score: 0.894 
POSSUM 2 Pre & 
intra 
General surgery; 30-
day morbidity 38 
Jones 
1992 262 
117 GI, vascular, renal 
& urology; elective 
& emergent 
All 30 day 0.82 
Brooks 
2005 267 
949 General, 
colorectal, upper 
GI, urology, head 
and neck 
All 30 day 0.92 
Surgical 
APGAR 
3 Intra Colorectal; 30 day 
mortality 260 
Gawande 
2007 260 
767 General and 
vascular 
All 30 day (Mortality and 
morbidity combined) 
0.72 
Regenbogen 
2009 271 
4119 General and 
Vascular 
All 30 day 0.73 
Haynes  
2011 272 
5909 Any non-cardiac All Inpatient 0.70 
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2.3.2 Quality assessment 
The quality assessment of included studies is summarised in Table11. Seven studies 
were multi-centre and 21 were single-centre. The data collection was prospective in 19 
studies, retrospective in seven, and based on administrative data in two studies. 16 
studies used mortality as an outcome measure, four used morbidity, and eight used 
both. The study endpoints included 30-day outcome in 12 papers, hospital discharge in 
15 papers and three papers also included shorter or longer follow-up times ranging 
from one day to one year. 19 studies out of the total 28 reported baseline patient 
characteristics of physiology / comorbidity, surgery and demographics; selection bias 
was evident in 12 studies.  
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Table 11: Characteristics of all included studies 
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Atherly265 2004 US 2167 M Administrative 
(ICD-9 codes) 
N N General, 
vascular 
All Charlson 
Comorbidity 
Index based on 
ICD-9 codes 
External Mortality 30 day 
Brooks267 2005 UK 949 S Prospective N N General, 
colorectal, 
upper GI, 
urology, 
head and 
neck 
All POSSUM 
P-POSSUM 
Surgical Risk 
Scale 
Temporal Mortality 30 day 
DasGupta276 2009 Canada 125 S Prospective Y:  >70y 
only 
Y General, 
abdominal, 
ortho, 
neuro-
surgery, 
carotid 
surgery 
Elective Detsky Index 
Edmonton Frail 
Scale 
External Morbidity Hospital 
discharge 
Davenport277 2006 US 5878 S Prospective N Y General, 
neuro-
surgery, 
ortho, 
All  ASA-PS External Morbidity 
Mortality 
30 day 
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plastic, 
thoracic, 
vascular 
 
Donati47 2004 Italy 1849 M Prospective N Y Abdominal, 
vascular, 
ortho, 
urology, 
endocrine, 
ENT, neuro, 
Gynae, eye, 
thoracic, 
other 
All Surgical Risk 
Score  
POSSUM 
P-POSSUM 
Temporal Mortality Hospital 
discharge 
Gawande260 2007 US 767  S Retrospective N Y General 
and 
vascular 
All Surgical 
APGAR score 
Temporal Major 
complicati
ons or 
Mortality 
(Combined 
end-point) 
30 day 
Goffi273 1999 Italy 187 S Prospective N N General  All ASA 
APACHE II on 
hospital 
admission 
APACHE II 
immediately 
External Combined 
end-point: 
Mortality  
Morbidity  
 
30 day 
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pre-op 
Hadjianastassi
ou278 
2004 UK 4494 S Retrospective N Y Maxillo-
facial, 
general, 
ortho, 
renal, 
urology, 
neuro 
All Surgical 
Mortality Score 
Internal Mortality Hospital 
discharge 
Haga270 2011 Japan 5272 M Prospective N Y GI and HPB Elective E-PASS 
mE-PASS 
P-POSSUM 
Surgical Risk 
Score (Donati) 
External Mortality Hospital 
discharge 
Haynes279  2011 Internat
ional 
5909 M Prospective N Y Any non-
cardiac 
All Surgical 
APGAR 
External Mortality 
Morbidity 
Hospital 
discharge 
Hightower274 2010 US 32 S Prospective Y:  major 
abdominal 
& fit 
enough for 
CPET 
Y Major 
abdominal 
(GI, 
urology) 
Elective ASA-PS External Morbidity 7 day 
Hobson280 2007 UK 163 S Prospective Y: 
emergent 
surgery 
N General, 
gynae,  
renal, 
Emergent POSSUM External Mortality 30 day 
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only urology, 
vascular 
P-POSSUM 
Jones262 1992 UK 117 S Prospective Y:  HDU 
admissions 
only 
N GI,  
vascular, 
renal and 
urology 
All POSSUM 
APACHE II 
External Morbidity 
Mortality 
30 day 
Kuzu281 2006 Turkey 460 S Prospective N Y GI, 
vascular, 
HPB, gynae 
Elective Nutritional 
Risk Index 
Maastricht 
Index 
Subjective 
Global 
Assessment 
Mini 
Nutritional 
Assessment 
External Mortality 
Morbidity 
Hospital 
discharge 
or 30day 
(whicheve
r later) 
Liebman282 2010 Nether-
lands 
33224 S Prospective N Y General 
and trauma 
Emergent IRIS 
(Identification 
of Risk in 
Surgical 
Patients) 
Internal Mortality 
Morbidity 
 
Hospital 
discharge 
Makary275 2010 US 594 S Prospective Y: elective 
only 
Y Un-selected 
inpatient 
Elective ASA, Lee RCRI 
and Eagle 
Scores alone 
External Morbidity Hospital 
discharge 
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and in 
combination 
with Frailty 
Index 
Nathanson283 2009 US 13,417 M Retrospective Y: post-op 
ICU 
admission 
only 
Y All 
excluding 
cardiac, 
neuro and 
trauma 
Elective & 
emergent 
in 
separate 
cohorts 
MPM0-III External Mortality Hospital 
discharge 
Neary269 2007 UK 2349 S Prospective Y: 
emergent & 
urgent only 
N General, 
vascular, 
ENT, 
urology, 
ortho, 
other 
Emergent 
and 
urgent 
RCRI 
P-POSSUM 
Surgical Risk 
Scale 
BHOM 
External Mortality 30day and 
1 year 
Organ268 2002 Aus-
tralia 
229 S Retrospective Y: ICU only N General, 
vascular, 
ENT, 
plastics, 
thoracic, 
urology, 
other 
All P-POSSUM External Mortality 30day 
Osler263 1998 US 5322 S Retrospective Y:  ICU only N Non-
cardiac 
All APACHE II 
International 
External Mortality Hospital 
discharge 
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Classification 
of Disease 
Illness Severity 
Score (ICISS) 
Pillai284 1999 New 
Zealand 
6492 M Retrospective N Y GI, breast, 
endocrine 
vascular, 
gynae 
ortho, HPB 
All Otago Surgical 
Audit Score 
External Morbidity Hospital 
discharge 
Regenbogen271 2009 US 4119 S Prospective N Y General 
and 
vascular 
All Surgical 
APGAR Score 
External Mortality 
Morbidity 
30 day 
Stachon285 2008 German
y 
271 S Prospective Y:  ICU only Y Ortho, 
spinal, 
trauma, 
visceral 
surgery, 
limb 
surgery 
All APACHE II  
SAPS II 
APACHEN 
SAPSN 
External Mortality Hospital 
discharge 
Stachon286 2008 German
y 
283  S Prospective Y:  ICU only Y Ortho, 
spinal, 
trauma, 
visceral 
surgery, 
limb 
surgery 
All DELAWARE 
(Dense 
Laboratory 
Whole Blood 
Applied Risk 
Estimation)  
APACHE II 
Temporal / 
external 
Mortality Hospital 
discharge 
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SAPS II 
Story287 2009 Australi
a 
256 S Retrospective Y:  >70y 
only 
Y General, 
colorectal, 
ortho, 
plastics, 
urology, 
vascular, 
other 
All Perioperative 
Mortality Risk 
Score 
Internal Mortality 30 day 
Sunda-
rarajan266 
2004 Australi
a 
2,461,8
30 
M Administrative 
(ICD-9 & 10 
codes) 
N Y All in-
patient 
surgery 
All Charlson 
Comorbidity 
Index using 
administrative 
data (ICD-9 
and ICD-10AM 
coding) 
External Mortality Hospital 
discharge 
Sutton46 2002 UK 1946 S Prospective N N GI, 
vascular, 
trauma 
All Surgical Risk 
Scale; ASA-PS 
Temporal Mortality Hospital 
discharge 
 
Single centre= S; Multicentre = M; Y=Yes; N=No; ICU = Intensive Care Unit 
* Definitions of validation cohorts:  External = validation in new cohort unrelated to derivation study; Internal = Validation in split sample of same study 
population as derivation cohort; Temporal = validation in new cohort from derivation study but same institution(s) 
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2.3.3 Outcomes reporting 
Outcomes are summarised in Table 12. Surgical mortality at 30 days varied between 
1.3% 265 and 12.2%,268 and at hospital discharge between 0.8% 276 and 24.7%.286  
All but one262 of the six studies which separately tested the discrimination of 
stratification tools for morbidity and mortality reported that morbidity prediction was 
less accurate. There was considerable heterogeneity in the definition of morbidity in the 
12 studies that reported this outcome (see Appendix 2 for summary), and in keeping 
with this, there was wide variation in complication rates in different studies (between 
6.7%277 and 50.4%).262 
2.3.4 Calibration 
Calibration was poorly reported: 16 studies did not report calibration at all; of the 
remaining 11 papers, two reported only whether the models were of ‘good fit’, without 
reporting the appropriate statistics. One paper did not report calibration in their 
results, despite stating in the methods that they would calculate it.275  
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Table 12: Outcomes, discrimination and calibration  
Author Models used End point 
Morbidity 
(%) 
AUROC 
morbidity 
(95% C.I.) 
Mortality 
(%) 
AUROC mortality (95% C.I.) 
Calibration 
(p value for HL 
statistic unless 
otherwise stated) 
Atherly, 2004265 Charlson Comorbidity Index 
using ICD-9 coding 
30 day NR NR 1.3 0.47 NR 
Aust, 2005288 UH formula based on NSQIP 
formula 
30 day NR NR 1.4 UH formula: 0.915 NR 
UH formula with op severity 
added 
UH with op severity: 0.941 NR 
Bedside UH formula Bedside UH formula: 0.816 NR 
Brooks, 2005267 POSSUM 30 day NR NR 8.4 POSSUM: 0.92 NR 
P-POSSUM P-POSSUM: 0.92 NR 
Surgical Risk Scale SRS: 0.89 NR 
DasGupta, 2009276 Detsky Index Hospital 
discharge 
25 Detsky: 
0.51 
(0.39-
0.63) 
0.8 NR NR 
Edmonton Frail Scale EFS: 0.69 
(0.58-
NR 
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0.79) 
Davenport, 
2006277 
NSQIP 30 day 6.7 NSQIP: 
0.769  
1.5 NSQIP: 0.958 NR 
ASA ASA-PS: 
0.722 
ASA-PS: 0.889 NR 
ASA and NSQIP combined NSQIP RF 
with ASA-
PS: 0.782 
NSQIP RF with ASA-PS: 0.960 NR 
Donati, 200447 Surgical Risk Score Hospital 
discharge 
NR NR 1.9 SRS: 0.888 (0.838-0.937) 0.744 
POSSUM POSSUM: 0.915 (0.884-0.947) 0.0004 
P-POSSUM P-POSSUM: 0.912 (0.898-0.924) 0.1528 
ASA ASA: 0.810 (0.792-0.828) NR 
Gawande, 2007260 Surgical APGAR score 30 day 9.1 NR 1.4 Combined outcome of mortality 
and morbidity: 0.72 
Pearson’s 
goodness of fit: 
0.57 
Goffi, 1999273 ASA 
Preoperative APACHE II 
30 day Overall: 
26.7 
Elective: 
15.9 
Emergent: 
NR Overall: 
8.6 
Elective: 
4.3 
Emergent: 
Combined outcome of mortality 
and morbidity:  
NR 
 
ASA: 0.777 NR 
Hospital Admission APACHE II: NR 
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57.1 20.4  0.866 
Immediate pre-op APACHE II: 
Overall: 0.894 
Elective surgery: 0.826 
Emergent surgery: 0.873 
Cancer surgery: 0.915 
Non-cancer surgery: 0.869   
NR 
Hadjuanastassiou, 
2004 278 
Surgical Mortality Score Hospital 
discharge 
NR NR 4.1 0.82 (0.78-0.85) 0.10 
Haga, 2011 270 E-PASS, mE-PASS, P-POSSUM, 
Surgical Risk Score (Donati) 
Hospital 
discharge 
 
30 day 
NR NR NR  Hospital 
discharge 
30d  
E-PASS 
 
0.86 
(0.79–
0.93) 
0.82 
(0.69–
0.95) 
NR 
mE-PASS 0.86 
(0.79–
0.92) 
0.81 
(0.66–
0.96) 
P-
POSSUM 
0.81 
(0.75–
0.88) 
0.74 
(0.63–
0.86) 
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Surgical 
Risk 
Score  
0.73 
(0.63–
0.83) 
- 
Haynes, 2011279 Surgical APGAR Hospital 
discharge 
9.2 
(major) 
0.70 1.4 0.77 NR 
Hightower, 
2010274 
ASA 7 day 50 0.688 
(0.523 - 
0.851) 
NR NR NR 
Hobson, 2007280 POSSUM 
P-POSSUM 
30 day NR NR 30 day: 
9.2 
30 day: 
POSSUM: 0.946 
PPOSSUM: 0.940 
NR 
Hospital 
discharge 
Hospital 
discharge: 
12.9 
Jones, 1992262 POSSUM 30 day 50.4 POSSUM: 
0.82 
11.1 POSSUM: 0.75 NR 
APACHE II APACHE II: 0.54 
Kuzu, 2006281 Subjective Global Assessment Hospital 
discharge 
or 30 day 
(which-
ever later) 
28.47 SGA:0.669 
 
4.34 SGA: 0.687 
 
NR 
Nutritional Risk Index NRI:0.659 NRI:0.797 
 
Maastricht Index MI:0.671 MI:0.743 
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Liebman, 2010282 IRIS  Hospital 
discharge 
13.3 0.77 2.2 0.90 NR 
Makary, 2010275 ASA , Lee and Eagle with and 
without Frailty Index added 
Hospital 
discharge 
Not stated 
for entire 
cohort 
ASA: 
0.626 
NR NR NR (but reported 
that this would 
be calculated in 
methods) ASA + 
Frailty: 
0.699 
Lee: 0.618 
Lee + 
Frailty: 
0.669 
Eagle: 
0.678 
Eagle + 
Frailty: 
0.714 
Nathanson, 
2009283 
MPM0-III Hospital 
discharge 
NR NR Elective: 
5.3 
Elective:0.79 Good fit 
Emergent: 
14.4 
Emergency: 0.79 
Neary, 2007269 RCRI 30 day NR NR 30 day: RCRI: NR 
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 and 1 year 6.0 
1 year: 
10.8 
30 day: 0.73  
1 year: 0.71   
P-POSSUM 
 
P-POSSUM: 
30 day: 0.90 
1 year: 0.90 
Good fit 
Surgical Risk Scale 
 
SRS: 
30 day: 0.85 
1 year: 0.84 
Good fit 
BHOM BHOM:  
30day: 0.84 
1 year: 0.86 
Good fit 
Organ, 2002268 P-POSSUM 30 day  NR NR 12.2 0.68 <0.001 
Osler, 1998263 APACHE II Hospital 
discharge 
NR NR 13.9 APACHE II: 0.806 0.002 
International Classification of 
Disease Illness Severity Score 
(ICISS) 
ICISS: 0.892 0.15 
APACHE and ICISS combined Combined: 0.903 0.038 
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Pillai, 1999284 Otago Surgical Audit Score Hospital 
discharge 
NR for 
validation 
cohort 
0.86 NR NR Good fit 
Regenbogen, 
2009271 
Surgical APGAR Score 30 day 14.1 0.73 2.3 0.81 NR 
Stachon, 2008285 APACHE II  Hospital 
discharge 
NR NR 24.7 APACHE II: 0.777 NR 
SAPS II SAPS II: 0.785 
APACHEN APACHEN: 0.829 
SAPSN SAPSN: 0.823 
Stachon, 2008286 Dense Laboratory Whole Blood 
Applied Risk Estimation 
(DELAWARE) 
Hospital 
discharge 
NR NR 23.3 DELAWARE: 0.813 0.44 
APACHE II 0.777 NR 
SAPS II 0.785 NR 
Story, 2009287 Perioperative Mortality Risk 
Score 
30 day NR NR 6.0 0.79 0.35 
Sundararajan, 
2004266  
Charlson Comorbidity Index 
using administrative data (ICD-
9 and ICD-10AM coding) 
Hospital 
discharge 
NR  NR Overall 
mortality 
not 
reported 
ICD-9 1996-7: 0.87 
ICD-9 1997-8: 0.86 
ICD-10 1998-9: 0.85 
ICD-10 1999-2000: 0.86 
NR 
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ICD-10 2000-1: 0.86 
ICD-10 2001-2: 0.85 
Sutton, 200246 Surgical Risk Scale Hospital 
discharge 
NR NR 2.41 SRS: 0.95 0.65 
ASA-PSS ASA: 0.93 NR 
NR = Not reported 
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2.3.5 Risk stratification tools using only preoperative data 
Four entirely preoperative risk stratification tools (ASA-PSS, Surgical Risk Scale [SRS], 
Surgical Risk Score, and the Charlson co-morbidity index, [CACI]) were validated in 
multiple studies. The Surgical Risk Scale and the Surgical Risk Score both contain the 
ASA-PSS, and the urgency and severity of surgery; both have also been multiply 
validated. The Surgical Risk Score47;270 was developed and originally validated in Italy47 
and contains the ASA-PSS, a 3-point scale modification of the Johns Hopkins surgical 
severity criteria and a binary definition of surgical urgency (elective vs. emergency).  
The only published study evaluating the Surgical Risk Score after its initial validation 
found it to be poorly predictive of inpatient mortality.270 The Surgical Risk Scale46;267;269 
uses the ASA-PSS alongside UK definitions of operative urgency (a 4-point scale defined 
by the UK National Confidential Enquiry into Post Operative Death and Outcome) and 
severity (the British United Provident Association [BUPA] classification which is used to 
rank surgical procedures for the purposes of financial billing in the private sector). Both 
studies validating this system after its initial development found it to be a moderately 
discriminant tool (AUROC>0.8).267;269  
A further 18 different risk stratification tools using solely preoperative data were 
validated in single publications. These tools are described in Appendix 3.  
2.3.6 Risk stratification tools incorporating intra- and post-operative data 
The POSSUM and P-POSSUM scores were the most frequently used in heterogeneous 
surgical cohorts. The POSSUM score was derived by multivariable logistic regression 
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analysis and contains 18 variables, of which 12 are measured preoperatively and six at 
hospital discharge; two separate equations, for morbidity and mortality, were 
developed and validated.38;289 After recognition that the POSSUM model over-predicted 
adverse outcome, the Portsmouth variation (P-POSSUM), was developed to predict 
mortality, using the same composite variables but a different calculation.259 P-POSSUM 
has been used in a larger number of more recent studies47;267-270;270 than the original 
POSSUM47;262;267 and with the exception of one UK study, 40 has been found to be of 
moderate to high discriminant accuracy (AUROC varying between 0.68 and 0.92).  
2.3.7 Models developed for purposes other than perioperative risk 
stratification 
The APACHE II scoring system was originally developed as a case-mix adjustment tool 
for use in critical care;258 the score consists of 12 physiological variables and an 
assessment of chronic health status. Only one of the four studies reporting the APACHE 
II score’s predictive precision used it in the way originally intended: by incorporating 
the most deranged physiological results within 24 hours of critical care admission.258 
One small study273 scored APACHE II on admission to hospital and immediately pre-
operatively and found it to be highly predictive of outcome. This approach has face 
validity as APACHE II is a summary measure of acute physiology and chronic health, 
both of which may influence surgical outcome.  
The Charlson comorbidity score was developed to predict 10-year mortality in medical 
patients.264 A combined age-comorbidity index was subsequently validated for the 
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prediction of long-term mortality in a population of patients who had essential 
hypertension or diabetes and were undergoing elective surgery. 261 It is the original 
Charlson score, however, which is used in two studies identified in this search to stratify 
risk of short-term outcome. 265;266 These two studies reported very different predictive 
accuracy for the Charlson score; however the largest single study included in this entire 
review found the Charlson score (measured using administrative data) to be a 
moderately accurate tool.266  
One study evaluated three scoring systems which were originally developed to classify 
patient nutritional status.281 All of these models demonstrated moderate or high 
precision for predicting postoperative mortality. It is perhaps unsurprising that these 
measures predicted outcome, as different measures of nutritional status are associated 
with adverse outcomes in general populations of hospitalised patients.290;291   
Two further papers reported the precision of scores incorporating measures of patient 
frailty.275;276 The Edmonton Frail Scale had moderate precision in the prediction of 
surgical morbidity.276 The addition of the Frailty Index to existing risk predictors such 
as the ASA-PSS, Lee Revised Cardiac Risk Index and the Eagle score improved their 
performance.275 Again, frailty has face validity as a predictor of adverse outcome given 
the known association with poor outcome in medical patients292 and after cardiac 
surgery.293  Both frailty294 and poor nutritional status295 are associated with reduced 
functional capacity which in turn is associated with poor perioperative outcome.296 The 
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incorporation of measures of frailty and nutritional status into risk prediction rules for 
adverse surgical outcome may merit further evaluation. 
2.4 Discussion 
The purpose of this systematic review was to identify all risk stratification tools which 
have been validated in heterogeneous patient cohorts, and to report and summarize 
their discrimination and calibration. A plethora of instruments have been identified, 
which have been developed and validated in single studies; this therefore unfortunately 
limits any assessment of their usefulness and generalizability. A smaller number of tools 
have been multiply validated which could be used universally for perioperative risk 
prediction; of these, the P-POSSUM and Surgical Risk Scale have been demonstrated to 
be the most consistently accurate systems.  
2.4.1 Risk stratification tools in practice: complexity versus parsimony 
There are two key considerations when assessing the clinical utility of the various risk 
stratification tools reviewed in our study. First, what level of predictive accuracy is fit 
for the purposes of risk stratification? Second, what is the likelihood that each of the 
described instruments may be used in everyday practice by clinicians? While the 
answer to the first question may be to aim as ‘high’ (accurate) as possible, this must also 
be balanced against the issues raised by the second question. Risk models incorporating 
over 30 variables may be highly accurate but are less likely to be routinely incorporated 
into pre-operative assessment processes than scores of similar performance that use 
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only a few data points. Furthermore, clinical experience shows that the clinician is less 
likely to use complex mathematical formulae, as opposed to additive scores, when 
attempting to risk-stratify patients at the bedside or in the preoperative clinic.236  
2.4.1.1 P-POSSUM  
The P-POSSUM model was developed in the UK, and has since been validated in Japan, 
Australia and Italy. While this is the most frequently and widely validated model 
identified by this study, it has some limitations. First, it includes both preoperative and 
intra-operative variables, and therefore cannot be used for preoperative risk prediction. 
Second, several of the variables are subjective (e.g. chest radiograph interpretation), 
carrying the risk of measurement error; furthermore, many of these investigations are 
no longer routinely implemented as part of the preoperative assessment process. Third, 
in common with the original POSSUM, the P-POSSUM tends to over-estimate risk in low-
risk patients. Fourth, it contains 18 variables, which must be entered into a regression 
equation to obtain a predicted percentage risk value: clinicians may not wish to use 
such a complex system. Finally, the inclusion of intra-operative variables, particularly 
blood loss, which may be influenced by surgical technique, runs the risk of concealing 
poor surgical performance, therefore jeopardising its face validity as a risk adjustment 
model for comparative audit of surgeons or institutions.  
2.4.1.2 Surgical Risk Scale (SRS) 
The SRS consists entirely of variables that are available before surgery, making it a 
useful tool for preoperative risk stratification for the purposes of clinical decision-
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making. However, there are also some limitations. First, it incorporates the ASA-PSS, 
which may be subject to inter-observer variability and therefore measurement error.297-
299   Second, the surgical severity coding is not intuitive, and some familiarity with the 
BUPA system would be required for bedside estimation, unless a reference manual was 
available. Finally, it has only been validated in single centre studies within the UK, 
therefore its generalizability to patient populations in the US and worldwide is 
unknown.  
2.4.1.3 Other options 
The ASA-PSS is widely used as an indicator of whether or not a patient falls into a high, 
medium or low risk population, but it was not originally intended to be used for the 
prediction of adverse outcome in individual subjects.62 It is perhaps surprising that the 
ASA-PSS was reported as having good discrimination for predicting postoperative 
mortality, as it is a very simple scoring system, which has been demonstrated to have 
only moderate to poor inter-rater reliability.297-300 Nevertheless, the ASA-PSS has face 
validity as an assessment of functional capacity, which is increasingly thought to be a 
significant predictor of patient outcome, as demonstrated by more sophisticated 
techniques such as cardiopulmonary exercise testing.165 While it is possible that this 
provides some explanation for the high discriminant accuracy for ASA-PSS found in this 
systematic review, it is possible that publication bias, favouring studies with ‘positive’ 
results, may also be a factor.   
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The BHOM (Biochemistry Haematology Outcome Model) is a parsimonious version of 
POSSUM, which omits the subjective variables such as chest radiography and ECG 
results. It also has the advantage of consisting of variables which are all available 
preoperatively, with the exception of operative severity. Given the BHOM’s similarity in 
predictive accuracy to P-POSSUM in the one study identified which made a direct 
comparison,269 this system warrants further evaluation. Finally, the Identification of 
Risk In Surgical Patients score (IRIS) was developed in the Netherlands and consists of 4 
variables (age, acuity of admission, acuity of surgery and severity of surgery). In the 
study which developed and validated it on separate cohorts, the validation AUROC was 
0.92.282 Again, further investigation of this simple system would be useful.   
2.4.2 Generalizability of findings 
2.4.2.1 Clinical and methodological heterogeneity  
Clinical heterogeneity (both within- and between-cohort patient heterogeneity) and 
methodological heterogeneity (between-study differences in the outcome measures 
used) are both likely to have had a significant influence on some of these findings. For 
example, between-cohort heterogeneity, and variation in how morbidity is defined (see 
Appendix 2), may explain the wide range of morbidity rates reported in different 
studies. Heterogeneity of morbidity definitions may also in part explain the lower 
accuracy of models for predicting morbidity compared with mortality. On a different 
note, this study included all populations of patients that were determined to be 
heterogeneous, using the definitions described in the methods. However, the degree of 
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heterogeneity varied between studies, including whether or not patients of all surgical 
urgency categories were included: this may have affected the predictive accuracy of 
models in different studies.  
2.4.2.2 Objective vs. subjective variables and issues surrounding data collection 
methodology 
As previously discussed, the variables included in risk stratification tools may be 
classified as objective (e.g. biochemistry and haematology assays), subjective (e.g. 
interpretation of chest radiographs) and patient reported (e.g. smoking history). In 
some clinical settings, the reliability of non-objective data may be questionable.  For 
example, previous reports have demonstrated significant inter-rater variation in the 
interpretation of both chest radiographs 301 and ECGs. 302 Patients may also under- or 
over-estimate various elements of their clinical or social history when questioned in the 
hospital setting. Despite these concerns, the discrimination of predictors incorporating 
patient-reported and subjective variables was high in the studies included. This may be 
due to publication bias; it may also be explained by the fact that in all of these studies, 
data were collected prospectively by trained staff. Previous work has demonstrated an 
association between inter-observer variability in the recording of risk and outcome 
measures, and the level of training that data collection staff have received.194 These 
caveats are important when considering the generalizability of this study’s findings to 
the everyday clinical setting, where data-reporting and interpretation may be 
conducted by different types and grades of clinical staff.  Finally, concerns have also 
been raised over the clinical accuracy of administrative data used for case-mix 
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adjustment purposes.221;303 However, one large study included in this review 266 showed 
high discriminant performance when using ICD-9 and 10 administrative coding data to 
define the Charlson Index variables.  
2.4.3 Limitations of this study 
This study is limited by a number of factors.  
First, the focus was on studies that measured the discrimination and/or calibration of 
risk stratification tools in cohorts that were heterogeneous in terms of surgical 
specialities; therefore, a large number of single-speciality cohort studies identified in 
the search were excluded from the analysis.  
Second, while the inclusion criteria for the review ensured that a standard measure of 
discrimination was reported (AUROC or c-statistic), many studies did not report 
measures of calibration. However, in a systematic review such as this, calibration may 
be seen to be a less important measure of goodness-of-fit than discrimination for a 
number of reasons. Calibration can only be used as a measure of performance for 
models that generate an individualized predicted percentage risk of an outcome (e.g. 
the POSSUM systems) as opposed to summative scores, which use an ordinal scale to 
indicate increasing risk (e.g. the ASA-PSS). Calibration drift is likely to occur over time 
and will be affected by changes in healthcare delivery; good calibration in a study over 
30 years ago may be unlikely to correspond to good calibration today.304;305 While such 
calibration drift may affect the usefulness of a model for predicting an individual 
patient’s risk of outcome, poorly calibrated but highly discriminant models will still be 
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of value for risk adjustment in comparative audit. Finally, the probability of the Hosmer-
Lemeshow statistic being significant (thereby indicating poor calibration) increases 
with the size of the population being studied.306 This may explain why many of the large 
high-quality studies which were evaluated did not report calibration, or reported that 
calibration was poor.  
Third, by using the area under the receiver-operator-characteristic curve as the sole 
measure of discrimination, a number of studies were excluded, particularly earlier 
papers which used correlation coefficients between risk scores and post-operative 
outcomes. This was felt to be necessary, as a uniform outcome measure provides clarity 
to the reader.  
Fourth, publication bias, where studies are preferentially submitted and accepted for 
publication if the results are ‘positive’ is likely to be a particular problem in cohort 
studies.  
Finally, despite an extensive literature search, it is possible that some studies which 
would have been eligible for inclusion may have been missed. Multiple strategies have 
been used to prevent this; however, in a review of this size, it is possible that a small 
number of appropriate articles may have been omitted.  
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2.4.4 Future directions 
Undertaking clinical risk prediction should be a key tenet of safe high quality patient 
care. It facilitates informed consent, and enables the perioperative team to plan their 
clinical management appropriately. Equally, accurate risk adjustment is required to 
enable meaningful comparative audit between teams and institutions, to facilitate 
quality improvement for patients and providers. While dozens of scores and models 
have been identified, which have been used to predict or adjust for risk, very few of 
these achieved the aspiration of being derived from entirely preoperative data, and of 
being accurate, parsimonious and simple to implement. The Surgical Risk Scale is the 
system that comes closest to achieving these goals; the P-POSSUM score is more 
accurate but its value is limited by the fact that some of the variables are only available 
after surgery has been completed. Future work which might be of value would include 
further comparison of the Surgical Risk Scale, P-POSSUM and objective models such as 
the BHOM in international multi-centre cohorts and further investigation of models 
which combine novel variables such as measures of functional capacity, nutritional 
status and frailty. 
There is another possible approach. The American College of Surgeons’ National 
Surgical Quality Improvement Programme (ACS-NSQIP) was created in the 1990s to 
facilitate risk-adjusted surgical outcomes reporting in Veterans’ Affairs hospitals, and 
now also includes a number of private sector institutions. Risk adjustment models are 
produced annually, and observed: expected (O:E) ratios of surgical outcomes are 
reported back to institutions and surgical teams to facilitate quality improvement. A 
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number of risk calculators have been published by the ACS-NSQIP to help clinicians to 
provide informed consent and plan perioperative care. However, none of these 
calculators have been included in this review, as they have all been developed and 
validated for use in either specific types of surgery (e.g. pancreatectomy,307 
bariatric308;309or colorectal309 surgery) or for specific outcomes (e.g. cardiac morbidity 
and mortality).310 A parsimonious, entirely preoperative NSQIP model for predicting 
mortality in heterogeneous cohorts would be of value in the US; its validation in 
international multi-centre studies would also be a worthwhile endeavour. 
Finally, while there are multiple studies aimed at developing and validating risk 
stratification tools,  how widely such tools are used is not clear. Use of mobile 
technology, such as apps to enable risk calculation using complex equations at the 
bedside, might increase the use of accurate risk stratification tools in day-to-day 
practice. Importantly, in surgical outcomes research, there is an absence of impact 
studies, measuring the effect of using risk stratification tools on clinician behaviour, 
patient outcome and resource utilization. Randomized controlled trials to evaluate 
impact, further validation of existing models across healthcare systems, and 
establishing the infrastructure required to facilitate such work, including the routine 
data collection of risk and outcome data, should be of the highest priority in health 
services research into surgical outcome.311 
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2.5 Conclusions 
1. The P-POSSUM predictor and the Surgical Risk Scale (SRS) were demonstrated to be 
the most consistently accurate tools that have been validated in multiple studies; 
however, both have limitations.  
2. Future work should focus on further evaluation of these and other parsimonious risk 
predictors, including validation in international cohorts. There is also a need for studies 
examining the impact that the use of these tools has on clinical decision-making and 
patient outcome. 
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Appendix 1: Search strategy 
Medline: 
risk adjustment.mp. or exp Health Care Reform/ or exp Risk Adjustment/ or exp 
"Outcome Assessment (Health Care)"/ or exp Models, Statistical/ or exp Risk/ OR exp 
Risk Assessment/ or risk prediction.mp. or exp Risk/ or exp Risk Factors/ OR predictive 
value of tests.mp. or exp "Predictive Value of Tests"/ OR exp Prognosis/ or risk 
stratification.mp. OR case mix adjustment.mp. or exp Risk Adjustment/ OR severity of 
illness index.mp. or exp "Severity of Illness Index"/ OR scoring system.mp. 
combined with: 
Surgical Procedures, Operative/ OR surgery.mp. or General Surgery/ OR operation.mp. 
or exp Postoperative Complications/ 
combined with: 
mortality.mp. or exp Hospital Mortality/ or exp Mortality/ OR morbidity.mp. or exp 
Morbidity/ OR outcome.mp. or exp Fatal Outcome/ or exp "Outcome Assessment 
(Health Care)"/ or exp "Outcome and Process Assessment (Health Care)"/ or exp 
Treatment Outcome/ OR postoperative complications.mp. or exp Postoperative 
Complications/ OR intraoperative complications.mp. or exp Intraoperative 
Complications/ OR exp Perioperative Care/ or perioperative complications.mp. OR 
prognosis.mp. or exp Prognosis/ 
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Embase: 
Risk Factor/ or risk adjust$.mp. OR cardiovascular risk/ or high risk patient/ or high 
risk population/ or risk assessment/ or risk factor OR risk stratification.mp. [mp=title, 
abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer] OR *"Scoring System"/ OR "Severity of Illness 
Index"/ OR Multivariate Logistic Regression Analysis/ or Logistic Regression Analysis 
OR logistic models/ or risk assessment/ or risk factors/ OR exp Scoring System OR 
Prediction/ or possum.mp. or Scoring System/ OR exp Risk Assessment/ or risk 
stratification.mp. OR predict$.mp. OR exp Quality Indicators, Health Care/ OR Risk 
Adjustment/ 
combined with: 
exp Surgery/ OR exp Surgical Procedures, Operative/ OR specialties, surgical/ or 
surgery/ OR surg$.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer] OR peri-operative 
period.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer] OR perioperative.mp. [mp=title, 
abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer] OR postoperative.mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer] OR perioperative care/ or intraoperative care/ or postoperative care/ or 
preoperative care 
122 
 
 
combined with: 
complicat$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer] OR adverse outcome/ or 
prediction/ or prognosis/ OR exp Postoperative Complication/co, di, ep, su, th 
[Complication, Diagnosis, Epidemiology, Surgery, Therapy] OR exp Perioperative 
Complication/ or exp Perioperative Period/ OR exp Mortality/ or exp Surgical 
Mortality/ OR exp Morbidity/ OR outcome.mp. or "Outcome Assessment (Health 
Care)"/ or "Outcome and Process Assessment (Health Care)" OR treatment outcome/ 
Limits: 
1980-31 August 2011 
Exclusions:  
("all infant (birth to 23 months)" or "all child (0 to 18 years)" or "newborn infant (birth 
to 1 month)" or "infant (1 to 23 months)" or "preschool child (2 to 5 years)" or "child (6 
to 12 years)" or "adolescent (13 to 18 years)") or (cats or cattle or chick embryo or dogs 
or goats or guinea pigs or hamsters or horses or mice or rabbits or rats or sheep or 
swine) or (communication disorders journals or dentistry journals or "history of 
medicine journals" or "history of medicine journals non index medicus" or "national 
aeronautics and space administration (nasa) journals" or reproduction journals) or 
Angioplasty, Balloon/ or Angioplasty, Laser/ or Angioplasty/ or Angioplasty, Balloon, 
Laser-Assisted/ or Angioplasty, Transluminal, Percutaneous Coronary/ or 
ANGIOPLASTY.mp. OR Eye/ or Ophthalmology/ or Eye Diseases/ or 
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OPTHALMOLOGY.mp. or Hearing Loss OR CARDIAC SURGERY.mp. or HEART 
SURGERY.mp. or Myocardial Revascularization/ or Coronary Artery Bypass/ or 
CORONARY SURGERY.mp. or Coronary Artery Bypass, Off-Pump/ 
Hand-searching of reference lists: 
The following keywords were searched separately on Medline, Embase and ISI Web of 
Science: 
POSSUM + surgery 
NSQIP 
E-PASS 
ACE-27 
APACHE  
In addition, the original development studies for all risk prediction models identified in 
the initial search were then snowballed by hand searching for citations on Medline, 
Embase and ISI Web of Science         
Inclusion / Exclusion criteria 
Studies were eligible if they fulfilled the following criteria: 
 Studies in adult humans undergoing non-cardiac non-neurological surgery 
 Study cohorts which included at least two different surgical sub-specialities 
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 Studies which described the predictive precision of risk models using analysis of 
Receiver Operator Characteristic curves 
Studies were excluded on the basis of these criteria: 
 Cohorts including children (under the age of 14 years) 
 Cohorts including patients undergoing cardiac surgery 
 Cohorts including patients who did not undergo surgery 
 Single speciality cohort studies (e.g. vascular, orthopaedic) 
 Studies of ambulatory (day-case) surgery 
 Studies describing the development of a risk prediction model without 
subsequent validation in a separate cohort (either in the original study or 
subsequent cohorts), with the exception of studies of data from the American 
College of Surgeons’ National Surgical Quality Improvement Programme   
 Studies in which the items comprising the risk stratification tool were not 
disclosed in the study report or available from other sources (such as references) 
 Studies using outcomes other than morbidity or mortality as their sole outcome 
measures (e.g. discharge destination, length of stay) 
Studies using only a single pathological outcome measure (e.g. re-operation, cardiac 
morbidity, infectious complications, renal failure) 
  
125 
 
 
Appendix 2: Morbidity Definitions 
 
Author Model(s) validated Morbidity definition 
Daley, 1997 NSQIP 
Cardiovascular: cardiac arrest requiring cardiopulmonary resuscitation, myocardial infarction, pulmonary oedema 
Respiratory: pneumonia, unplanned intubation, pulmonary embolism, failure to wean from the ventilator 48 hours 
after operation,  
Renal: progressive renal insufficiency, renal failure requiring dialysis, urinary tract infection, 
Neurological: cerebrovascular accident (stroke), coma persisting > 24 hours postoperatively, other neurologic 
deficits (eg, peripheral neuropathy),  
Infectious: systemic sepsis. 
Wound: superficial wound infection; deep wound infection; wound dehiscence 
Other: prolonged ileus, bleeding requiring > 4 U of transfused blood, graft or prosthesis failure, deep vein 
thrombophlebitis,  
DasGupta, 
2009 
Detsky Index 
Edmonton Frail Scale 
Cardiac: ischemia, congestive heart failure, new arrhythmia or sudden death: 
Respiratory: pneumonia, significant bronchospasm, deep venous thrombosis or pulmonary embolism (DVT or PE), or 
the excessive need for respiratory support 
Delirium:  required the acute onset and fluctuating course of at least one of the following symptoms, as outlined in 
the Diagnostic and Statistical Manual of Mental Disorders, Revised third edition (DSMIIIR), occurring anytime on or 
after postoperative day 1:  
Disorganized thinking or inattention, altered level of consciousness, psychomotor agitation, disorientation or 
memory impairment, new perceptual disturbances, or new sleep disturbances (e.g., agitation at night or excessive 
drowsiness during the day). 
If patients had a known diagnosis of dementia or were on cholinesterase inhibitors, the 
occurrence of delirium required more than just disorientation or memory impairment. 
Davenport, 
2006 
NSQIP 
One or more of 21 specific NSQIP defined complications: not listed 
Gawande, 
2007 
Surgical APGAR score 
According to NSQIP’s established definitions: 
Cardiovascular: cardiac arrest requiring CPR, MI, 
126 
 
 
Respiratory: Respiratory: pneumonia, unplanned intubation, pulmonary embolism, failure to wean from the 
ventilator 48 hours after operation 
Renal: acute renal failure 
Neurological: coma for 24 hours or longer, stroke,  
Infectious: septic shock, sepsis, systemic inflammatory response syndrome  
Wound: wound disruption, deep or organ space surgical site infection  
Other: bleeding requiring >4 U red cell transfusion within 72 hours after operation, deep venous thrombosis, and 
vascular graft failure 
Goffi, 1999 
ASA-PSS 
APACHE II 
Major  
Cardiac failure  
Abdominal sepsis  
Haemoperitoneum  
Respiratory failure  
Intestinal obstruction  
Renal failure  
Minor  
Urinary infection  
Respiratory infection 
Wound infection  
Haynes, 2011 Surgical APGAR NSQIP defined (see Gawande 2007) 
Jones, 1992 
POSSUM 
APACHE II 
Cardiovascular: Myocardial infarct; Cardiac failure; Hypotension (<90mmHg for 2 h); 
Respiratory failure;  
Renal: Impaired renal function (urea increase > 5 mmol/l from preoperative level) 
Infection: Chest; Wound; Urinary tract; Deep; Septicaemia; Pyrexia of unknown origin; Other 
Wound dehiscence: Superficial; Deep; Anastomotic leak 
Haemorrhage: Wound; Deep; Other 
Thrombo-embolic: Deep vein thrombosis; Pulmonary embolus; Cerebrovascular accident; Other; 
Other: Any other complication 
Kuzu, 2006 
Nutritional Risk Index 
Maastricht Index 
Subjective Global 
Cardiovascular: Myocardial Infarct; Cardiac failure; Hypotension 
Respiratory: Atelectasis; Bronchopleural fistula; Chest infection; Empyema; Persistent air leak; Respiratory failure; 
Pulmonary embolus 
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Assessment 
Mini Nutritional 
Assessment 
GI/liver: Gastrointestinal hemorrhage; Hepatic dysfunction 
Renal: Impaired renal function; Urinary extravasation/ ureterohydronephrosis; Urinary infection 
Infectious: Pyrexia of unknown origin; Septicemia and bacteremia; Septic shock 
Neurological: Cerebrovascular accident 
Wound: Abscess (intraperitoneal/extraperitoneal); Anastomotic leakage; Deep haemorrhage; Superficial and deep 
surgical site infection; Wound dehiscence; Wound haemorrhage 
Thrombosis: Deep venous thrombosis and/or graft thrombosis: 
Liebman, 
2010 
IRIS (Identification of Risk 
in Surgical Patients) 
Cardiovascular: Myocardial infarction 
Respiratory:  Pneumonia 
GI: Intra-abdominal abscess; Anastomotic leak 
Renal: urinary tract infection 
Neurological: CVA  
Infectious: sepsis 
Wound: Deep wound infection; Re-bleeding or significant wound haematoma 
Thrombosis and ⁄ or pulmonary emboli  
Pressure ulcers 
Other: Miscellaneous; Multiple Organ Failure 
Makary, 
2010 
ASA, Lee RCRI and Eagle 
Scores alone combined 
with Frailty Index 
NSQIP defined 
Pillai, 1999 Otago Surgical Audit Score 
Complications classed according to severity: 
0: no complication; technical complications (some): e.g. anaesthetic compications; Non-operative complications: e.g. 
no lesion found, PUO 
1: Minor: Patient discomfort e.g. postoperative atelectasis; urinary retention 
2: Intermediate: significant compromise: e.g. prolonged ileus; DVT 
3: Severe: Major threat to life: e.g. DIC; MI; renal failure 
Story, 2009 
Perioperative mortality 
risk score 
Unplanned ICU admission: decision made to admit to ICU, Coronary Care unit or High dependency unit made during 
or after surgery 
Systemic inflammation: New finding of at least two of the following: 
Temp>38.3 or <36; WCC>12,000c/ml; RR>20 breaths/min; HR >90bpm; or a positive blood culture alone 
Acute renal impairment: Creatinine increase >20% pre-op value or admission to ICU for RRT 
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Appendix 3: Risk stratification tools validated in single studies  
Author Model Outcome 
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Beattie, 
2009312 
New 
Anaemia 
Model 
90d 
mortality 
10 X       Hb&   X   RD   
Periop 
beta 
blockers, 
CCBs ACEI 
Inpatient 
stay>5d 
pre-
operatively 
 
Any 
post-op 
NSAIDs 
RBC 
transfus
ion at 
any 
stage 
DasGupta, 
2009276 
Detsky 
 
Morbidity 
to 
hospital 
discharge 
9 X    X     X X      
General 
poor 
functional 
status 
  
DasGupta, 
2009276 
Edmon-
ton Frail 
Scale 
Morbidity 
to 
hospital 
discharge 
                    
Hadjuanast
assiou, 
2004278 
Surgical 
Mortality 
Score 
Mortality 
to 
hospital 
discharge 
6 X X   X X           
Onset time 
of surgery 
Duration of 
surgery 
  
Haga, 
2011313 
E-PASS 
Mortality 
to 
hospital 
discharge 
and 30d 
10 X      X   X* X* X   X  
Body 
weight 
Performanc
e status 
Blood loss 
Duration of 
surgery 
Incision 
type 
 
Haga, mE-PASS Mortality 7 X    X  X   X* X* X   X  Performanc   
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2011313 to 
hospital 
discharge 
and 30d 
e status 
Kuzu, 
2006281 
Nutrit-
ional Risk 
Index 
 
Mortality 
and 
morbidity 
at 30d or 
Hospital 
discharge 
3         Alb        
Normal 
weight 
Current 
weight 
  
Kuzu, 
2006281 
Mini 
Nutri-
tional 
Assess-
ment 
Mortality 
and 
morbidity 
at 30d or 
Hospital 
discharge 
18                 
Height 
Weight 
BMI 
Nutritional 
history 
Subjective 
assessment
s of general 
well-being 
and 
comorbiditi
es 
  
Kuzu, 
2006281 
Maas-
tricht 
Index 
Mortality 
and 
morbidity 
at 30d or 
Hospital 
discharge 
4        
Lym
pho
cyte
s 
Alb 
Pre-
album
in 
       
Ideal 
weight 
  
Liebman, 
2010282 
IRIS 
Mortality 
& 
Morbidity 
to 
hospital 
discharge 
4 X    X X           
Hospital 
admission 
status 
(acute vs 
non-acute) 
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Makary, 
2010275 
Eagle 
score 
Morbidity 
to 
hospital 
discharge 
5 X         X$ X    DM     
Makary, 
2010275 
Frailty 
index 
Morbidity 
to 
hospital 
discharge 
5                 
Shrinking 
Decreased 
Grip 
strength 
Exhaustion 
Low 
physical 
activity 
Slow 
walking 
speed 
  
Nathanson, 
2009283 
MPM0-III 
Mortality 
to 
hospital 
discharge 
                    
Neary, 
2007269 
BHOM 
30d and 
1y 
mortality 
8 X X   X   
Hb 
WC
C 
Ur 
Na 
K 
 
          
Neary, 
2007269 
RCRI 
30d and 
1y 
mortality 
6     X     X X  CVAR RD ID     
Osler, 
1998263 
ICISS 
Mortality 
to 
hospital 
discharge 
                 
PRODUCT 
OF 
SURVIVAL 
RISK 
RATIOS OF 
ALL ICD-9 
CLASSIFICA
TION 
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CODES 
Pillai, 
1999284 
Otago 
Morbidity 
to 
hospital 
discharge 
12 X X X  X X           
Admission 
type 
Number of 
operations 
Pre-
operative 
LOS 
Day case vs 
In-patient 
surgery 
 
Duration of 
surgery 
Operator 
grade 
Wound 
category 
 
Stachon, 
2008285 
SAPS II 
 
Mortality 
to 
hospital 
discharge 
15                    
Stachon, 
2008285 
APACHEN 
 
Mortality 
to 
hospital 
discharge 
15                 
Nucleated 
red cell 
assay 
added to 
APACHE II 
score as an 
independen
t variable 
  
Stachon, 
2008285 
SAPSN 
Mortality 
to 
hospital 
discharge 
16                 
Nucleated 
red cell 
assay 
added to 
SAPS II 
score as an 
independen
t variable 
  
Stachon, 
2008286 
DELAWA
RE 
Mortality 
to 
9 X       
Plts 
WC
ALT 
CK 
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hospital 
discharge 
C Chol 
K 
TGC 
CRP 
Story, 
2009287 
Peri-
operative 
risk score 
30d 
Mortality 
6 X      X  Alb          
Acute 
renal 
impair
ment 
Unplan
ned ICU 
admissi
on 
Inflam
mation 
 
* : Cardiac co-morbidity classed as single variable 
+:  Described as Pulmonary co-morbidities 
++: Described as CNS comorbidities 
&: WHO classification of anaemia 
** Davenport: Cardiac disease defined as previous PTCA or previous cardiac operation 
*** Hall: Angina, MI, previous PTCA and previous CABG all classed separately in model  
$: Eagle criteria: score separately for history of angina vs history of MI 
 
 
AC: Any cancer; Alb: Serum Albumin; ALP: Serum Alkaline Phosphatase; ARF: Acute renal failure; Bili: Serum Bilirubin; BUN: Blood Urea Nitrogen; Chemo: Chemotherapy; Co: Coma ; 
CNST: CNST tumour; Creat: Serum creatinine; CVA: Cerebrovascular accident without residual deficit; CVAD: Cerebrovascular accident with residual deficit; DC: Disseminated cancer; 
Dia: Dialysis dependent renal failure; DM: Any definition of Diabetes Mellitus; Hb: Haemoglobin; HP: Hemiplegia; ID: Insulin dependent; IS: Impaired sensorium; NID: Non-insulin 
dependent diabetes; Plt: Platelet count; RD: Other definition of renal dysfunction; RT: Radiotherapy; SGOT: Serum glutamic oxaloacetic transaminase 
Ur: Serum urea; WCC: White cell count; Work RVU: Work relative value units 
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Chapter Three: Validation of six 
perioperative risk stratification tools in 
a UK surgical population 
3.1 Introduction  
3.1.1 Background 
In Chapter 2, a qualitative systematic review found that the Portsmouth Physiological 
and Operative Severity Score for the enumeration of Mortality and morbidity (P-
POSSUM) and Surgical Risk Scale (SRS) were the two most consistently validated risk 
stratification tools in heterogeneous populations of patients undergoing non-cardiac, 
non-neurological surgery. In addition, the ASA-PSS had been evaluated in several 
studies.  
It was also observed that there is a lack of risk prediction tools which use solely 
preoperative data and which are multiply validated and accurate.  
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3.1.2 Aims 
1. To compare the discrimination and calibration of P-POSSUM and SRS and also 
the original POSSUM and American Society of Anesthesiologists’ Physical Status 
Score (ASA-PSS), for a variety of surgical outcomes in a sample of patients who 
underwent major non-cardiac surgery and were recruited into studies by 
UCL/UCLH Surgical Outcomes Research Centre (SOuRCe).  
2. To test the predictive accuracy of the POSSUM physiology score, which in its 
entirety is available preoperatively, and to compare its performance in this 
cohort with that of  existing validated risk prediction tools.  
3.1.3 Objectives 
1. To describe the general characteristics of the study population used throughout 
the remainder of this thesis 
2. To calculate the population and sub-population mortalities according to risk 
categories derived from the various risk stratification tools 
3. To determine and compare the predictive accuracy (discrimination) and 
calibration for each risk stratification tool for a variety of postoperative 
outcomes  
4. To discuss the strengths and weaknesses of the different risk stratification tools 
for this population and to make recommendations for use of these rules in 
clinical practice.  
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3.2 Methods 
3.2.1 Background and ethical considerations 
This is a prospectively conducted observational cohort study with long-term follow up 
of vital status (alive or dead). It studies two separate cohorts of patients who underwent 
elective major non-cardiac, non-neurological surgery at the Middlesex Hospital, London 
UK, between 2001 and 2005.  
Cohort One was recruited into a prospective, observational cohort study conducted 
within the UCL/UCLH Surgical Outcomes Research Centre, (SOuRCe), which validated 
the Post Operative Morbidity Survey183, for the first time in the UK.56 This study 
underwent full ethics review and received approval from the Joint UCLH/UCL 
Committee on the Ethics of Human Research (reference number 01/0116). All patients 
who were over the age of 18 years and admitted for major elective surgery between  
July 2001 and  September 2003 were eligible for inclusion. All individuals fulfilling these 
criteria were approached for consent and consenting patients were enrolled into the 
study.  
Cohort Two was monitored as part of a service evaluation of the Departments of 
Surgery and Anaesthesia at the Middlesex Hospital between March 2004 and April 
2005. This service evaluation was also conducted by SOuRCe. This was approved by the 
local Research Ethics Committee and patient consent was deemed not to be required. 
This study terminated when SOuRCe at the Middlesex Hospital closed in April 2005.  
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Approval for disclosure of data held on the Central Register for flagging of patients to 
provide fact of death or exit from the NHS was granted by the Ethics and Confidentiality 
Committee of the National Information Governance Board in June 2009.  
3.2.2 Inclusion criteria 
Cohort One 
Major elective surgery was defined as procedures expected to last more than two hours 
or with an anticipated blood loss greater than 500 ml. Patients in whom the planned 
surgery included any of the following procedures were eligible for recruitment:  
 Orthopaedic surgery:  revision hip arthroplasty, total hip replacement, total knee 
replacement, fusion/instrumentation of multiple lumbar or thoracic vertebrae; 
 General abdominal surgery: laparotomy including partial hepatectomy, 
pancreatic surgery, re‐operative colon surgery, abdomino-perineal resections, 
anterior resections, pan-proctocolectomies, hepatobiliary bypass procedures; 
 Urological surgery: radical prostatectomy, radical cystectomy, radical 
nephrectomy.  
Cohort Two 
In the second study, the definition of major elective surgery was broadened to include 
patients undergoing the following vascular surgical procedures:  aortic aneurysm 
repair; carotid endarterectomy; arterial reconstruction; and amputation for vascular 
disease.  
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3.2.3  Dataset 
3.2.3.1 Perioperative data (SOuRCe dataset) 
Irrespective of cohort, the following data were collected on all patients: patient 
demographics (age, date of birth); measures of perioperative risk (ASA-PSS score and 
the elements of POSSUM scores); name of planned and actual operation; date of surgery; 
postoperative destination; length of stay on the critical care unit and in the hospital; 
vital status at hospital discharge; and post-hospital discharge destination. The Post 
Operative Morbidity Survey (POMS) was administered on days 3, 5, 8 and 15 after 
surgery. All data were collected prospectively by one of two study nurses who had 
received specific training in how to identify and interpret both all of the preoperative 
risk and postoperative outcome variables within the dataset. Required data were 
collected through review of clinical notes and charts, direct patient questioning and 
examination, retrieval of data from the hospital information technology system and/or 
consultation with the patients’ clinical teams.  
3.2.3.2 Post-discharge follow up 
Data linkage between the SOuRCe dataset and the Medical Research Information Service 
(MRIS) at the NHS Information Centre provided mortality data for the cohort. Patient 
records were linked using patient name, date of birth, postcode (at time of surgery) and 
NHS number. All patients who could be traced and had not exited the NHS were ‘flagged’ 
for mortality status. The MRIS provided updated records on the cohort every three 
months, commencing in January 2010. The cohort was right-censored on 1 March 2012. 
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3.2.4 Risk stratification tools 
POSSUM mortality and morbidity models, P-POSSUM, SRS and ASA-PSS were all 
evaluated. In addition, the preoperative POSSUM (POSSUM physiology) score and the 
additive POSSUM (calculated as the sum of the POSSUM score, without entering the 
POSSUM variables into regression equations) were evaluated.  
3.2.5 Analysis 
3.2.5.1 General description of study population 
Comparisons were made between Cohorts One and Two, and between the four different 
surgical specialities for the whole cohort.   
For between-cohort analyses, group means were compared using two sample t-tests. 
Pearson’s Chi-squared test was used for comparing group proportions, except for the 
comparison of ethnicity for which the Fisher’s Exact Test was used (because of small 
numbers in the ‘non-white’ categories).  
For between-speciality analyses, group proportions were compared using Chi-squared 
tests (three degrees of freedom); Bonferroni’s correction was used when undertaking 
multiple paired comparisons using Chi squared testing to isolate which group(s) 
differed from the other(s). Between-speciality comparison of means was undertaken 
using one-way Analysis of Variance (ANOVA) with Bonferroni’s correction for multiple 
testing.   
139 
 
 
All p-values were two-sided and p<0.05 was considered to be statistically significant.  
Where Bonferroni corrected p values are quoted, these are denoted p’.  
3.2.5.2 Risk stratification tools: general description 
The distribution of scores in the study population was calculated for each of the risk 
stratification tools being evaluated. Outcomes for patients in the overall cohort were 
described in terms of four ‘risk categories’ for each score. For the ASA-PSS, risk 
categories were defined according to the established classification system (I-IV). For the 
POSSUM, P-POSSUM, additive POSSUM and POSSUM physiology predictors, four 
categories of risk were defined on the basis of dividing the study population into evenly 
distributed quartiles. These groups were labelled Category One to Four with Category 
One being the lowest risk and Category Four being the highest risk. For the SRS, it was 
not possible to divide the population into evenly distributed quartiles; therefore, the 
categories were determined by ensuring as near to equal spread as possible between 
three groups, and one further smaller group at the highest end of predicted risk. As with 
the various POSSUM risk stratification tools, these groups were labelled Category One to 
Four with Category One being the lowest risk, and Category Four being the highest risk. 
In addition, the population mortalities for the highest risk 10% of patients according to 
POSSUM (total score and physiology score) were separately calculated.  
3.2.5.2 Risk stratification tools: discrimination 
The primary measure of discrimination was the area under the Receiver-Operator-
Characteristic (ROC) curve (AUROC). ROC curves were plotted for all models for each of 
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the outcomes being studied, and the area under the ROC curve for each risk 
stratification tool was calculated using a trapezoidal method. Standard error and 95% 
confidence intervals were also calculated.  
The accuracy of the POSSUM (mortality equation), P-POSSUM, SRS, ASA-PSS, POSSUM 
Physiology score and additive POSSUM scores were each assessed for prediction of 
inpatient, thirty day and one-year mortality. In addition, the accuracy of the POSSUM 
(morbidity equation), POSSUM Physiology, additive POSSUM, SRS and ASA-PSS were 
assessed for prediction of postoperative morbidity (defined by at least one positive Post 
Operative Morbidity Survey (POMS) at any stage postoperatively).  
Next, the AUROC for each of the risk stratification tools was compared with the ‘gold 
standard’ for each outcome, which was defined as the tool with the highest AUROC on 
the previous analysis. This comparison was conducted using Chi squared tests, and both 
raw and adjusted p values (using Bonferroni’s correction, denoted p’) were calculated 
and reported.  
Predictive precision was classed as poor if AUROC <0.7; moderate if 0.70 – 0.9 and high 
if ≥0.90.249  Again, p values were considered significant if <0.05.  
3.2.5.3 Risk stratification tools: Calibration 
Calibration was measured by calculation of the Pearson Chi squared statistic for the 
POSSUM and P-POSSUM models. On Chi squared testing, if p<0.05, then this was 
considered significant and the risk stratification tool was interpreted to be poorly 
calibrated for that outcome. Calibration was not measured for the other risk 
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stratification tools, as they are scoring systems rather than regression models 
producing estimates of percentage risk.  
 
Stata InterCooled (Release 12.1) software (StataCorp LP, College Station, Texas, USA) 
was used for all analyses 
 
3.3 Results 
3.3.1 Characteristics of the study population  
In total, data were analysed for 1362 patients.  
450 patients were enrolled into Cohort One. Of these, nine had their surgery cancelled, 
and three were withdrawn from the study (one withdrew their consent, one was found 
to be participating in an interventional study, and one was withdrawn by their 
attending consultant). Therefore data were analysed for 438 patients.  
Data were collected on 996 patients in Cohort Two.  Of these, 72 patients were excluded, 
as follows: no surgery (n=7); patient previously enrolled in Cohort One (n=21); 
duplicate patient (n=29); no trace records available for long-term follow up (n=13) and 
lost to follow up (n=2).   Therefore data were analysed for 924 patients. 
142 
 
 
The cohorts were similar in terms of age, gender and surgical speciality, except that 
Cohort One did not include any vascular surgical patients (see Table 13). 
3.3.1.2 Estimates of perioperative risk according to different risk stratification tools 
There were small, but statistically significant, differences in the POSSUM and p-POSSUM 
predicted mortality, POSSUM predicted morbidity and distribution of Surgical Risk Scale 
categories between the two cohorts, with Cohort One predicted to be higher risk. 
Overall, predicted mortality and morbidity was high: mean POSSUM predicted 
morbidity was 28.04% (standard deviation, s.d. =19.07) and mortality 6.33% (s.d. = 
7.81) was for the entire cohort of 1362 patients. P-POSSUM predicted mortality was 
somewhat lower (mean =1.93%; s.d. =3.81). There was no difference in ASA-PSS scores 
between the two cohorts.  
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Table 13: Baseline patient characteristics 
 
 Overall population Cohort 1 Cohort 2 p value 
Number 1362 438 924  
Mean age (s.d.) 63.53 (15.26) 62.95 (15.65) 63.80 (15.08) NS 
Female (%)  773 (56.75) 259 (59.13) 514 (55.63) NS  
Ethnicity: n (%) *  
Black 69 (5.1) 20 (4.6) 49 (5.3) NS 
White 1198 (88.0) 404 (92.2) 794 (85.9) p<0.001 
Asian 44 (3.2) 7 (1.6) 37 (4.0) p<0.03 
Other 49 (3.6) 5 (1.1) 44 (4.8) p<0.001 
Missing 2 (0.2) 2 (0.5) 0 p<0.0001 
POSSUM predicted mortality risk (%) :   
Mean (s.d.) 6.3 (7.8) 7.9 (10.3) 5.6 (6.2) p<0.0001 
Median (IQR) 3.7 (2.6-6.5) 4.2 (2.9- 8.3) 3.47 (2.5-6.0)  
p-POSSUM predicted mortality risk (%):  
Mean (s.d.) 1.93 (3.8) 2.5 (5.4) 1.7 (2.8) p<0.001 
Median (IQR) 1.0 (0.6-1.8) 1.1 (0.7- 2.2)    0.82 (0.6-1.6)  
POSSUM predicted morbidity risk (%):  
Mean (s.d.) 28.0 (19.1) 31.9 (21.3) 26.2 (17.7) p<0.0001 
Median (IQR) 21.1 (14.6-34.8) 23.9 (16.3-42.3) 19.7 (14.2-32.7)  
Speciality: n (%)   
 Orthopaedic 855 (62.8) 288 (65.8) 567 (61.4) NS  
General 296 (21.7) 101 (23.1) 195 (21.1) NS  
Urology 147 (10.8) 49 (11.2) 98 (10.6) NS  
Vascular  64 (4.7) 0 (0) 64 (6.9) p<0.0001 
ASA-PSS Score: n (%)   
 I  223 (16.4) 79 (18.0) 144 (15.6) 
NS 
II 808 (59.3) 253 (57.8) 555 (60.1) 
III 299 (22.0) 99 (22.6) 200 (21.7) 
IV 13 (1.0) 2 (0.5) 11 (1.2) 
Missing  19 (1.4) 5 (1.1) 14 (1.5) 
Surgical Risk Scale Category: n (%) 
 One (score 3-5) 302 (22.5) 81 (18.7) 221 (24.3) 
 
p<0.005 
 
Two (score 6) 669 (49.8) 213 (49.2) 456 (50.1) 
Three (score7-8) 316 (23.5) 125 (28.9) 191 (21.0) 
Four (score ≥9) 56 (4.2) 14 (3.2) 42 (4.6) 
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3.3.2 Comparison of surgical specialities  
Across the overall population of 1362 patients, 855 (62.8%) patients underwent 
orthopaedic surgery, 296 (21.7%) general surgery, 147 (10.8%) urological surgery and 
64 (4.7%) vascular surgery.  Comparisons of baseline characteristics according to 
surgical speciality are reported below, and in Table 14.  
Comparison of means between speciality groups was undertaken using ANOVA. When 
interpreting these results, it should be noted that Bartlett’s test of equal variances was 
statistically significant in all analyses. This is likely to be because both the variances and 
the group sizes were substantially different.  
There was a difference in gender distribution between surgical specialities (p<0.001). 
On ANOVA, the F test was positive for all variables where this analysis was undertaken: 
age (F [3, 1358] = 43.84; P<0.0001), POSSUM predicted morbidity (F [3, 1358] = 78.13; 
p<0.0001), POSSUM predicted mortality (F [3, 1358] = 55.60; p<0.0001), p-POSSUM 
predicted mortality (F [3, 1358] = 25.95; p<0.0001) and postoperative length of stay (F 
[3, 1358] = 15.70; p<0.0001.  Therefore, the means of these variables were compared 
between surgical speciality groups. Including adjustment with Bonferroni’s correction 
for multiple analyses the following comparisons were statistically significant:  
 Age:  all comparisons (p’<0.01) except for vascular versus orthopaedic surgery 
(NS);  
 POSSUM predicted morbidity: orthopaedics compared with each other speciality 
individually (p’<0.001); all other comparisons NS 
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 POSSUM predicted mortality risk: orthopaedics versus general; orthopaedics 
versus urology (both p’<0.001); orthopaedics versus vascular (p’<0.01); all other 
comparisons NS 
 p -POSSUM predicted mortality: orthopaedics versus general; orthopaedics 
versus urology (both p’<0.001); orthopaedics versus vascular p’<0.01; all other 
comparisons NS 
 Postoperative length of stay: orthopaedics versus general (p’<0.001); all other 
comparisons: NS 
Table 14: Comparison of baseline characteristics for the overall population according to 
surgical speciality 
 Overall 
population 
(n=1362) 
Orthopaedic 
(n=855) 
General 
(n=296) 
Urology 
(n=147) 
Vascular 
(n-64) 
Age [years]: mean(sd) 63.52   
(15.26) 
65.92  
(14.75) 
60.28   
(14.52) 
52.93   
(15.40) 
70.89    
(9.95) 
Female (%) 56.75 61.75 55.41 46.26 20.31 
POSSUM predicted 
mortality (%) 
6.3   
(7.8) 
4.4   
(4.3) 
10.1 
(11.1)          
9.6  
(11.5)          
7.5 
(6.7)          
p-POSSUM predicted 
mortality (%) 
1.9 
(3.8) 
1.3   
(2.4) 
3.1    
(5.1)          
3.2    
(6.3) 
2.5    
(3.1) 
POSSUM predicted 
morbidity (%) 
28.0  
(19.1) 
22.5  
(13.1)          
38.8   
(23.5) 
36.2 
 (24.5)        
33.9   
 (19.9) 
Postoperative length of 
stay (days): mean (s.d.)  
13.0  
(15.1) 
11.0    
(12.2) 
17.6   
(18.4) 
14.4    
(19.7) 
16.1  
(16.8)           
Postoperative length of 
stay (days): median 
9 8 13 9 9 
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3.3.3 Overall population mortality according to risk prediction categories 
3.3.3.1. ASA-PSS grade 
The distribution of ASA-PSS scores in the overall population is presented in Figure 5 
and population mortality by ASA-PSS score is summarised in Table 15. ASA-PSS scores 
were missing for 19 patients. There were more inpatient deaths in the ASA-PSS Class III 
group when paired comparisons were made with ASA-PSS I and II patients (ASA-PSS I 
versus III p’<0.05; ASA-PSS II versus III p’<0.001).  However, here was no difference in 
30-day mortality between ASA-PSS grades. 
One-year mortality was similar in ASA-PSS I and II patients and in ASA-PSS III and IV 
patients. One-year mortality was significantly lower in ASA-PSS I patients when 
compared with ASA-PSS III (p’<0.001) and with IV (p’<0.001).  ASA-PSS Class II one-
year mortality was also lower than Class III (p’<0.001) and IV (p’<0.05).  
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Five-year mortality remained similar in ASA-PSS III and ASA-PSS IV patients. Five-year 
mortality for patients graded as ASA-PSS I was lower than that for patients categorised 
as ASA-PSS II (p’<0.05), ASA-PSS III (p’<0.001) and ASA-PSS IV (p’<0.001).   
Mortality in ASA-PSS II patients was lower at five years than ASA-PSS III (p’<0.001) and 
ASA-PSS IV patients (p’<0.05).  
 
Figure 5:  Distribution of ASA-PSS scores in overall population (n=1343) 
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 Hospital  
n=1343* 
30-day  
n=1343* 
One-year  
n=1329* 
Five-year  
n=1321* 
All patients  1.5 1.1 6.8 21.0 
I  0.5 0.9 2.3 8.6 
II 0.7 0.7 5.3 17.8 
III 4.7 2.3 14.2 37.8 
IV 0 0 23.1 46.2 
*Note smaller sample size, as ASA-PSS scores were missing for 19 patients  
Table 15:  Percentage mortality of overall population at four endpoints according to ASA-
PSS category 
 
3.3.3.2 Surgical Risk Scale 
The distribution of the Surgical Risk Scale (SRS) in the overall population is presented in 
Figure 6. Figure 7 presents the distribution of the SRS into four categories of increasing 
risk as follows: Category One (SRS≤5; n=302), Category Two (SRS=6; n=669), Category 
Three (SRS=7; n=316) and Category Four (SRS ≥8; n=75). Mortality according to SRS 
categories is summarised in Table 16. Hospital mortality was lower in Category One 
patients than in Category Three (p’<0.05) and Category Four patients (p’<0.001). 
Similarly, Category Two patients had a lower hospital mortality than Category Three 
(p’<0.005) and Category Four (p’<0.001) patients. Similar patterns were seen with one-
year mortality: Category One versus Three (p’<0.001); Category One versus Four 
(p’<0.001); Category Two versus Three (p’<0.001) and Four (p’<0.001).  
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At five years, observed mortality in Category Three and Four patients was similar; 
however, with this one exception, there were significant differences in mortality 
between all categories (Category One versus Two:  p’<0.02; all other comparisons 
p’<0.001).   
 
 
Figure 6:  Distribution of SRS scores in overall population (n=1343) 
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Figure 7: Distribution of SRS Categories (n=1343) 
 
SRS score (Category) Hospital  
n=1343 
30-day  
n=1343 
One-year  
n=1329 
Five-year  
n=1321 
All patients (n=1343)* 1.5 1.1 6.8 21.0 
3-5 (Category One) 0.3 0.7 2.3 9.4 
6 (Category Two) 0.6 0.6 4.2 16.6 
7 (Category Three) 3.5 2.2 13.8 35.5 
≥8 (Category Four) 8.8 3.5 25.0 53.6 
*SRS scores missing for 19 patients 
Table 16:  Percentage population mortality by SRS category  
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3.3.3.3 Additive POSSUM score 
The distribution of the additive POSSUM score is presented in Figure 8.  
 
Figure 8: Distribution of Additive POSSUM scores (n=1362) 
 
Patients were subdivided into quartiles of predicted risk of mortality according to the 
additive POSSUM score as follows: Category One (score ≤ 24, n=349); Category Two 
(score 25-27, n=421); Category Three (score 27-31, n=294); and Category Four (score 
≥32, n = 298). Mortality according to these categories of predicted risk is summarised in 
Table 17. 
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Additive POSSUM score   
(risk category) 
Inpatient  
n=1362; (%) 
30 day  
n=1362; (%) 
1 year  
n=1347; (%) 
5 year  
n=1339; (%) 
All patients  1.5 1.1 6.8 21.0 
≤24 (Category 1) 0.00 0.0 0.86 5.78 
 25-27 (Category 2) 0.24 0.71 2.89 14.49 
 28-31 (Category 3) 2.04 1.70 6.48 24.48 
≥32 (Category 4) 4.70 2.35 20.00 43.60 
 
Table 17:  Percentage population mortality by Additive POSSUM risk category 
 
Thirty-day mortality was lower in Category One patients than Category Three (p’<0.03); 
all other comparisons were non-significant. Hospital mortality was lower in Category 
One versus Category Three (p’<0.05) and Category Four (p’<0.001) patients and 
Category Two versus Category Four patients (p’<0.001).  
At one year, there was no difference in mortality between Category One and Two 
patients or between Category Three and Four patients; however there were significant 
differences between all other risk categories (all comparisons p’<0.001). At five years, 
mortality was significantly different for all category comparisons (p’<0.001 for all 
comparisons with the exception of Category Two versus Category Three (p’<0.005).  
The observed mortality of the estimated highest risk 10% of this cohort (Additive 
POSSUM ≥36; n=144) was as follows: 6.3% before hospital discharge; 3.5% at thirty 
days; 16.0% at six months and 25.7% at one year. By five years, 52.8% of this highest 
risk category had died.  
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3.3.3.4 POSSUM and P-POSSUM  
The distribution of POSSUM and P-POSSUM predicted mortality risks are shown in 
Figures 9 and 10 respectively. The predicted and observed (at each of the four 
endpoints) mortality by the four quartile categories of P-POSSUM predicted mortality 
are shown in Table 18.  
 
Figure 9: Distribution of POSSUM predicted mortality risk (n=1362) 
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Figure 10: Distribution of P-POSSUM predicted mortality risk (n=1362) 
 
Risk category  Mean percentage 
P-POSSUM 
predicted 
mortality 
(standard error) 
 
95% C.I. Inpatient  
n=1362; 
(%) 
30 day  
n=1362; 
(%) 
1 year  
n=1347; 
(%) 
5 year  
n=1339; 
(%) 
All patients  1.9 (0.10) 1.7-2.1 1.5 1.1 6.8 21.0 
Category One 0.5  (0.01)     0.47-0.49 0.00 0.00 0.9 5.4 
Category Two 0.8 (0.00) 0.76-0.78 0.3 0.9 3.2 14.5 
Category Three 1.2 (0.01) 1.21-1.26 0.9 0.9 4.1 20.0 
Category Four 5.2 (0.4) 4.54-5.94 5.0 2.6 19.2 43.0 
Table 18: Predicted versus observed mortality for categories of risk according to P-
POSSUM prediction at four end-points 
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3.3.3.5 POSSUM Physiology score 
The distributions of POSSUM physiology score are shown in Figure 11. Again, four risk 
categories were defined based on quartiles of the study population: Category One (score 
≤14; n=334), Category Two (score 15-16; n=364), Category Three (score 17-18; n=337) 
and Category Four (score ≥19; n=327).  Population mortalities for each of these 
categories at the four measured end-points are detailed in Table 19. The patients who 
were classified as being in the highest risk 10% according to POSSUM physiology score 
(score ≥21; n=167) had a mortality of 5.4% while in hospital, 3.0% at thirty days, 10.2% 
at 6 months, 17.4% at one year and 40.7% at 5 years.  
 
Figure 11:  Distribution of POSSUM physiology scores 
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POSSUM physiology 
score (risk category)  
Inpatient  
n=1362; (%) 
30 day  
n=1362; (%) 
1 year  
n=1347; (%) 
5 year  
n=1339; (%) 
All patients  1.5 1.1 6.8 21.0 
≤14 (Category 1) 0.00 0.00 3.9 13.0 
 15-16 (Category 2) 1.1 0.6 4.4 15.1 
17-18 (Category 3) 1.2 1.5 5.2 20.6 
≥19 (Category 4) 4.0 2.5 14.3 35.0 
p value p<0.001 p=0.014 p<0.001 p<0.001 
Table 19:  Percentage population mortality by POSSUM physiology category 
 
 
3.3.4 Accuracy of risk stratification tools for predicting postoperative 
outcomes 
3.3.4.1 Inpatient mortality 
Data were analysed for 1343 patients: there were 1362 in the overall cohort, and ASA-
PSS data were missing for 19 patients. Hospital mortality was 1.54% (21 deaths). ROC 
curve analyses are presented in Table 20 and Figure 12.  All models demonstrated 
moderate discrimination for the prediction of hospital mortality. Only the ASA-PSS was 
significantly less accurate than the gold standard (P-POSSUM) (see table 21). Neither 
POSSUM model was well calibrated for this population; on examination of the observed: 
expected (O: E) ratios for deciles of risk, both POSSUM mortality models significantly 
over-predicted hospital death across the range of risks.  
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Risk stratification 
tool 
AUROC Standard 
Error 
95% C.I. Pearson Chi2 p value (for 
probability >Chi2) 
P-POSSUM  0.85        0.03     0.78- 0.91 498.87 <0.0001 
POSSUM 
mortality 
0.84        0.04         0.77- 0.91 421.74 <0.0001  
Additive POSSUM 0.84 0.04 0.78-0.91   
POSSUM 
physiology  
0.77        0.05         0.67- 0.87   
SRS 0.77        0.05         0.68- 0.87   
ASA-PSS 0.73                0.05 0.62-0.83   
 
Table 20:  Discrimination and calibration of risk stratification tools for inpatient 
mortality 
 
Figure 12:  ROC curves for inpatient mortality (AUROC shown in legend) 
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Risk stratification 
tool 
AUROC Standard  
Error 
Chi2 d.f. Probability 
>Chi2 
Bonferroni 
Probability 
>Chi2 
p-POSSUM  0.85       0.03     
POSSUM 
mortality 
0.84        0.04      1.60 1 0.21       1.00 
Additive POSSUM 0.84 0.03 1.10 1 0.29 1.00 
POSSUM 
physiology  
0.77     0.05 2.42         1 0.12      0.60 
SRS 0.77         0.05 3.31      1 0.07   0.35 
ASA-PSS 0.73       0.05 6.52        1 0.01       0.05 
 
Table 21: Comparison of ROC curves for prediction of inpatient mortality 
 
3.3.4.2 30-day mortality 
Data were analysed for 1343 patients of the overall cohort: ASA-PSS scores were 
missing in 19 patients. Thirty-day mortality was 1.10% (15 deaths). ROC curve analyses 
are detailed in Table 22 and Figure 13.  The POSSUM mortality equation, p-POSSUM, 
POSSUM physiology and additive POSSUM scores were all moderately accurate 
predictors of thirty-day mortality. The AUROCs for the SRS and ASA-PSS indicated poor 
accuracy, although neither AUROC value was statistically different from the ‘gold 
standard’ p-POSSUM model when Bonferroni’s correction was applied (see Table 23). 
Neither POSSUM mortality model were well calibrated for this population.  
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Risk stratification 
tool 
AUROC Standard 
Error 
95% C.I Pearson Chi2 p value (for 
probability 
>Chi2) 
p-POSSUM  0.76 0.05 0.65 - 0.86 425.66 <0.0001 
POSSUM 
mortality 
0.75        0.06         0.63 - 0.86 389.20 <0.0001 
Additive POSSUM  0.75 0.06 0.64 - 0.86   
POSSUM 
physiology  
0.74        0.06         0.63 - 0.86   
SRS 0.67        0.07         0.52 - 0.81   
ASA-PSS 0.61        0.08         0.46 - 0.76   
 
Table 22:  Discrimination and calibration of risk stratification tools for 30 day mortality 
 
Figure 13:  ROC curves for 30-day mortality (AUROC shown in legend) 
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Risk stratification 
tool 
AUROC Standard 
Error 
Chi2 d.f Probability>Chi2 Bonferroni 
Probability 
>Chi2 
p-POSSUM 
mortality 
0.76 0.05     
POSSUM 
mortality 
0.75      0.06   0.93 1 0.34   1.00 
Additive POSSUM 0.75 0.06 1.08 1 0.30 1.00 
POSSUM 
physiology  
0.74        0.06         0.09 1 0.76 1.00 
SRS 0.67        0.07         2.33 1 0.13 0.63 
ASA-PSS 0.61        0.08         4.68 1 0.03 0.15 
Table 23:  Comparison of ROC curves for prediction of 30-day mortality 
 
3.3.4.3. Morbidity 
Data were analysed for 1343 patients. Morbidity (defined as any positive POMS during 
postoperative stay) occurred in 73.0% of patients (n=994). ROC curve analyses are 
detailed in Table 24 and Figure 14.  The POSSUM morbidity predictor and additive 
POSSUM score were both moderately precise predictors of inpatient morbidity, and 
although the AUROC look similar, statistical comparison revealed a significant 
difference in discrimination; this is most likely to be due to the very high event rate in 
this analysis (see Table 25). The SRS, ASA-PSS and POSSUM physiology score were all 
poor predictors of morbidity. The POSSUM morbidity model was poorly calibrated for 
this population.   
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Risk stratification 
tool 
AUROC Standard 
Error 
95% C.I. Pearson Chi2 p value (for 
probability >Chi2) 
POSSUM morbidity 0.73        0.01      0.71 - 0.76 673.39 <0.0001 
Additive POSSUM  0.73 0.01        0.70 - 0.75   
SRS 0.67       0.01         0.64 - 0.70   
ASA-PSS 0.59       0.01 0.57 - 0.62   
POSSUM physiology  0.58        0.02         0.55 - 0.61   
 
Table 24: Discrimination and calibration of ROC curves for Day 5 POMS defined  
morbidity  
 
 
Figure 14: ROC curves for inpatient morbidity (AUROC shown in legend) 
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Risk stratification 
tool 
AUROC Standard 
Error 
Chi2 d.f. Probability 
>Chi2 
Bonferroni 
Probability 
>Chi2 
POSSUM 
morbidity  
0.73       0.01     
Additive POSSUM 0.73       0.01 47.42      1 <0.0001 <0.0001 
SRS 0.67        0.01      16.93      1 <0.0001 <0.001 
ASA-PSS 0.60        0.01      61.22      1 <0.0001 <0.0001 
POSSUM 
physiology 
0.58     0.02 155.10     1 <0.0001 <0.0001 
 
Table 25: Comparison of ROC curves for prediction of inpatient morbidity  
 
3.3.4.4 One - year mortality 
Data were analysed for 1329 patients: 19 patients did not have an ASA-PSS score and 14 
patients either exited the NHS before one year follow-up could be completed or were 
censored with no known date of exit. One-year mortality was 6.8% (92 deaths). The P-
POSSUM, POSSUM mortality and total POSSUM predictors all demonstrated high-
moderate accuracy and were not significantly different from each other. The SRS was 
moderately precise, but the ASA-PSS and POSSUM physiology scores were poor 
predictors of one-year mortality; these three scores all demonstrated significantly 
different accuracy from the gold standard (P-POSSUM). However, despite high 
precision, the calibration of the P-POSSUM was poor for one year mortality prediction in 
this population; analysis of deciles of O:E ratios for mean observed versus predicted risk 
showed that P-POSSUM significantly under-predicted one year mortality.  
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Risk 
stratification 
tool 
AUROC Standard 
Error 
95% confidence 
intervals 
Pearson 
Chi2 
p value (for 
probability >Chi2) 
P-POSSUM 0.80       0.02         0.75 - 0.84 538.25 <0.0001 
POSSUM 
mortality 
0.80        0.02         0.75 -  0.84 446.28 <0.0001 
Additive 
POSSUM 
0.80        0.02        0.75 - 0.85   
SRS 0.71      0.03 0.66 - 0.76   
POSSUM 
physiology  
0.67       0.03 0.61 -  0.73   
ASA-PSS 0.66              0.03 0.61 - 0.71   
 
Table 26: Discrimination and calibration of risk stratification tools for one-year mortality  
 
Figure 15:  ROC curves for one-year mortality (AUROC shown in legend) 
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Risk 
stratification 
tool 
AUROC Standard 
Error 
Chi2 d.f. Probability>Chi2 Bonferroni 
Probability 
>Chi2 
POSSUM 
mortality  
0.80        0.02     
p-POSSUM 0.80   0.02       0.27      1 0.61       1.00 
Additive 
POSSUM 
0.80 0.02 1.12 1 0.29 1.00 
SRS 0.71        0.03 21.65      1 <0.003 <0.02 
POSSUM 
physiology  
0.67        0.03 18.69      1 <0.0001 <0.0001 
ASA-PSS 0.66        0.03      17.65     1 <0.0001 <0.002 
 
Table 27: Comparison of ROC curves for prediction of one-year mortality 
3.4 Discussion 
3.4.1 Summary of findings 
The POSSUM risk stratification tools (both the original model and the P-POSSUM variant 
as well as the additive POSSUM) are able to discriminate between patients at different 
levels of risk for the prediction of mortality with high precision for death while in 
hospital and with moderate precision for death within thirty days. In addition, they have 
good precision for predicting mortality within one year of surgery.  While the POSSUM 
physiology score had good precision for inpatient and thirty day mortality and fitted the 
data well (adequate calibration), it was a poor predictor of one year mortality. All the 
evaluated risk stratification tools were more precise predictors of inpatient mortality 
than 30 day mortality. They were also all better predictors of mortality at any of the 
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measured end-points, than morbidity as defined by a positive POMS result at any stage 
during the inpatient episode. 
Although by the standards defined in the analysis plan, the P-POSSUM, total POSSUM 
and POSSUM mortality predictors reached high-moderate precision for inpatient 
mortality precision (all AUROC ≥0.84), these systems were not significantly better than 
the Surgical Risk Scale and POSSUM physiology score (both AUROC 0.77) on statistical 
analysis. However, this lack of statistical difference may be due to a Type 1 error, as the 
event rate was very low (inpatient mortality 1.5%).  
Both POSSUM and P-POSSUM were poorly calibrated for this population.  
3.4.2 Results in context 
These results are consistent with the findings of the systematic review in Chapter 2: the 
POSSUM and P-POSSUM rules are moderately accurate tools for the prediction of 
adverse perioperative outcome. The SRS was less accurate; the difference was not 
statistically significant but this may have been due to inadequate study power. As the 
SRS can be calculated preoperatively, it may be a useful predictor for use in clinical 
practice; similarly the POSSUM physiology score was a moderate discriminator of 30- 
day and inpatient outcome.   
Mortality rates for this cohort in the immediate perioperative period (inpatient and 30- 
day) are comparable with those quoted in the literature. The inpatient mortality in a UK 
database (CHKS) analysis of over four million non-cardiac non-neurosurgical 
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admissions was 1.9%,7 while the inpatient death rate for SOuRCe cohort in this study 
was 1.54%; however, the cohort characteristics were different (SOuRCe cohort – major 
elective surgery, CHKS database – all inpatient surgery, including minor surgery and 
emergency surgery). The European Surgical Outcomes Study (EuSOS) reported an 
overall in-hospital mortality of 4.0%; however, 24.7% of patients in the EUSOS study 
had urgent or emergency operations.2 In the systematic review in Chapter two of this 
thesis, inpatient mortality (where it was reported) in unselected cohorts varied 
between 0.8 276 and 4.3%.281 
The accuracy and calibration of all the risk stratification tools evaluated for predicting 
postoperative morbidity was poor. This is consistent with the results of the systematic 
review which found that all but one of the studies where both mortality and morbidity 
were measured, predictive precision was higher for mortality. The main reason for 
these findings is likely to be variation in the way in which complications are described 
in different clinical and academic settings. Although the POMS is a standardised 
validated outcome measure, the definitions of morbidity which are used in the POMS 
mean that morbidity estimates may be higher than when other methods are used to 
define complications.183 If a different POMS related outcome measure (for example 
Day15 POMS status) had been used, the results might have been quite different. From 
these data, and those in the systematic review, it may be concluded that the lack of 
standardisation in the definition and measurement of postoperative morbidity obviate 
the potential usefulness of morbidity prediction tools.  
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In interpreting these results, consideration must be given to the purpose of using these 
tools. Broadly speaking, there are three reasons why clinicians would choose to use a 
clinical prediction rule: to guide perioperative management, to facilitate and improve 
the quality of informed patient consent, and to enable comparative audit of outcomes 
between individual clinicians, teams or institutions. Each of these will now be discussed 
in turn.  
3.4.2.1 Using risk stratification tools to guide perioperative management 
A number of recent reports have highlighted failings in preoperative risk assessment for 
surgical patients, leading to high risk patients being managed in low acuity ward areas, 
even though they may have benefitted from a higher level of care (Level two or three 
critical care or Post Anaesthetic Care Unit).7;237;241 Two of these papers define the high 
risk category as those patients with a predicted mortality of >5%, and suggest that these 
patients should be cared for in critical care postoperatively. 7;237   
The recent NCEPOD report showed that anaesthetists considered 20% of the patients 
who had surgery during the time of the audit to be high risk. It is unlikely, that at least in 
the near future, that 20% of patients in the UK might be offered critical care or PACU 
admission in the postoperative period. Clinical experience shows that despite scoring 
systems such as the POSSUM predictors being widely known about, and calculators 
being available on the internet and through smart phone apps, they are not widely used. 
There may be a number of reasons for this, including uncertainty over the accuracy of 
these tools, and lack of willingness to sit at a computer / calculator and enter the 
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numbers into the required equations. There are also concerns over the calibration of 
these tools over time, which are borne out by the results from this study: the original 
POSSUM model was poorly calibrated for inpatient mortality prediction, whereas the P-
POSSUM and additive POSSUM scores fitted the data better. As surgical and anaesthesia 
techniques improve, calibration drift will continue to occur; however, the systematic 
review data and this study demonstrate that the additive POSSUM score itself has 
remained an accurate discriminator of risk. Therefore there may be merit in simply 
using the total score as a marker of perioperative risk.  
This study shows that the predictive accuracy of the POSSUM physiology score was not 
significantly different to the gold standard P-POSSUM score for the prediction of 
inpatient mortality. This lack of difference may be due to lack of statistical power. 
Nevertheless, by the criteria set out at the beginning, POSSUM physiology was 
moderately precise (AUROC 0.77). The population of patients with a POSSUM 
physiology score of ≥21 (10% of the study population) had an inpatient mortality rate 
of 5.39%. Therefore, based on these data, it would be reasonable to consider 
postoperative critical care for all patients in whom major elective surgery is planned, 
and who scored a POSSUM physiology total of ≥21. This would enable planned referral 
to critical care or PACU for patients from the preoperative assessment clinic. While the 
tool is not sufficiently precise to enable it to be the sole determinant of perioperative 
management strategy, it would be a reasonable adjunct to clinical judgement, and other 
risk stratification tools such as cardiopulmonary exercise testing.  
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The POSSUM total score was an accurate discriminator of inpatient mortality. Patients 
in the top quartile of risk as predicted by a total POSSUM score of ≥31 were part of a 
population with an inpatient mortality of 4.70%; the highest risk 10% of the cohort 
(POSSUM total ≥36) had an inpatient mortality of 6.25%. Therefore, for patients who 
had not been previously booked critical care beds on the basis of POSSUM physiology 
score alone, if at the end of surgery the estimated POSSUM total score is ≥36, then 
critical care admission should be strongly recommended; it should also be considered 
for patients with a score of ≥31, although this may encompass a large number of 
perioperative patients, and therefore may not be practicable. However, ensuring a 
higher level of surveillance on a regular ward, for example by “outreach” or “patient at 
risk” teams, would potentially be of benefit in ensuring early detection of complications, 
and appropriate escalation of management. This sort of approach, of re-evaluating risk 
at the end of surgery as part of a ‘bundle’ of care, is advocated in recent guidance.237  
3.4.2.2 Using risk stratification tools to improve informed consent 
The General Medical Council’s guidance ‘Consent: patients and doctors making 
decisions together’, 314 has this to say about the communication of risks to patients: 
“You must tell patients if an investigation or treatment might result in a serious adverse 
outcome, even if the likelihood is very small. You should also tell patients about less serious 
side effects or complications if they occur frequently, and explain what the patient should 
do if they experience any of them.” 
Elsewhere in the guidance it states: 
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“Your discussions with patients should focus on their individual situation and the risk to 
them.” 
Therefore, the communication of individualised estimations of mortality and morbidity 
are both required as part of the informed consent process. As the POSSUM physiology 
score demonstrated reasonable precision for the prediction of inpatient death, to use 
this as a tool to guide the preoperative consent process in patients having major elective 
surgery is valid. While it is not an ideal predictor (as would be defined by an AUROC 
>0.9) it is certainly more accurate than quoting the population risk for the procedure 
overall, which may be default standard practice at present. Therefore, as with the use of 
these tools for guiding perioperative management strategy, it would be reasonable to 
use the POSSUM physiology score as part of a multi-modal assessment which may 
personalise and improve the quality of informed consent.  
3.4.2.3 Using risk stratification tools for risk adjustment for comparative audit 
The calibration of the prediction rules is particularly important when considering their 
use for comparative audit. If calibration is imprecise, it is possible that problems may go 
unnoticed, if observed: expected ratios are satisfactory. In Copeland’s original POSSUM 
paper, the cohort mortality was 4.0%;38 and in Prytherch’s first external validation of 
the P-POSSUM in 1998, mortality was 2.9%.69 The mortality in this study cohort was 
1.1% at 30 days and 1.6% at hospital discharge. These differences in mortality may be 
due to improvements in standards of care which have occurred over time, or differences 
in the characteristics of the patient populations which were studied; either way, the 
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difference in calibration of the POSSUM and P-POSSUM models between previously 
published studies and this one can be clearly seen.  
3.4.3 Limitations of this study 
The main limitation of this study is that it was conducted in an elective population of 
patients; therefore its generalizability to non-elective patients is unknown. Second, 
these are data from 2001-5; changes in practice may mean that the discrimination and 
calibration of the prediction rules which have been established in this study are no 
longer representative even of elective surgical cohorts in 2013. Nevertheless, as 
previously stated, the mortality rates of this population are consistent with 
contemporary estimates and changes in practice are less likely to affect the 
discrimination of such measures; it is predominantly calibration that would be affected 
by changes (improvements) in clinical care; these data suggest that both the POSSUM 
and P-POSSUM tools are poorly calibrated for this cohort.  
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3. 5 Conclusions 
1.  The additive POSSUM score is a moderately accurate predictor of short term outcome 
(inpatient and 30 day mortality) in patients undergoing elective major non-cardiac 
surgery, and comparable with the POSSUM and P-POSSUM regression models. 
2. The POSSUM physiology score has moderate precision for the prediction of 
postoperative mortality, and therefore may be used as part of a multi-modal assessment 
process to guide perioperative patient management and improve the quality of 
informed consent. 
3. The POSSUM and P-POSSUM models were poorly calibrated for this population of 
patients.  
4. The SRS and ASA-PSS were not accurate predictors of 30-day mortality in this cohort 
of patients.  
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Chapter Four: Epidemiology of outcome 
after major non-cardiac surgery 
4.1 Aim and Objectives 
This chapter reports the postoperative outcomes of the SOuRCe cohort of patients who 
underwent major non-cardiac surgery at the Middlesex Hospital between 2001 and 
2005.  
4.1.1 Aim 
1. To describe the epidemiology of postoperative morbidity in the Middlesex Hospital 
SOuRCe cohort, and to analyse its relationship with other outcomes, both in the shorter 
term (inpatient and 30-day) and longer term (years).  
2. To use these data to determine whether Day 5 POMS has face validity as a measure of 
postoperative morbidity 
4.1.2 Objectives: 
1. Description of the epidemiology of postoperative morbidity, as measured by the 
Post Operative Morbidity Survey 
2. Analysis of the univariate relationships between risk (stratified by the P-
POSSUM, additive POSSUM, POSSUM physiology, Surgical Risk Scale and ASA-PS 
predictors) and shorter and longer-term mortality 
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3. Analysis of the univariate relationships between postoperative morbidity (POMS 
defined: overall, by physiological domain and by postoperative day) and shorter 
and longer-term mortality (dichotomous outcome at different end-points) 
4. Analysis of the univariate relationship between duration of morbidity and 
longer-term survival.  
5. To measure the relationship between Day 5 POMS and other postoperative 
outcomes in order to make an assessment of the face validity of Day 5 POMS as a 
point-prevalence measure of postoperative morbidity.  
4.2 Methods 
4.2.1 Background 
This was a prospective observational longitudinal cohort study. The cohort studied is 
the same as in Chapter 3 (known from here forward as the SOuRCe cohort). 
Recruitment, ethics, data collection methods and dataset have all been described in 
detail in Chapter 3; however, a brief summary is as follows:  
The SOuRCe cohort comprised 1362 patients who had major inpatient surgery 
(orthopaedic, urological, general or vascular) between 2001 and 2005 at the Middlesex 
Hospital, London.  Data collected on all of these patients included the variables of 
POSSUM, ASA-PSS grade, and surgical type and severity. Post operative morbidity was 
measured on days 3, 5, 8 and 15 postoperatively by administration of the Post Operative 
Morbidity Survey. Local ethics committee approval was granted for the local collection 
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of perioperative data; the National Information Governance Board’s Ethics and 
Confidentiality Committee granted approval (Section 251 exemption) for the linkage of 
these data to long-term mortality statistics 
4.2.2 Analysis Plan  
4.2.2.1 General description of study population and postoperative morbidity 
The demographic characteristics of the study population have been described in 
Chapter 3. Mortality is reported as a dichotomous outcome at four end-points: one 
location based (inpatient mortality) and three time-based (30-day, one and five years). 
Morbidity is reported as a dichotomous outcome under the following definitions: any 
inpatient morbidity (POMS positive at any stage); POMS domain defined (separate 
dichotomous outcomes for each of the nine domains); POMS day defined (separate 
dichotomous outcomes for each of the four days - (3, 5, 8 and 15) - on which POMS was 
measured) 
4.2.2.2 Long-term survival 
Univariate analysis of long term survival using Kaplan Meier curves compared patients 
by risk category for the ASA-PS, additive POSSUM score, POSSUM physiology score and 
Surgical Risk Scale, using the category definitions described in Chapter 3.  
Kaplan Meier curves were also used for univariate comparison of patients with and 
without any POMS defined morbidity, and for patients categorised by POMS defined 
morbidity status on each of Days 3, 5, 8 and 15.  
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4.2.2.3 Severity / duration of morbidity 
The POMS has not been validated as a cumulative score to reflect severity of 
morbidity.56 However, there are known associations between patient risk and 
postoperative length of stay,165 and between complications and length of stay;165;183 
furthermore, previous studies have shown that there is a strong correlation between 
severity of complications and length of stay. 195 It is therefore proposed that the 
duration of morbidity, defined as the ‘final morbidity day’ (FMD) is a reasonable 
surrogate for severity of complications: that is, that patients who remain in hospital 
with postoperative morbidity on Day 15 and therefore have a longer duration of 
postoperative morbidity,  have more significant complication(s) than patients whose 
last morbidity day was 8, 5 or 3; similarly, patients who are in the ‘FMD 8’  category 
have more significant morbidity than FMD 3 or 5, and so on.  
Kaplan-Meier survival curves were constructed for univariate comparison of long-term 
survival based on morbidity severity, as defined by ‘Final Morbidity Day’.  
4.2.2.4 Statistical analysis 
Bi-variate analyses of dichotomous outcomes (mortality, morbidity) were conducted 
using Chi squared testing with Bonferroni’s correction for multiple comparisons when 
multiple end-points were evaluated.  The Student’s t-test (2-sided) was used for 
comparison of means (length of stay). Survival times were compared using Log-rank 
statistics.  A p value of <0.05 was considered significant. Bonferroni corrected p values 
are denoted p’.  
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Stata InterCooled (Release 12.1) software (StataCorp LP, College Station, Texas, USA) 
was used for all analyses and calculations 
4.3 Results 
4.3.1 General description 
Long-term follow up data were available for 1347 patients; (lost to follow up n=1; no 
trace n=14). The mortality rates by cohort at hospital discharge, 30 days, one year and 
five years is summarised in Table 28. 
 Overall Cohort One  Cohort Two 
Inpatient N 1362 438 924 
Mortality: n (%) 21 (1.5) 5 (1.1) 16 (1.7) 
30 day n 1362 438 924 
Mortality: n (%) 15 (1.1) 3 (0.7) 12 (1.3) 
1  year n  1347 432 915 
Mortality: n (%) 92 (6.8) 33 (7.5) 59 (6.6) 
5  year  n 1339 424 915 
Mortality: n (%) 277 (20.7) 86 (20.3)  191 (20.9) 
 
Table 28 : Comparison of mortality at different endpoints between Cohort One and Two 
 
4.3.2 Mortality by surgical speciality – univariate analyses 
There were statistically significant differences between surgical specialities for both 30 
day (p<0.01) and inpatient (p<0.001) mortality (see Table 29). 
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Using Chi squared testing to compare thirty day mortality between the four specialities 
a significant difference was found between the groups; paired comparisons (using 
Bonferroni’s correction, and p’ values) showed that this difference was due to lower 
mortality in urology (p’<0.05) and orthopaedics (p’<0.005) when compared with 
vascular surgery. Inpatient mortality was lower in orthopaedics than general (p’<0.001) 
and vascular surgery (p’<0.001).  All other paired comparisons demonstrated similar 
inpatient mortality rates between specialities.    
At one year, orthopaedic patient mortality was significantly lower than that for general 
and vascular patients (orthopaedic versus general p’<0.001; orthopaedic versus 
vascular p’<0.001) There was no significant difference between urology and vascular, or 
urology and orthopaedic mortality at one year.  However, mortality was significantly 
lower at one year after urological surgery when compared with the general surgery 
cohort (p’<0.05).   
At five years, mortality was significantly lower in orthopaedic patients when compared 
to general surgery (p’<0.001) and vascular (p’<0.001). Five year mortality after 
urological surgery was significantly lower than after general surgery (p’<0.001) but not 
significantly different to the vascular and orthopaedic cohorts.  
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 Inpatient 
mortality  
n=1362 (%) 
30 day mortality  
n=1362 (%) 
1 year mortality  
n=1347 (%) 
5 year mortality 
n=1339 (%) 
All patients 1.5 1.1 6.8 20.7 
Orthopaedics  0.5 0.6 2.9 13.4 
Urology  1.4 0.0 6.2 18.3 
General 3.3 2.4 16.4 40.4 
Vascular 7.8 4.7 15.9 32.8 
p value p<0.001 p<0.01 p<0.001 p<0.001 
 
Table 29: Postoperative mortality according to surgical speciality 
 
4.3.3 Inpatient morbidity: overview 
Figure 16 shows the prevalence of postoperative morbidity (as defined by POMS on any 
of days 3, 5 8 or 15) in the whole population of patients studied.  
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Figure 16:  Prevalence of POMS defined morbidity occurring on any of Days 3, 5, 8 or 15 
postoperatively (n=1362) 
 
Table 30 summarises POMS defined morbidity across surgical specialities. There were 
significant differences in postoperative morbidity between specialities, both overall 
(occurrence of any morbidity as defined by a positive POMS), and on comparing the 
proportion of patients who scored on the POMS on each postoperative day on which it 
was measured. There were also significant differences in POMS defined morbidity in 
seven out of nine domains, with the exceptions of the wound and haematology 
categories.  In the pulmonary, infection, renal, gastrointestinal and pain domains these 
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differences were accounted for by a lower incidence of morbidity in orthopaedic 
patients when compared to each of the other surgical specialities. Vascular patients 
were significantly more likely to develop cardiac or neurological morbidity.  
 Total 
(n=1362) 
Orthopaedic 
(n=855) 
General 
(n=296) 
Urology 
(n=147) 
Vascular 
(n-64) 
 p’ value 
Any Morbidity 72.9 62.9 90.9 91.2 82.8 <0.001 
Pulmonary 33.1 22.6 52.4 50.3 45.3 <0.001 
Infection 40.3 32.4 47.3 64.6 57.8 <0.001 
Renal 43.6 31.1 59.5 76.2 62.5 <0.001 
Gastrointestinal 40.9 23.9 83.8 55.1 39.1 <0.001 
Cardiac 6.8 5.6 7.4 4.8 23.4 <0.001 
Neurological 2.9 2.5 2.0 4.8 9.4 <0.01 
Wound 11.0 11.1 11.5 9.5 10.9 NS 
Haematology 8.1 7.8 6.8 10.9 10.9 NS 
Pain 33.4 20.1 60.8 53.7 37.5 <0.001 
Day 3 POMS positive 67.8 55.6 90.2 90.5 75.0 <0.001 
Day 5 POMS positive 50.0 35.8 77.4 70.1 64.1 <0.001 
Day 8 POMS positive 31.5 21.0 53.0 44.9 42.2 <0.001 
Day 15 POMS 
positive 
15.6 8.2 29.4 26.5 25.0 <0.001 
Table 30: POMS comparisons between surgical specialities (percentages) 
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4.3.4 Patterns of morbidity after different types of surgery 
The patterns of morbidity in the four different surgical speciality cohorts are graphically 
displayed in Figures 17 to 24. There was a significant difference between the prevalence 
of the top five domains of morbidity (pulmonary, infection, gastrointestinal, renal or 
pain) and the bottom four (cardiac, wound, neurological or haematological morbidity) 
(947 versus 313 patients; p<0.0001).  
 
Figure 17: Domains of POMS defined morbidity after orthopaedic surgery (n=855) 
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Figure 18:  Prevalence of POMS defined morbidity after orthopaedic surgery (n=855)  
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Figure 19: Domains of POMS defined morbidity after general surgery (n=296) 
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Figure 20: Prevalence of POMS defined morbidity after general surgery (n=296)
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Figure 21: Domains of POMS defined morbidity after urological surgery (n=147) 
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Figure 22: Prevalence of POMS defined morbidity after urological surgery (n=147)  
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Figure 23: Domains of POMS defined morbidity after vascular surgery (n=64) 
189 
 
 
 
Figure 24: Prevalence of POMS defined morbidity after vascular surgery (n=64)  
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4.3.5 Patterns of morbidity according to postoperative day 
The patterns of morbidity changed over the postoperative period. For seven out of the 
nine domains, morbidity prevalence was highest on Day 3 postoperatively and reduced 
over time. However, cardiac morbidity peaked on Day 5 (see Figure 30) and wound 
morbidity, while uncommon in the immediate postoperative period, became more 
common as time progressed, peaking on Day 8 (see Figure 31) 
 
Figure 25:  Prevalence of POMS defined morbidity in overall cohort (n=1362)  
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Figure 26: Prevalence of day 3 morbidity in overall cohort (n=1362) 
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Figure 27: Prevalence of day 5 morbidity in overall cohort (n=1362) 
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Figure 28: Prevalence of day 8 morbidity in overall cohort (n=1362) 
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Figure 29: Prevalence of day 15 morbidity in overall cohort 
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Figure 30:  Prevalence of cardiac morbidity in overall cohort (n=1362) 
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Figure 31:  Prevalence of wound morbidity in overall cohort (n=1362) 
 
4.3.6 Postoperative survival by perioperative risk category 
Long term survival according to different methods of categorising perioperative risk 
(additive POSSUM, POSSUM physiology, P-POSSUM, Surgical Risk Scale and ASA-PSS) 
are depicted using Kaplan-Meier curves in Figures 32 to 36. Log-rank statistics testing 
for differences in survival were significant for all methods of classifying risk. However, 
visual examination of the Kaplan-Meier curves shows that there is overlap in the 
confidence intervals between some risk categories. With the additive POSSUM score, 
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there is overlap between Categories One, Two and Three both in the early and later 
analysis stages (figure 32). However, pair-wise comparisons using log-rank statistics 
show a significant difference in survival between all of the individual classes (Category 
Two versus Three, p<0.001; all other comparisons, p<0.0001).  Similar overlap between 
Categories One, Two and Three is seen with the POSSUM physiology score (figure 33). 
With the SRS, overlap is seen between Categories One and Two, and Categories Three 
and Four (figure 35). Finally, with the ASA-PSS, there is overlap in confidence intervals 
between all four categories (figure 36).  
 
Figure 32:  Univariate analysis of long-term survival by Additive POSSUM category 
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Figure 33:  Univariate analysis of long-term survival by POSSUM physiology category  
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Figure 34: Univariate analysis of long-term survival by P-POSSUM predicted mortality 
category  
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Figure 35:  Univariate analysis of long-term survival by Surgical Risk Scale category 
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Figure 36 Univariate analysis of long-term survival by ASA-PS class 
 
4.3.7 Relationship between POMS defined morbidity and postoperative 
mortality 
Comparisons of patients with and without POMS defined morbidity overall, and at 
different time points are tabulated in Tables 31 to 35. On univariate analysis, the 
occurrence of postoperative morbidity (either any POMS defined morbidity, or the 
occurrence of POMS defined morbidity on any of days 3, 5, 8 or 15 postoperatively) is 
associated with significantly higher mortality both at one year and five years (p’<0.01 
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for both one-year and five-year mortality with Bonferroni correction for five 
comparisons, as five different measures of morbidity were used).  
 
 30 day 
(n=1362) 
Inpatient 
(n=1362) 
1 year 
(n=1347) 
5 year 
(n=1339) 
Any morbidity (n=994; 73.0%) 1.3 1.9 8.6 24.5 
No morbidity (n=368; 27.0%) 0.5 0.5 1.9 9.0 
p value NS NS <0.001 <0.001 
p’ value NS NS <0.01 <0.01 
Table 31: Mortality according to development of any POMS defined morbidity 
 
 30 day 
(n=1362) 
Inpatient 
(n=1362) 
1 year 
(n=1347) 
5 year 
(n=1339) 
Day 3 POMS + (n=923; 67.8%) 1.4 2.1 9.2 26.4 
Day 3 POMS – (n=439; 32.2%) 0.5 0.5 1.8 8.7 
p value NS <0.03 <0.001 <0.001 
p’ value NS NS <0.01 <0.01 
Table 32: Mortality according to POMS status on Postoperative Day 3 
 
 30 day  
(n=1362) 
Inpatient  
(n=1362) 
1 year  
(n=1347) 
5 year  
(n=1339) 
Day 5 POMS+ (n=679; 49.9%) 1.6 2.4 10.5 29.2 
Day 5 POMS – (n=683; 50.2%) 0.6 0.7 3.2 12.3 
p value NS <0.02 <0.001 <0.001 
p’ value NS NS <0.01 <0.01 
Table 33: Mortality according to POMS status on Postoperative Day 5   
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 30 day 
(n=1362) 
Inpatient 
(n=1362) 
1 year 
(n=1347) 
5 year  
(n=1339) 
Day 8 POMS + (n=429; 31.5%) 2.1 4.0 13.2 34.5 
Day 8 POMS – (n=933; 68.5%) 0.6 0.4 3.9 14.3 
p value <0.02 <0.001 <0.001 <0.001 
p’ value NS <0.01 <0.01 <0.01 
Table 34: Mortality according to POMS status on Postoperative Day 8 
 
 30 day  
(n=1362) 
Inpatient 
(n=1362) 
1 year  
(n=1347) 
5 year  
(n=1339) 
Day 15 POMS+ (n=212; 15.6%) 2.8 7.1 19.6 43.5 
Day 15 POMS- (n=1150; 84.4%) 0.8 0.5 4.5 16.5 
p value p<0.01 <0.001 <0.001 <0.001 
p’ value NS <0.01 <0.01 <0.01 
Table 35: Mortality according to POMS status on Postoperative Day 15 
 
 
4.3.8 Long term survival by postoperative morbidity status 
Kaplan Meier survival curves comparing patients with and without postoperative 
morbidity are shown in figures 37-41. 
Log-rank statistics show a significant difference in long-term survival between patients 
with and without morbidity overall, and on each of Days 3, 5, 8 and 15.  
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Figure 37: Univariate analysis of survival: any POMS defined inpatient morbidity 
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Figure 38: Univariate analysis of survival: Day 3 POMS status  
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Figure 39: Univariate analysis of survival: Day 5 POMS status  
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Figure 40: Univariate analysis of survival: Day 8 POMS status  
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Figure 41: Univariate analysis of survival: Day 15 POMS status  
 
4.3.9 Long term survival and postoperative morbidity domains 
The relationship between each domain and long term survival was plotted using Kaplan 
Meier survival curves and log-rank testing the difference. The survival curve for 
pulmonary morbidity is shown in figure 42. Log rank comparisons of long term survival 
between patients who did and did not develop pulmonary, renal, infectious, 
gastrointestinal, neurological, cardiac and pain morbidity all showed  statistically 
significant differences (p<0.0001). There was also a significant difference in survival 
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between patients who were positive and negative for haematological morbidity, with a 
p value of 0.0023. There was no difference in long term outcome based on the 
development of wound morbidity (p=0.4187) 
Kaplan Meier curves were also plotted (not shown) with the observations deleted for 
patients who died either within thirty days or while still in hospital after surgery (n=23; 
1.7%); these also showed a significant difference in long-term survival based on 
patients overall POMS morbidity status, and their status on days 3, 5, 8 and 15 (log rank 
p<0.0001 for any POMS morbidity and for pulmonary, renal, infection, gastrointestinal, 
cardiac, neurological and pain domains; p=0.038 for haematology and p=0.5004 for 
wound).  
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Figure 42:  Long term survival by incidence of pulmonary morbidity  
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4.3.10 Postoperative length of stay and Long term survival by duration of 
postoperative morbidity (Final Morbidity Day) 
Table 36 shows postoperative length of stay data based on the duration of 
postoperative morbidity.  
Postoperative 
length of stay 
No morbidity 
(n=368) 
FMD 3 
(n=266) 
FMD 5 
(n=278) 
FMD 8 
(n=238)  
FMD 15 
(n=212) 
Mean (sd) 5.88 (3.04) 7.95 (4.43) 10.36 (10.70) 14.69 (8.77) 33.54 (25.27) 
Median (IQR) 6 (4-7) 7 (6-9) 8  (7-11) 13 (11-15) 25 (19.5-36) 
 
Table 36: Relationship between Final Morbidity Day (FMD) and postoperative length of 
stay 
 
Figure 43 depicts the univariate analysis of long-term survival by duration of 
postoperative morbidity, as defined by the ‘Final Morbidity Day’ (FMD). Again, although 
the overall log-rank statistic indicates a significant difference between survival by the 
FMD category, visual inspection of the graph shows overlap in confidence intervals. 
Pair-wise analysis of FMD status reveals no significant difference in long-term survival 
between FMD 3 and 5 patients (p=0.0924) and between FMD5 and 8 patients 
(p=0.1244).  All other pair-wise comparisons were statistically significant.  
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Figure 43:  Univariate analysis of survival by final morbidity day (FMD) 
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4.3.11 Relationship between POMS status on POD5 and postoperative 
length of stay 
Mean length of stay in patients who survived hospital admission and who were POMS 
positive on Day 5 postoperatively was significantly higher than those who were POMS 
negative (See Table 37).  
 Median LOS Mean LOS (sd) p value 
Overall 9 12.69 (14.55)  
Day 5 POMS- 6 7.64 (6.09) 
p< 0.0001 
Day 5 POMS+ 13 17.87 (18.37) 
 
Table 37 Postoperative length of stay (inpatient survivors only) 
 
4.3.12 Relationship between POMS status on Day 5 and postoperative 
mortality 
Inpatient mortality was significantly higher in patients who had any of pulmonary, 
gastrointestinal or neurological morbidity on day 5 compared with patients who did not 
(see Table 38).  Inpatient and thirty-day mortality were both significantly higher in 
patients who had renal morbidity on day 5 postoperatively (see Table 38 and 39). 
Thirty day mortality was significantly higher in the patient group with haematological 
morbidity on day 5. The significance levels of all these results were corrected for 
multiple comparisons.  
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POMS status on day 5 was predictive of one year mortality in all domains with the 
exception of wound and infectious morbidity (see table 40).  Similarly at 5 years, Day 5 
POMS status differentiated between survivors and non-survivors, with the exception of 
wound, infectious and cardiac morbidity (p=0.05 for cardiac morbidity). (See Table 41)  
Morbidity domain Number of 
patients 
POMS + 
Mortality if 
negative; (%) 
Mortality if 
positive; (%) 
p’ value 
(Bonferroni 
correction for 
10 analyses)  
Any morbidity  679 0.7 2.4 NS (p’=0.15) 
Pulmonary  166 0.8 6.6 <0.01 
Infection  288 1.3 2.4 NS (p’=1.0) 
Renal 296 1.0 3.6 <0.05 
Gastrointestinal 376 0.8 3.5 <0.01 
Cardiac 50 1.4 6.0 NS (p’=0.09) 
Neurological 18 1.3 22.2 <0.01 
Wound 59 1.5 1.7 NS (p’=1.0) 
Haematology 27 1.4 7.4 NS (p’=0.12) 
Pain 149 1.2 4.0 NS (p’=0.09) 
Table 388  Univariate analyses of Day 5 POMS defined morbidity and in-hospital 
mortality 
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Morbidity domain Number of 
patients 
POMS + 
Mortality if 
negative; 
n (%) 
Mortality if 
positive; 
n (%) 
p’ value 
(Bonferroni 
correction for 
10 analyses)  
Any morbidity  679 0.6 1.6 NS (p’=0.67) 
Pulmonary  166 0.8 3.6 NS (p’=0.059) 
Infection  288 1.1 1.4 NS (p’=1.0) 
Renal 296 0.7 2.6 <0.05 
Gastrointestinal 376 0.7 2.1 NS (p’=0.25) 
Cardiac 50 1.0 4.0 NS (p’=0.45) 
Neurological 18 1.0 5.6 NS (p’=0.68) 
Wound 59 1.2 0.0 NS (p’=1.0) 
Haematology 27 1.0 7.4 <0.05 
Pain 149 1.0 2.0 NS (p’=1.0) 
Table 39  Univariate analyses of Day 5 POMS defined morbidity and 30 day mortality  
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Morbidity domain Number of 
patients 
POMS + 
Mortality if 
negative (%) 
Mortality if 
positive (%) 
p’ value 
(Bonferroni 
correction for 10 
analyses)  
Any morbidity  679 3.2 10.5 <0.01 
Pulmonary  166 5.1 19.5 <0.01 
Infection  288 5.9 10.2 NS (p’=0.12) 
Renal 296 5.0 13.3 <0.01 
Gastrointestinal 376 4.5 13.0 <0.01 
Cardiac 50 6.4 18.4 <0.05 
Neurological 18 6.5 33.3 <0.01 
Wound 59 7.0 3.5 NS (p’=1.0) 
Haematology 27 6.4 29.6 <0.01 
Pain 149 5.3 19.2 <0.01 
Table 39  Univariate analyses of Day 5 POMS defined morbidity and one year 
mortality 
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Morbidity domain Number of 
patients 
POMS + 
Mortality if 
negative (%) 
Mortality if 
positive (%) 
p’ value 
(Bonferroni 
correction for 
10 analyses)  
Any morbidity  679 12.30 29.22 <0.01 
Pulmonary  166 17.94 40.49 <0.01 
Infection  288 19.11 26.60 NS (p’=0.06) 
Renal 296 16.87 34.12 <0.01 
Gastrointestinal 376 15.64 34.06 <0.01 
Cardiac 50 20.08 36.73 NS (p’=0.05) 
Neurological 18 20.21 55.56 <0.01 
Wound 59 20.92 15.52 NS (p’=1.0) 
Haematology 27 20.20 40.44 <0.05 
Pain 149 19.01 34.48 <0.01 
Table 40  Univariate analyses of Day 5 POMS defined morbidity and five year 
mortality 
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4.4 Discussion 
4.4.1 Summary of findings 
There were no significant differences in mortality at hospital discharge, 30 days, 1 year 
or 5 years between the two cohorts of SOuRCe patients.  
Shorter-term (30 day and inpatient) mortality varied between surgical specialities: it 
was significantly worse for vascular and general surgery than for orthopaedics or 
urology. There were also differences in mortality between surgical specialities at one 
and five years postoperatively.  
There were differences in the prevalence and patterns of morbidity between surgical 
specialities. Overall, pulmonary, infection, gastrointestinal, renal and pain morbidity 
were more common than neurological, cardiac, wound or haematological complications. 
For most types of morbidity the prevalence was highest at the beginning of the 
postoperative period and dropped on successive postoperative days; however, cardiac 
complications peaked on day 5 and wound complications peaked on day 8. 
Log-rank testing of Kaplan-Meier survival curves comparing outcome for patients in 
different categories of perioperative risk showed significant differences between risk 
groups for all the risk stratification tools which were tested (additive POSSUM, POSSUM 
physiology score, SRS and ASA-PS); however, there was overlap in confidence intervals 
for many of these comparisons.  
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Univariate analyses showed significant differences in mortality at one and five years 
between patients who did and did not develop any POMS defined morbidity at any point 
during the inpatient stay, and also based on POMS status on Days 3 and 5. POMS 
positive status on Days 8 or 15 was also associated with higher inpatient death rate, as 
well as higher one and five year mortality. Comparing survival for patients according to 
their POMS status on each of days 3, 5, 8 and 15, and overall POMS status showed 
significant differences in outcome. Survival distributions were also significantly 
different for patients who developed any of the individual types of morbidity recorded 
by the POMS, with the exception of wound morbidity.  
Comparing patients with different durations of postoperative morbidity, as defined by 
the ‘Final Morbidity Day’, showed that FMD 15 was associated with significantly worse 
long-term survival when compared with the other classes.  
Univariate analysis showed significant associations between each of pulmonary, renal, 
gastrointestinal, haematological, and neurological morbidity on Day 5 and shorter-term 
mortality. With the exception of infection and wound classes, complications in any of 
the individual POMS domains on Day 5 were all significantly associated with one year 
mortality.  At five years, mortality was significantly higher for patients who had any 
type of morbidity on Day 5 apart from infectious, wound or cardiac.  
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4.4.2 Results in context 
4.4.2.1 Surgical speciality and postoperative morbidity 
The differences in patterns of morbidity between surgical specialities are plausible and 
consistent with the literature.44;315 One would expect that there would be less morbidity 
in patients having orthopaedic surgery (which in the majority of cases were joint 
replacement procedures aimed at alleviating pain and improving quality of life), than in 
patients having cancer surgery or vascular surgery. Similarly, vascular patients, who by 
definition have atherosclerotic disease, had higher rates of cardiac and neurological 
morbidity, which again is consistent with other reports.  
4.4.2.2 Surgical speciality and long-term mortality 
Again, it is not surprising that there were significant differences in long-term mortality 
between surgical specialities on univariate analyses. For example, it is probable that 
patients undergoing vascular surgery for example, are more likely to have significant 
cardiac or other atherosclerotic disease than those undergoing urological surgery. 
However, the main implication of this confirmed difference in outcome between 
surgical specialities is that it suggests that surgical speciality should be included as a co-
variate in multivariable analysis of long-term survival, even if the POSSUM score is used 
as a risk adjuster. POSSUM, while considering the urgency and severity of the surgical 
procedure, does not include speciality as a variable; furthermore, the original POSSUM 
development cohort consisted of general, urological and vascular patients (no 
orthopaedics) and therefore it is possible that surgical speciality may not have been 
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included in the original multivariable analysis which developed the POSSUM. Even if 
surgical speciality was included, it may not have been associated with differences in 
outcome as the population of patients was more homogeneous.38  In the ACS-NSQIP, 
different risk adjustment models are constructed for different surgical specialities, as 
the most significant predictors vary between groups.316;317 
4.4.2.3 Patterns of postoperative morbidity 
With two exceptions, different types of morbidity were most common on Day 3 and the 
prevalence fell steadily after that. Cardiac morbidity peaked on Day 5. This might be 
considered surprising given that previous reports suggest that postoperative 
myocardial infarction (MI) is most likely to occur within the first three days of 
surgery.318;319 There are likely to be two main reasons for this discrepancy. The first, is 
that the cardiac domain of the POMS records the occurrence of cardiovascular events or 
interventions in the previous 24 hours (so the incidence of cardiac morbidity is actually 
highest on day 4 compared with days 2, 7 and 14). The second is that at least one of the 
diagnostic criteria for cardiac morbidity (hypotension requiring pharmacological 
therapy or >200ml/hour of fluid therapy) may have non-cardiac aetiology (for example 
sepsis or bleeding).  
Wound morbidity peaked on Day 8.  Although there is a great deal in the literature 
about the incidence and risk factors for wound complications,320-322 I was unable to find 
any studies which specifically reported the pattern of timing of surgical wound 
morbidity.   
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4.4.2.4 Type and timing of morbidity and postoperative mortality 
With the exception of wound complications, the occurrence of any of the other types of 
morbidity was associated with reduced long-term survival on univariate analysis. This 
is consistent with the ACS-NSQIP study examining the relationship between 
postoperative morbidity and long-term outcome.151  
The occurrence of morbidity on any of the four postoperative days on which the POMS 
was recorded, was also associated with a reduction in long-term survival. There has 
been previous discussion about the validity of Day 3 POMS as a true reflection of 
morbidity, as some of the interventions on which POMS morbidity is defined (for 
example, administration of oxygen therapy or parenteral opioids) may under some 
circumstances be part of the normal package of postoperative care, rather than being 
evidence of harm.56  Therefore, it might appear surprising that POMS on Day 3 was 
associated with reduced long-term survival, especially given that the majority of 
patients had POMS defined morbidity on Day 3 (67.8%). Explanations for this might 
include interaction with (confounding by) the operative type and severity or with 
preoperative risk. The magnitude of the risk which postoperative morbidity carries for 
long-term survival cannot be estimated on univariate analyses, and therefore 
multivariable analysis is required to estimate the magnitude of the hazard and whether 
this risk is still apparent when confounding factors are considered. This analysis is the 
subject of Chapter 5.  
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4.4.2.4 Duration of complications and long-term survival 
Univariate analyses showed a significant difference in long-term survival between 
patients who remained in hospital with complications on Day 15 and those who 
recovered more quickly. The hypothesis that duration of illness is related to severity of 
illness and length of stay has face validity and is consistent with previous reports, both 
in surgery and in other settings (for example, critical care).323;324   
 
4.4.2.5 Relationship between Day 5 POMS and other outcomes 
In choosing a particular day on which to measure the POMS, one must bear in mind that 
changes in healthcare delivery over the past decade, and in particular the 
implementation of enhanced recovery pathways, have led to dramatic reductions in 
postoperative length of stay.325 The median postoperative hospital length of stay for 
patients in this study (between 2001 and 2005) was 9 days, and for orthopaedic 
patients it was 8 days; current SOuRCe data (not within this thesis) show that median 
length of stay after primary joint replacement at UCLH is now 6 days. Hospital Episode 
Statistics data reveal that the national median hospital length of stay for primary hip 
and knee replacement is now just four days, for colectomy is 7.6 days, and for rectal 
excision is 9 days. Therefore, while the presence of POMS defined morbidity on Day 8 or 
15 may be indicative of the most serious complications, if either of these were to be 
used as a single measure of postoperative outcome, it is possible that a low incidence 
may mean larger than feasible sample sizes are necessary for clinical trials. It is also 
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possible that significant morbidity (with long-term implications) might be missed in 
patients who have been discharged home within seven days.  
When considering an outcome measure for clinical effectiveness studies in general, one 
must give consideration to the incidence (for the purposes of power calculations) and 
the clinical relevance of the proposed measure. Validation of outcome measures 
requires (amongst other things) establishing face and content validity (‘on the face of it’, 
does the instrument measure the relevant outcome and does it do so 
comprehensively?), construct validity (does the measure fit with our understanding of 
the outcome and the implications of the outcome?). The POMS as a whole has already 
been validated against these and other criteria;56 Day 5 POMS on its own also fits well 
with these criteria. Nearly 50% of patients in this study had POMS defined morbidity on 
Day 5. There were significant associations on univariate analysis between Day 5 
morbidity and shorter term mortality (inpatient, thirty day or both) for five out of the 
nine POMS domains. The Day 5 POMS positive group of patients also had a significantly 
longer length of hospital stay, and higher mortality at one and five years. Although 
measurement of POMS at four time points and recording the final morbidity day would 
be better descriptors of postoperative morbidity and its duration and severity, if a 
single point prevalence estimate of postoperative harm is required, then Day 5 POMS 
would be a valid choice.   
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4.4.3 Limitations of this study 
The main limitation of this study, as with previous chapters, is lack of generalizability to 
cohorts which include patients having emergency surgery. The population is also 
unevenly distributed between surgical specialties – there are very few patients having 
vascular surgery, and the number of patients’ undergoing orthopaedic surgery was 
disproportionately high; this is of importance, as these patients have been shown to 
have considerably lower morbidity than other patient groups.  
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4.5 Conclusions 
1. The type and prevalence of morbidity varies with surgical speciality; 
postoperative mortality rates, both shorter and longer-term also varied between 
different surgical specialties. Postoperative outcomes were worse for patients 
undergoing vascular and general surgery compared with urology and 
orthopaedics.   
2. Univariate analysis demonstrated differences in longer-term survival between 
patients in different risk groups as determined by POSSUM category.  
3. There are significant relationships on univariate analyses between postoperative 
morbidity and longer-term mortality. The occurrence of morbidity at any stage 
postoperatively, as well as individual types of complication were all associated 
with reduced longer-term survival.  
4. Increased duration of morbidity, as defined by the ‘Final Morbidity Day’ is 
associated with increased length of hospital stay and reduced longer-term 
survival on univariate analysis. 
5. POMS defined morbidity on Day 5 after surgery is a valid measure of 
postoperative harm and would be a valid single outcome measure in clinical 
effectiveness studies.  
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Chapter Five: Survival after 
postoperative morbidity – a 
longitudinal prospective observational 
cohort study 
5.1 Introduction and aims 
This study explores the long-term outcome of patients who underwent major non-
cardiac non-neurosurgical procedures at the Middlesex Hospital between 2001 and 
2005. The cohort is the same as that discussed in Chapters 3 and 4.  
The aims of this chapter were: 
1. To build a Cox proportional hazards model for long-term survival of the SOuRCe 
cohort.  
2. To determine whether postoperative morbidity is an independent risk factor for 
reduced long-term survival 
5.2 Methods 
5.2.1 Overview 
This was an observational cohort (long-term follow-up) study. Perioperative patient 
data (demographics, the POSSUM predictor and the Post Operative Morbidity Survey, 
[POMS]) were linked with mortality data which was provided by the Medical Research 
228 
 
 
Information Service (NHS Information Centre). Multivariable analysis using Cox 
Proportional Hazards modelling was used to determine the relationship between 
perioperative risk and outcome, and long term survival.  
5.2.2 Patients and data 
The 1362 patients from the SOuRCe cohort were eligible for inclusion. Patient 
recruitment and selection is described in Chapter 3. Patients were excluded if data 
linkage with the Medical Research Information Service (MRIS) database was not 
possible for any reason. Patients who died within 15 days of surgery were also excluded 
from the analysis as Day 15 POMS status was included as an explanatory variable. 
Additionally, patients who were lost to follow up for any reason were excluded. The 
dataset is as described in Chapters 3 and 4. Linkage between the SOuRCe dataset and 
the NHS Information Centre MRIS dataset was achieved using patient name, date of 
birth, postcode and NHS number.  Time zero was operation date; right-censoring 
occurred on 1 March 2012.  
 
5.2.3 Statistical Approach 
5.2.3.1 Determination of variables to enter into analysis 
Independent variables were selected on the basis of known association with short- and 
long term mortality and /or morbidity from univariate analysis and / or the published 
literature. Based on the results of Chapters 3 and 4,  P-POSSUM predicted mortality was 
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chosen as a marker of perioperative risk; neither ASA-PS nor Surgical Risk Scale were 
included in models as P-POSSUM was shown to be a more highly discriminant predictor 
for this cohort. P-POSSUM predicted mortality was entered as a continuous variable. 
Surgical speciality and gender were included as indicator variables; gender was 
considered a potential confounder, as men are known to have a shorter life expectancy 
than women.326  
Postoperative morbidity was entered into the analysis in a number of ways, all of which 
were based on POMS results. The occurrence of morbidity at any stage during the 
postoperative stay was entered as separate indicator variables for each of the nine 
POMS domains, with an additional variable for the occurrence of any POMS-defined 
morbidity during the inpatient episode.  While POMS is a validated measure of 
postoperative harm, it has not been validated as a ‘score’ (that is, it is not valid to 
consider that the number of POMS domains scored is directly related to the severity of 
morbidity).56 However, the relationship between the duration of morbidity (Final 
Morbidity Day, FMD), length of stay and long-term survival was established in Chapter 
4; therefore FMD was entered for each patient as multiple dichotomous variables.  
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5.2.3.2 Interactions 
Based on established knowledge, and the results of univariate analysis, interactions 
between the following variables were tested:  
 Gastrointestinal morbidity and general surgery 
 Renal morbidity and urological surgery 
 cardiac morbidity and vascular surgery 
 wound morbidity and orthopaedic surgery  
5.2.3.3 Post-estimation analyses 
After constructing an initial model, the Proportional Hazards (PH) assumption was 
tested using Schoenfeld’s partial residuals and the result confirmed by visual 
examination of a log-minus-log survival plot.  Both tests showed that the PH assumption 
was seriously violated. Plotting baseline cumulative hazard for patients with and 
without morbidity on Day 15 postoperatively demonstrated a ‘step’ in the cumulative 
hazard at approximately three years postoperatively in the ‘Day 15 positive’ group (see 
Figure 44). It is also intuitive that the impact (if any) of surgery and / or postoperative 
morbidity on long term outcome is likely to vary over time. Therefore, time was 
included as an interaction with duration of postoperative morbidity, in order to avoid 
the need to comply with the PH assumption.327 The postoperative era was split into 
three periods: 0-365days, 366-1095 days, more than 1095 days.  The full model 
included the interactions of each of these time categories with each of the final 
morbidity day categories.  
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Figure 44: Baseline Cumulative Hazard graph for cohort based on Day 15 POMS status  
 
5.2.3.4 Development of final model 
The choice of variables to enter into the final model was based on significance testing; 
initially variables were dropped based on p values > 0.10 then p>0.05. Model fit was 
assessed with Likelihood Ratio testing against the full model.  
All statistical analyses were conducted using Stata InterCooled (Release 12.1) software 
(StataCorp LP, College Station, Texas, USA).   
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5.3 Results 
5.3.1 Description of cohort 
Of the SOuRCe cohort of 1362 patients, data were analysed for 1342.  The reasons for 20 
exclusions were as follows: missing follow-up data (n=13) and death within 15 days of 
surgery (n=7).  There were 383 deaths in the final group (28.1%); maximum duration of 
follow up was 10.66 years (3895 days) median follow up was 6.51 years (2375 days, 
IQR 2696 to 2899).    
5.3.2 Model development 
The full model consisted of 49 variables; these are listed, along with individual Hazard 
Ratios, standard errors, p values and 95% confidence intervals in Table 42. The 
Likelihood Ratio test was associated with a Chi Squared of 316.99, giving a p value of 
<0.0001, thus demonstrating good fit.  The variables which are listed as ‘omitted’ were 
excluded from the analysis on the basis of collinearity with other variables. The full 
model was narrowed down to a final model of six variables, which is described in Table 
43. The LR Chi squared for the final model was 262.49, giving a p value of <0.0001. On 
Likelihood Ratio testing with the original full model, the p value was 0.0507, indicating 
that the final model was not significantly different from the full model and therefore 
also had good fit.  
 
          
       
233 
 
 
Variable Hazard 
ratio 
Standard 
error 
p value 95% C.I. 
Patient / Surgical risk factors 
P-POSSUM  1.072 0.010 <0.001 1.053- 1.091 
Male gender 1.231 0.132 0.053 0.997 -1.520 
Orthopaedics 1.552 0.619 0.271 0.710 -3.393 
General 3.687 1.742 0.006 1.460 -9.310 
Vascular 2.413 1.127 0.059 0.966 - 6.030 
Urology 1 (reference) 
POMS defined morbidity domains 
Pulmonary  1.055 0.149 0.705 0.800 - 1.392 
Infection 1.047 0.128 0.707 0.824 -1.331 
Renal 1.108 0.145 0.434 0. 857 - 1.432 
Gastrointestinal 0.794 0.127 0.150 0.581 - 1.087 
Cardiac 1.274 0.243 0.204 0.877 - 1.852 
Neurological 1.951 0.437 0.003 1.257 - 3.027 
Haematological 1.129 0.193 0.477 0.808 -1.580 
Pain 0.923 0.132 0.575 0.697 -1.221 
Wound 0.790 0.193 0.335 0.489 -1.275 
Time dependent interactions between duration of morbidity and longer-term survival 
FMD15 + post-op Year 1 8.956 4.625 <0.001 3.255 - 24.641 
FMD15+ post-op Year 2&3 9.107 4.388 <0.001 3.541 - 23.418 
FMD15+ post-op ≥ Year 4 1.668 0.504 0.091 0.922 - 3.014 
FMD8 + post-op Year 1 3.278 1.774 0.028 1.134 -9.472 
FMD8 + post-op Year 2&3 5.130 2.476 0.001 1.992 -13.214 
FMD8 + post-op ≥ Year 4 1.426 0.388 0.192 0.837 - 2.432 
FMD5 + post-op Year 1 2.891 1.558 0.049 1.006 - 8.312 
FMD5 + post-op Year 2&3 4.778 2.273 0.001 1.881 - 12.140 
FMD5 + post-op ≥ Year 4 1.140 0.302 0.620 0.679 -1.915 
FMD3 + post-op Year 1 2.641 1.464 0.008 0.891 - 7.829 
FMD3 + post-op Year 2&3 4.168 1.998 0.003 1.629 -10.666 
FMD3 + post-op ≥ Year 4 1.221 0.300 0.416 0.755 - 1.975 
Interactions between types of surgery and POMS defined morbidity 
General / GI morbidity  0.876 0.284 0.682 0.463 -1.654 
Orthopaedics  / Wound morbidity  1.268 0.406 0.459 0.677 -2.373 
Urology  / Renal morbidity  1.053 0.469 0.907 0.440 - 2.519 
Vascular /Cardiac morbidity  1.780 0.769 0.177 0.771 - 4.107 
  
Table 41: Full Cox Proportional Hazards models for long term survival after major 
surgery 
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5.3.3 Relationship between perioperative risk, postoperative morbidity 
and long-term survival 
These data show that, independent of pre and intra-operative risk factors, the 
occurrence of neurological morbidity after surgery (prevalence 2.9%) is associated with 
a relative hazard for long term mortality of 2.53 (p<0.001; 95% C.I. 1.66 - 3.84). 
Furthermore, if a patient remains in hospital on Day 15 post-surgery with any type of 
morbidity as defined by the Post-Operative Morbidity Survey (prevalence 15.6%), the 
relative hazard for death in the first 12 months post surgery is 3.52 (p<0.001; 95% C.I. 
2.23-5.43) and for the next 2 years is 2.33 (p<0.001; 95% C.I. 1.56-3.50).   
Variable Hazard 
Ratio 
Standard 
error 
p value 95% C.I. 
p-POSSUM percentage risk 1.07 0.01 <0.001 1.06-1.09 
General surgery 2.23 0.26 <0.001 1.84-2.85 
Vascular surgery 2.41    0.49 <0.001 1.62-3.58 
Neurological morbidity 2.53 0.54 <0.001  1.66 - 3.84 
FMD15 + Postoperative Year 1 3.52 0.78 <0.001  2.23-5.43 
FMD15 + Postoperative Year 2-3 2.33 0.48 <0.001  1.56-3.50 
 
Table 42:  Final Cox Proportional Hazards Model for long term mortality after major 
surgery 
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5.4 Discussion 
5.4.1 Summary of findings 
Cox Proportional Hazards Modelling demonstrates that, patients with prolonged 
postoperative morbidity (as defined by remaining in hospital with POMS defined 
morbidity on Day 15 post-surgery) have a risk- adjusted mortality rate over 3.5 times 
higher than those who do not in the first year after surgery, and more than twice as high 
in the second and third postoperative years. After 3 years, the hazard for early mortality 
of prolonged postoperative morbidity returns to baseline when adjusted for other risk 
factors. Of specific postoperative complications, neurological morbidity was the only 
POMS defined domain which was independently associated with reduced postoperative 
survival. 
5.4.2 Results in context of previously published work 
The results differ from a previously published report (Khuri’s 2005 paper analysing 
long-term survival in over 100,000 patients from the ACS-NSQIP)151 in so far as the 
significance of the impact of major complications on longer term outcome is dependent 
on the duration  of time since the surgical (and morbidity) insult. By using time as an 
interaction term with postoperative morbidity the temporal relationship between short 
and long term outcome has been elucidated in greater depth than previous reports. This 
was necessary because the initial analysis revealed that proportionality could not be 
demonstrated, therefore implying that the difference between the hazards in different 
risk groups varied over time.  This was subsequently clearly demonstrated in the final 
236 
 
 
analyses. Proportionality testing was not declared in Khuri’s paper, and in fact, the ‘step’ 
change in mortality rate which occurred at varying times postoperatively for different 
surgical procedures was highlighted in the results (see Figure 1 in the Introduction). 
These diagrams indicate that even in the NSQIP cohort, the hazard may in fact vary 
(most likely, reduce) with time, as has been found in the SOuRCe cohort.  
With the exception of Khuri’s paper detailed above, all the studies identified on review 
of the literature which have previously examined the relationship between 
perioperative complications and long-term survival, were conducted in cohorts of 
patients undergoing cancer surgery.328-335 As the majority of patients in our study were 
undergoing elective non-cancer surgery, these findings have important implications for 
the informed consent process for patients undergoing surgery which may be life-
enhancing (such as joint replacement) rather than life-saving. 
 
5.4.3 Clinical implications 
The significance of these results can be gauged by comparing against the findings 
epidemiological studies of clinical and environmental risk factors which are frequently 
discussed in the medical literature and in the general press. The SOuRCe study 
population was predominantly middle-aged (median age 66 years; IQR 56-75); in a 
similarly aged population, the adjusted relative hazard conferred by smoking more than 
20 cigarettes per day was 2.62 (95% C.I. 2.20 to 3.12) for women and 3.04 (95% C.I. 
2.71 to 3.40) for men.336  Diabetes mellitus was shown to confer an adjusted relative 
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hazard for all-cause mortality of 2.3 (95% C.I. 1.6 to 3.2) in one study with a median 
follow up time of 5.2 years. In Caucasian adults, obesity has been found to be associated 
with a progressive increase in relative hazard (compared with a BMI 22.5-24.9) of 1.44 
(95% CI, 1.38 to 1.50) for a BMI of 30.0 to 34.9; 1.88 (95% CI, 1.77 to 2.00) for a BMI of 
35.0 to 39.9; and 2.51 (95% CI, 2.30 to 2.73) for a BMI of 40.0 to 49.9.337  With 
prolonged morbidity, the relative hazard for year after surgery is 3.52 and for the next 
two years it is 2.33. While after this, relative hazard falls back to baseline, postoperative 
morbidity is still a significant, and importantly, potentially preventable source of long-
term harm to patients.  
Short–term postoperative morbidity and mortality continues to vary across providers 
and healthcare systems,2;338 and evidence that these variations can be minimised is 
accumulating.  The ACS-NSQIP is one enterprise that shows that open and careful 
scrutiny of surgical outcome leads to improvements.339;340 Initiatives such as the World 
Health Organisation Safer Surgery Checklist, have demonstrated that instigating simple 
measures to improve process in the perioperative period may lead to a reduction in 
short-term mortality and morbidity.341 Wider implementation of strategies such as goal-
directed fluid therapy,144 enhanced recovery (or ‘fast- track surgery’) programmes,342 
and the expansion of critical care facilities so that a greater number of high risk patients 
can be managed in high-acuity ward areas2 is required to reduce the disease burden 
which arises from the development of postoperative complications. 
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Furthermore, excess mortality may not be the only consequence of perioperative 
complications. It is known from long term follow up studies in other areas such as 
critical care that even if a patient survives their illness, general health may 
deteriorate.343 A recent study of patients who survived 5 years after surgery for 
oesophageal cancer, has shown a significant difference in health-related quality of life 
(related principally to dyspnoea, fatigue and eating habits) between patients who did 
and did not have major perioperative complications. 344 A similar relationship between 
perioperative morbidity  and longer term HRQOL has also been demonstrated in 
colorectal surgery.345 Nevertheless, it remains the case that whatever the preoperative 
risk is, a significant proportion of perioperative morbidity may be avoidable, and 
therefore clinical and health economic strategies should focus on preventing harm.  
Previous work has demonstrated substantial international variation in postoperative 
morbidity rates.346 Despite this, perioperative morbidity is not routinely measured or 
reported in many healthcare systems, including the UK NHS. Surgical mortality is often 
used as a marker of quality; however for many procedures, short-term postoperative 
mortality remains low; therefore very large sample sizes are required to be able to 
conduct meaningful comparisons between healthcare providers.2 347 These data 
demonstrate that the adverse health impact of a complicated postoperative course 
persists far beyond the endpoints at which surgical mortality is usually measured (such 
as 30-day or even one-year). Therefore, it is proposed that prolonged postoperative 
morbidity measured in this way, using a validated and objective outcome measure, may 
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be an important indicator of the quality of surgical healthcare, for the purposes of 
research, benchmarking and quality improvement.  
5.4.4 Other potential explanations 
Can the results of this study be explained in any other way? Inaccurate risk adjustment 
may lead to spurious associations being found. The use of the P-POSSUM model to 
adjust for perioperative risk seems valid based on the systematic review detailed in 
Chapter 2 and the analysis of Receiver Operator Characteristic curves for this cohort in 
Chapter 3. Importantly, the final model is clinically plausible: for example, POMS defined 
neurological morbidity has also been shown to be associated with an increased long-
term hazard (not time dependent) – this is consistent with the literature reporting the 
lasting harm associated with postoperative cognitive dysfunction and delirium.178  
It is also possible that the inflammatory response which is presumed to lead to 
increased longer term mortality, may exist sub-clinically and therefore undetected, even 
before surgery, and may therefore be the cause rather than the result of postoperative 
complications, subsequently leading to long-term risk. For example, low serum 
endotoxin core antibody (EndoCAb) levels are predictive of postoperative 
complications both in cardiac 23 and non-cardiac surgery, 24 and independently of 
POSSUM risk score.24  However, if the long-term outcome of patients with complications 
was ‘pre-determined’ by an unknown or unmeasured risk factor, then one might expect 
that risk to be consistent over time, rather than changing, as is the case with the effect of 
complications on mortality found in this study.  
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5.4.5 Limitations of this study 
The first limitation is generalizability; this was a single centre study and the patient 
population was entirely elective; it is possible that different risk factors would have 
been significant if emergency surgical patients had been included. Second, no 
adjustment was made for the effect that social deprivation might have had on outcome. 
Although a previous study looking at a sub-group of the orthopaedic patients in this 
cohort concluded that there was minimal socio-demographic gradient in risk or 
postoperative complications,348 life expectancy is strongly related to index of 
deprivation349 and therefore this may have influenced long-term survival. Third, the risk 
adjustment was confined by the limitations of the original SOuRCe dataset, and there 
are risk factors for both perioperative and long-term outcome which were not included 
in the model (diabetes mellitus for example). It is therefore possible that the case-mix 
adjustment was not as precise as possible and that the presence of latent, unmeasured 
confounding may have lead to an overestimation of the association between 
postoperative morbidity and long-term outcome. However, the P-POSSUM model has 
been widely validated as a perioperative risk adjuster, and in this population, we found 
it to be highly discriminant for the prediction of short-term mortality, therefore 
justifying its use. Finally, it is possible that our study may have been insufficiently 
powered to detect some significant predictors of reduced long-term survival. In 
particular, cardiac morbidity looked on the initial model to be significant; however, the 
confidence intervals were wide and in the stepwise analyses this lost statistical 
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significance. Analysis of a larger cohort using similar indicator variables would be a 
useful aim of future work.  
5.5 Conclusions 
1.  Independent of preoperative risk, postoperative neurological morbidity is associated 
with reduced long-term survival 
2.  Independent of preoperative risk, prolonged postoperative morbidity is associated 
with reduced survival for the first three years after surgery, with over three times 
higher than adjusted baseline hazard in the first postoperative year, and over twice the 
adjusted baseline hazard for two years after that.  
3. Prolonged postoperative morbidity may be a valid indicator of the quality of 
perioperative healthcare. 
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Chapter Six: Conclusions and future 
work 
6.1 Summary of contents of thesis 
Predicting risk and measuring outcome of major surgery is important to both patients 
and providers of healthcare. A number of studies and reports from within the UK and 
beyond have highlighted failings in current systems both in measuring risk and 
outcome, and also in acting on the results of these measurements. Recent reports have 
highlighted that clinicians seem reluctant to undertake routine perioperative risk 
prediction. This is a missed opportunity, as conducting such measurements would 
provide an individualised estimate of perioperative risk, thereby facilitating a more 
informative consent process for the patient, and enabling the perioperative team to plan 
their strategy of care more appropriately. This is particularly important as the evidence 
shows us that there is significant variation in patient outcomes and standards of care 
between healthcare institutions. Accurate perioperative risk prediction would enable 
the implementation of strategies aimed at modifying surgical risk and allow limited 
resources –such as the provision of planned postoperative critical care – to be allocated 
to those patients who would be most likely to benefit. The failure of clinicians to widely 
adopt the use of risk prediction tools in perioperative medicine may in part be due to a 
lack of understanding of the accuracy of these tools, and of their strengths and 
limitations.  
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This thesis has attempted to advance knowledge in how to predict risk and measure 
outcome. A systematic review of risk stratification tools identified two tools in 
particular – the P-POSSUM model and the Surgical Risk Scale – as being the instruments 
which have been most consistently and well validated for the prediction of mortality 
after surgery in heterogeneous populations of patients. A single-centre study of 1362 
patients who had major inpatient orthopaedic, general, urological or vascular surgery, 
demonstrated that the P-POSSUM model was an accurate predictor of short-term 
mortality, although it was poorly calibrated, consistently over-predicting risk of adverse 
outcome. The Surgical Risk Scale performed poorly in this population. A simple additive 
POSSUM score was also found to be an accurate predictor of short-term mortality, and 
use of such a scoring scheme, rather than a regression model, might be of greater appeal 
to clinicians in day-to-day practice. Additionally, the POSSUM physiology score was also 
found to be a moderately precise predictor of short-term mortality and merits further 
validation in multicentre cohorts.  
The epidemiology of postoperative morbidity was described using a validated measure 
of morbidity (the Post Operative Morbidity Survey, POMS) and mortality measured at a 
variety of shorter and longer term endpoints. Mortality, morbidity and length of stay 
varied between surgical specialities. A clear relationship between postoperative 
morbidity as measured by the POMS, and resource utilisation (length of stay), short 
term mortality and long-term survival was demonstrated on univariate analyses. In 
addition, the Day 5 POMS was found to have face validity as a single measure of 
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postoperative morbidity, with significant associations observed between individual 
POMS domains measured on Day 5, and short and longer term mortality.  
The various threads of this thesis were drawn together in a final study evaluating the 
independent relationships between perioperative risk (measured using the P-POSSUM), 
surgical speciality, and postoperative morbidity. POMS-defined neurological morbidity 
confers a clinically and statistically significant long-term risk of premature death, 
independent of premorbid status as measured by P-POSSUM. Prolonged postoperative 
morbidity, defined as remaining in hospital on Day 15 post-surgery, with POMS-defined 
morbidity, and which afflicted 15% of the study population, was associated with more 
than 3.5 times the baseline adjusted hazard of death for one year after surgery, and 
more than twice the hazard for the next two years after that. I believe this to be the first 
study to specifically link prolonged morbidity, of any severity, with a longer term risk of 
premature death. This may also be the first study to demonstrate a fluctuating temporal 
relationship between postoperative morbidity and the longer-term risk of reduced 
survival:  although the risk persists long after the patient is discharged from hospital, 
the magnitude of this risk reduces over time, returning to baseline after three years. 
Prolonged postoperative morbidity, measured in this objective and validated manner, 
would be an important indicator of the quality of surgical healthcare, which could be 
used both for the purposes of comparative audit, and as an outcome measure in clinical 
studies.  
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6.2 Future directions 
6.2.1 Risk stratification 
The P-POSSUM model is a valid, accurate predictor of postoperative mortality. Impact 
studies should be the next step in the evaluation of this risk prediction system.248 A 
suitable study design might be a stepped-wedge cluster randomised controlled trial, in 
which the intervention is the implementation of risk prediction using P-POSSUM 
(perhaps using POSSUM physiology preoperatively, and then recalculating P-POSSUM at 
the end of surgery) and the subsequently the individualised modification of 
perioperative management in accordance with the predicted level of patient risk.  
6.2.2 Morbidity measurement 
The relationship demonstrated between short term morbidity and longer term 
mortality supports the argument for the routine measurement of postoperative 
morbidity as an indicator of the quality of surgical healthcare. However, the rate-
limiting step in such an initiative would be the identification of resources to support it – 
particularly with the current financial constraints on the NHS. Health economic studies 
are required to evaluate the cost-effectiveness of measuring morbidity (either POMS 
measured on Day 5 or morbidity in patients with prolonged length of hospital stay, or 
both). Evaluation of novel technology would enhance efforts to reduce the resources 
required to measure both risk adjustment variables and the POMS, such as introducing 
automated linkage with hospital Information Technology systems. Perhaps most 
effective, however, would be either a ‘carrot’ (for example CQUIN incentive) or a ‘stick’ 
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(mandatory implementation of outcomes data collection demanded by the Department 
of Health). The latter approach, albeit with some government investment, has led to the 
development of the NSQIP in the US. There is some hope in the UK that the ‘carrot’ 
approach may work: the enrolment of over 90% of general adult critical care units in 
England with the Case-Mix Programme of the Intensive Care National Audit & Research 
Centre is a good example of clinical engagement with the aim of measuring risk adjusted 
outcome, for the purposes of quality improvement. The anaesthesia profession in the 
UK has a great track record of engaging in short-term data collection exercises, such as 
EuSOS,2 the NCEPOD audits,241 or the Royal College of Anaesthetists’ National Audit 
Projects (NAPs)350;351 Such successes give hope that the aspiration of routine 
perioperative outcome collection is not an impossible dream. 
6.2.3 Conclusion 
The P-POSSUM and Surgical Risk Scale are at least moderately accurate predictors of 
short term postoperative mortality. The POSSUM physiology score warrants further 
evaluation as a preoperative risk predictor. Prolonged postoperative morbidity is an 
independent predictor of longer term mortality, and would be an important and 
relevant measure of the quality of surgical healthcare. The implementation of routine 
measurement of risk adjusted morbidity and mortality after major surgery should be 
prioritised as an aim of health services research into surgical outcome in the future.  
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Appendix: Peer reviewed publications from this thesis 
 
Chapter One: 
Moonesinghe SR, Mythen MG, Grocott MP. High risk surgery: epidemiology and 
outcomes. Anesth Analg. 2011 Apr; 112(4): 891-901 
Moonesinghe SR, Mythen MG, Grocott MP. Patient related risk factors for postoperative 
adverse events. Curr Opin Crit Care. 2009 Aug; 15(4): 320-7  
 
 
Chapter Two: 
Moonesinghe SR, Mythen MG, Das P, Rowan KM, Grocott MPW. Risk stratification tools 
in major non-cardiac surgery: qualitative systematic review. Anesthesiology. In press.  
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